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Abstract 
Neuroblastoma is a paediatric cancer derived from the sympathoadrenal cell lineage. Most cases are 
diagnosed in children under the age of 5 and neuroblastoma is responsible for 15% of paediatric 
oncology deaths. Neuroblastoma tumours demonstrate remarkable clinical variability which reflects 
their significant biological heterogeneity. Currently, even with intensive multimodal treatment, 
patients with high-risk disease have a poor prognosis. Therefore, further understanding of the 
biology of neuroblastoma may contribute to developing novel therapeutic approaches. Potassium 
(K+) channels are involved in the regulation of many biological processes associated with cancer; 
including cell proliferation, apoptosis, migration and angiogenesis. Overexpression of multiple K+ 
channels has been demonstrated in a number of types of cancer. However, the role of K+ channels in 
neuroblastoma has yet to be extensively evaluated. 
In this study K+ channel gene expression was assessed initially in primary neuroblastoma tumours 
and in two high-risk, human neuroblastoma-derived cell lines: BE2C and SKNAS. Quantitative PCR, 
western blotting and immunocytochemistry were used to assess K+ channel expression in BE2C and 
SKNAS cells. KCNQ2/Kv7.2, a voltage-gated K+ channel, was found to be highly expressed in the BE2C 
cell line and expression of KCNQ2/Kv7.2 was 101 fold greater in BE2C cells relative to SKNAS cells. 
Furthermore, functional assays demonstrated that XE991, a compound which inhibits KCNQ/Kv7 
channels, reduced BE2C cell proliferation in vitro. In addition, XE991 was found to induce 
morphological changes in BE2C cells, akin to neuronal differentiation, in vitro. The effect of XE991 on 
BE2C cell proliferation in vivo was investigated using the chick embryo model, however no significant 
effect was detected.   
We have established that K+ channels are expressed by neuroblastoma cells and differential 
expression exists between two neuroblastoma cell lines. KCNQ2 expression may contribute to the 
biological heterogeneity observed in neuroblastoma cell lines and primary tumours. Furthermore, it 
is evident that modulation of KCNQ2/Kv7.2 has a role in BE2C cell behaviour in vitro.  
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Chapter 1: Introduction 
   2 
1.1 Neuroblastoma  
1.1.1 Overview 
Neuroblastoma is a malignant tumour derived from neural crest cells of the sympathetic nervous 
system and is most commonly diagnosed in childhood. Neuroblastoma is characterised by 
remarkable biological and histological heterogeneity. This is reflected by diverse clinical outcomes 
ranging from spontaneous regression without treatment to metastatic disease resistant to 
multimodal therapy [1].  
1.1.2 Epidemiology, genetic predisposition and risk factors 
Neuroblastoma is a rare tumour, nevertheless it is the most frequently diagnosed malignancy of 
infancy (<1 year of age). The median age at diagnosis is 18 months and 40% of cases are diagnosed in 
infants [1]. In children aged 0-14 the incidence of neuroblastoma is 9-12 per million and the 
mortality rate is 9.1 per million [2-4].  
Familial cases of neuroblastoma account for 1-2% of cases and median age of diagnosis is 9 months 
[5]. Activating mutations of the ALK gene are detected in the majority of hereditary neuroblastomas 
[6]. Heterozygous germline mutations of PHOX2B are associated with a subset of familial 
neuroblastoma cases and often present in conjunction with other neural crest disorders, congenital 
hypoventilation syndrome and Hirschsprung’s disease [7]. 
In contrast to most adult malignancies, where clear aetiological factors have been identified, the 
aetiology of paediatric cancers is largely unknown and this applies to neuroblastoma. The embryonal 
origin of tumour cells and young age at onset suggest pre- and perinatal exposures may be of 
significance. Several factors have been investigated including maternal smoking and alcohol 
consumption, prenatal hormone exposure, gestational weight and age, however no consistent 
associations have been demonstrated in large studies [8, 9]. 
1.1.3 The neural crest 
The neural crest is a population of multipotent embryonic cells which give rise to a number of 
diverse cell lineages [10]. The cells from which neuroblastoma tumours arise, sympathetic ganglion 
neurons, are derivatives of neural crest cell (NCC) progenitors [11]. Embryonic NCC migration and 
maturation is mediated by a complex network of extrinsic signals; deregulation of which may 
predispose multipotent neural crest precursors to malignant transformation [10]. In addition, 
transgenic expression of genes involved in neural crest development e.g. MYCN, ALK, PHOX2B, 
recapitulates neuroblastoma in genetically engineered murine models, further supporting the 
prenatal origin of neuroblastoma [12, 13]. 
   3 
1.1.3.1 Development of sympathetic nervous system  
The ectoderm differentiates into the neural plate and the non-neural ectoderm, the interface of 
these regions is the neural plate border [14]. Inductive influences from the ectoderm, 
neuroepithelium and mesoderm induce NCC formation at the neural plate borders [15, 16]. Prior to 
migration NCCs undergo complete or partial epithelial-to-mesenchymal transition (EMT), which 
confers enhanced migratory ability and decreased need for intercellular contact [17, 18]. Neural 
crest specifiers form a transcriptional network to promote degradation of the basement membrane 
and down-regulate cell adhesion molecules e.g. N-Cam, N-cadherin, cadherin 6B [19].   
Pre-migratory neural crest cells express neural crest specifiers responsible for survival, migration and 
maintaining multipotency e.g. FOXD3 and SOX10 [20, 21]. MYCN influences NCC migration and 
expansion and is highly expressed in early migratory NCCs. Expression is reduced differentiating 
sympathetic neurons and absent in adult tissues [22]. 
After delaminating from the neural tube truncal NCCs take two migratory pathways; those destined 
to become melanocytes migrate dorsolaterally into the ectoderm. NCCs destined to colonise 
sympathetic ganglia, dorsal root ganglia and adrenal medullae migrate ventrolaterally [11, 23]. 
Migrating NCCs are exposed to multiple microenvironments and migration cues, which are essential 
in the control of the motility, directionality and specificity of cellular movements [24, 25]. Ephrin 
proteins, expressed in the posterior section of each sclerotome, bind to NCC surface Eph receptors, 
initiating a process which limits cell motility, thus controlling the specificity of cellular movements 
[26]. Sympathetic precursor NCCs expressing chemokine receptor type 4 (CXCR4) are drawn to the 
dorsal aorta and the region surrounding the gut by the chemotactic CXCR4 ligand, stromal cell-
derived factor 1 (SDF-1) [27].  
In the area of the dorsal aorta aggregated NCCs form sympathoadrenal progenitor cells prior to 
divergence into two cell lineages: sympathetic ganglion neurons and adrenal chromaffin cells [11]. 
Under instruction of bone morphogenetic proteins (BMPs), secreted by the cells of the wall of the 
dorsal aorta, NCCs destined to become sympathetic neurons acquire neuronal and 
catecholaminergic properties (Figure 1.1) [28]. BMPs initiate achaete-scute homolog 1 (ASCL1) 
production [29]. ASCL1 is the first marker of neuronal specification ASCL1 and promotes the 
expression of paired-like homeobox 2A (PHOX2A) and 2B (PHOX2B). These genes together drive the 
expression of enzymes necessary for catecholamine synthesis, tyrosine hydroxylase (TH) and 
dopamine ß-hydroxylase (DBH) [30]. PHOX2B also initiates terminal sympathoadrenal 
differentiation. Loss-of-function studies demonstrate that ASCL1 and PHOX2B null mice fail to 
properly develop autonomic ganglia [31]. Heart and neural crest derivatives expressed transcript 2 
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(HAND2) is expressed independently of ASCL1 and HAND2-null allele mice showed reduced number 
of sympathetic neurons and TH and DBH expression [32] 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Neural crest cell migration and sympathoadrenal differentiation. Neural crest cells 
destined to become cells of the sympathoadrenal lineage delaminate from the neural plate borders 
and migrate to the region of the dorsal aorta (DA). Bone morphogenetic signalling (BMP) signalling 
initiates differentiation of the sympathoadrenal precursor and multiple transcription factors are 
involved in this process. At this stage cells committed to becoming sympathetic ganglia acquire the 
catecholaminergic enzymes, dopamine-ß hydroxylase (DBH) and tyrosine hydroxylase (TH). 
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1.1.4 Molecular biology 
Advances in molecular biology research have substantially increased the understanding of the 
genetic events which drive the development and progression of neuroblastoma. In particular, DNA 
content, structural chromosomal changes and amplification of the MYCN gene play a significant role. 
The outcome of these alterations is a loss of balance between cell proliferation and cell death. 
Neuroblastoma tumours demonstrate significant clinical heterogeneity, this perhaps reflects the 
absence of a single genetic alteration common to all tumours [34]. 
1.1.4.1 DNA content 
Virtually all cancers demonstrate aneuploidy, an abnormal number of chromosomes [35]. A diploid 
cell has 46 chromosomes, the majority of neuroblastoma tumour cells are either hyperdiploid (58-80 
chromosomes) or near-diploid (35-57 chromosomes) [36]. Genetic models suggest more malignant 
tumours maintain near-diploid DNA content due to a fundamental defect in genomic stability, 
resulting in chromosomal rearrangements and unbalanced translocations. Importantly, tumours 
which have near- diploid DNA content tend confer a worse prognosis compared with hyperdiploid 
tumours. Ploidy is one of the genetic variables included in the INRG pretreatment classification 
schema [37] 
1.1.4.2 Segmental chromosomal aberrations 
Somatically acquired segmental chromosome aberrations (SCAs) with associated DNA copy number 
alterations occur almost always in high-risk neuroblastoma [34]. Deletion at the chromosomal region 
1p36 is observed in 25-35% of cases [38]. Gain of 1-3 additional copies of chromosome 17q is the 
most common genetic aberration in neuroblastoma, occurring in 48-83% of cases. [39, 40]. Both 
chromosome 1p deletion and 17q gain are correlated with unfavourable prognostic features, 
including MYCN amplification and older age at diagnosis [40]. 
Allelic loss of chromosomal region 11q23 occurs in 15-20% of primary neuroblastoma tumours [41]. 
Chromosome 11q deletion is inversely associated with MYCN amplification, therefore is a powerful 
prognostic marker in non-MYCN amplified tumours and is included as prognostic criterion in the 
INRG pretreatment classification schema [40, 42]. 
1.1.4.3 The MYCN proto-oncogene  
The MYCN proto-oncogene is located on chromosome 2p24. Amplification (increased number of 
copies) of this gene occurs in a subset of neuroblastoma tumours and confers a poor prognosis for 
patients [37]. MYCN amplification is detected by fluorescence or chromogenic in situ hybridisation 
and is most commonly seen as extra-chromosomal chromatin bodies (double minutes) or less 
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commonly as multiple copies of MYCN gene integrated as tandem repeats into one chromosome 
(homogenously staining region) [43].  
MYCN encodes for the n-myc protein, which together with c-myc and l-myc belong to the myc family 
of basic helix-loop-helix (bHLH) proteins which function as transcription factors [44]. The n-myc 
oncoprotein possesses a leucine zipper motif which allows it to form dimers with multiple proteins 
including the Max/Mad network, a group of interacting factors which influence gene transcription. 
N-myc translocates to the nucleus and dimerises with the protein max, this dimer then binds to the 
E-box sequence (CANNTG) in DNA promoter to regulate gene transcription. Max also 
heterodimerises with the Mad family of proteins and mad-max heterodimers function as 
transcriptional repressors at E-box sites [45].  
Amplification of the MYCN gene leads to overexpression and increased transcriptional 
activation/repression of over 200 genes; the overall effect of which is permissive to tumour 
development and survival. Upregulated genes are related to proliferation, drug resistance and 
angiogenesis, whereas downregulated genes include those involved in cell cycle, apoptosis and 
differentiation [46]. In genetically engineered murine models (GEMM) [47], MYCN overexpression 
alone is insufficient to recapitulate tumourigenesis; this requires additional genetic aberrations e.g. 
MYCN transgene amplification and MYCN-induced up-regulation of Sirtuin 1 and Sirtuin 2, both of 
which increase MYCN stability [48]. Consequently, a proportion of these mice spontaneously 
developed neuroblastoma tumours which display similar localisation, histology and chromosomal 
aberrations to human tumours [13]. 
MYCN amplification is observed in 16-35% of neuroblastoma cases [40, 49] and is firmly associated 
with advanced disease and poor prognosis regardless of stage of disease or age at diagnosis [37]. In 
children < 18 months, with metastatic disease and MYCN amplification 5-year overall survival is 34%, 
this is remarkably lower than in the same cohort lacking MYCN amplification (82%) [37]. 
Knockdown of MYCN expression in murine models of neuroblastoma demonstrated an increase in 
tumour apoptosis and cellular differentiation and suppression of cell growth [47]. Inhibition of MYCN 
is therefore an attractive therapeutic approach. However, the structure of MYCN largely prevents 
direct inhibition. Indirect mechanisms of inhibiting MYCN are being pursued, this includes inhibiting 
MYCN-dependent transcription e.g. BET-bromodomain inhibitors, histone deacetyltransferases 
inhibition, interfering with MYCN stabilisation e.g. aurora kinase inhibitors, MDM2 inhibition and 
inducing differentiation e.g. retinoic acid [46]. 
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1.1.5 Neuroblastoma and the hallmarks of cancer 
The previous section discussed a number of genetic aberrations that contribute to the development 
and biological heterogeneity of neuroblastoma tumours. The question remains as to how does each 
genetic aberration contribute to the development of neuroblastoma; a complex process which 
requires the evolution of a sympathetic neuroblast into a malignant tumour. This evolution is a 
highly multifaceted process which requires the acquisition of complex biological capabilities. 
Hanahan and Weinberg have described eight hallmark features of cancer and two enabling 
characteristics which a tumour acquires as it progresses [50]. These characteristics are discussed 
below in the context of neuroblastoma (Figure 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
1.1.5.1 Sustained proliferative signalling  
Cell proliferation is necessary for growth and normal tissue function and is strictly coordinated to 
maintain normal architecture and function [50]. The process of cell proliferation can be resolved into 
the following sequence of events; binding of growth factor to specific receptor on cell membrane; 
activation of the growth factor receptor; signal transduction to the nucleus; activation of nuclear 
regulatory factors that regulate DNA transcription; entry into the cell cycle and cell division. A 
feature of all tumours is deregulation of cell proliferation and any of the aforementioned steps may 
Figure 1.2: The hallmarks of cancer and neuroblastoma. Hanahan and Weinberg (2011) [50] have 
described hallmark and enabling characteristics which a cancer cell acquires during the complex 
process of tumourigenesis. These characteristics (dark blue boxes) are applicable to 
neuroblastoma tumours. There are multiple genes and genetic events which contribute to the 
acquisition each characteristic in neuroblastoma (light blue boxes).  
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be corrupted; thereby endowing cells with the essential trait of maintaining proliferative signalling 
[51]. Mutated or over-expressed proto-oncogenes promote uncontrolled cell proliferation through 
several mechanisms and two oncogenes implicated in oncogenesis in neuroblastoma, MYCN and 
ALK, are discussed below. 
Neuroblastoma growth is regulated by a multitude of cytokines and growth factors that interact with 
cell surface non-receptor and receptor tyrosine kinases (RTKs) [52]. Anaplastic lymphoma kinase 
(ALK) is an RTK expressed in the developing embryonal and neonatal brain [53]. Activating mutations 
of ALK lead to enhanced kinase function, ligand-independent activation and loss of auto-inhibition 
[54], resulting in the activation of a plethora of downstream signalling pathways which facilitate 
cellular processes required for oncogenesis including cell proliferation, growth and survival [53]. 
Oncogenic mutations of ALK are detected in the majority of hereditary neuroblastomas and 7-10% of 
sporadic cases of neuroblastoma; ALK therefore provides an attractive molecular target for therapy 
in neuroblastoma and inhibitors of ALK are currently in phase I/II clinical trials [6, 53].  
A well-characterised function of MYCN is to promote proliferation and cell cycle progression. In the 
embryonic period this is critical for normal neuronal and brain development [44]. In neuroblastoma, 
MYCN amplification leads to a hazardous combination of activation of cell cycle drivers and 
suppression of anti-proliferative proteins. MYCN acts a powerful inhibitor of cell differentiation 
through negative regulation of tropomyosin related kinase A (TrkA) expression. Consequently cells 
become arrested in the proliferative stage and are unable to terminally differentiate into post-
mitotic sympathetic neurons [55].  
Cyclin-dependent kinase 4 (CDK4) is a direct transcriptional target of MYCN. CDK4 forms a complex 
with cyclin D2 which hyperphosphorylates the Rb: E2F1 complex; thus allowing E2F1 to initiate 
transcription of genes involved in cell cycle progression leading to uncontrolled proliferation [56, 
57].  
1.1.5.2 Evasion of growth suppression 
Neoplastic cells must also overcome intrinsic cellular mechanisms that oppose uncontrolled cell 
proliferation. Tumour suppressor genes (TSGs) are a vital component of cellular anti-proliferative 
mechanisms through their role in inhibition of uncontrolled cell cycle progression, response to 
oncogene activation and DNA damage. TP53 is an archetypal TSG and is mutated in a multitude of 
human cancers [58]. Multiple cellular stimuli including anoxia, DNA damage and inappropriate 
oncogenic signalling stimulate p53 activity which functions to repress unrestrained cell proliferation. 
The primordial response to DNA damage is activation of temporary cell cycle arrest (quiescence) to 
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allow DNA damage repair. If the DNA damage is irreparable p53 can induce cell cycle arrest 
(senescence) and cell death (apoptosis). [50, 51].  
In neuroblastoma mutational inactivation of TP53 is highly uncommon (<2%) at diagnosis [59]. 
Alternative mechanisms of p53 inactivation in neuroblastoma have been proposed including 
cytoplasmic sequestration, increased mouse double minute 2 homolog (MDM2) activity and 
inactivation of the p14ARF gene. MDM2 is a known oncoprotein that destabilises/sequesters p53 
thereby limiting its activity and p14ARF protects p53 from MDM2 mediated degradation [60, 61] 
The retinoblastoma (RB) gene, the prototypical tumour suppressor gene, represses proliferation by 
controlling the G1-S checkpoint of the cell cycle [50]. In heritable cases of retinoblastoma affected 
children possess a germline mutation of the RB gene, a subsequent somatic mutation leads to 
biallelic inactivation [62]. In the 1970s Knudson and Strong demonstrated a heritable component to 
neuroblastoma, therefore in a similar manner to the RB gene it would have been expected that a 
neuroblastoma tumour suppressor gene would have been discovered; however such a gene remains 
elusive [63].  
Chromosome 1p and 11q deletion and their association with high-risk neuroblastoma suggests a 
putative location for a TSG and several candidates have been identified, but their contribution to 
tumourigenesis and prognostic significance remains to be identified [64]. Furthermore, genome-
wide association studies (GWAS) have been undertaken to detect DNA polymorphisms linked to 
oncogene activation or loss of tumour suppression [34]. Resultantly, multiple genetics associations 
with neuroblastoma have been identified e.g. BARD1, ATRX, LIN28B, but each association has a 
relatively modest effect size. It is evident multiple polymorphisms cooperate to contribute to 
tumourigenesis [65].  
1.1.5.3 Evasion of apoptosis 
In addition to uninhibited proliferation tumour cells must resist powerful mechanisms of cell death. 
Apoptotic cell death is primarily executed through the extrinsic or intrinsic pathways which 
ultimately results in the activation of a proteolytic cascade of caspases leading to cell death. In 
neuroblastoma multiple genetic aberrations occur to protect tumour cells from apoptosis [50, 66]. 
The intrinsic (mitochondrial) pathway of apoptosis is triggered by various stimuli and leads to 
permeabilisation of the mitochondrial membrane which allows the release of initiators of apoptotic 
pathways e.g. cytochrome c. The Bcl-2 family of proteins play a pivotal role in the regulation 
mitochondrial apoptotic pathways and elevated expression of the anti-apoptotic members of the 
Bcl-2 family (Bcl-2, Mcl-1 and Bcl-xL) has been observed in both neuroblastoma primary tumours and 
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cells lines [67-69]. Caspase-8 is a key regulator of apoptosis induction through the extrinsic pathway. 
Hypermethylation of a regulatory region in the CASP8 gene has been identified to account for its loss 
of expression in neuroblastoma tumours [70, 71].  
Somewhat paradoxically MYCN, through transcriptional activation of p53, is a powerful inducer of 
apoptosis [59]. This perhaps underpins the mechanism as to why MYCN amplified tumours initially 
demonstrate sensitivity to chemotherapy, as p53-mediated apoptotic pathways are functional. 
However, as chemotherapy tends to induce mutations in p53, this results in a loss of anti-apoptotic 
function, leading to relapse and chemoresistance [46]. Whether MYCN promotes a net tumourigenic 
effect is reliant upon on the cooperation of anti-apoptotic proteins e.g. Bcl-2.  
1.1.5.4 Replicative immortality 
Telomeres are specialised structures present at the ends of chromosomes. During each cell division 
there is progressive shortening of telomeres at the end of chromosomes. Short telomeres are 
recognised by the cell’s DNA repair machinery e.g. p53 and RB which induce cell cycle arrest and 
senescence. Senescence describes an irreversible entrance into a non-proliferative but viable state. 
In circumstances where p53 or RB are inactivated e.g. cancer cells, the cells utilise the non-
homologous joining pathway in an attempt to save the cell. This inappropriate repair results in 
massive genomic instability and leads to mitotic catastrophe; characterised by significant apoptosis. 
Germline cells and stem cells both express telomerase; a specialised reverse transcriptase able to 
extend telomeres and is virtually absent from somatic cells. However if a cell manages to reactivate 
telomerase during the period of genomic instability then cell death is avoidable. Cancer cells achieve 
immortality through upregulation of telomerase thus maintaining telomere length. [50, 51]. 
In neuroblastoma telomerase activity is upregulated and correlates with advanced disease and poor 
prognosis. In stage 4S disease lack of telomerase activity is linked with spontaneous regression. [72]. 
Whole genome sequencing has found TERT (encoding telomerase) promoter rearrangements, in 
approximately 25% of patients, leading to enhancer hijacking and activation. TERT is also a direct 
transcriptional target of MYCN [73].  
Alternative lengthening of telomeres (ALT) is a non-telomerase mechanism of telomerase 
lengthening and occurs in approximately 10% of human cancers [74]. ATRX is an RNA helicase 
involved in chromatin remodelling, telomere maintenance and suppressor of ALT [75]. ATRX loss of 
function mutations occur in 9-10% of sporadic neuroblastomas suggesting a role for ATRX mutations 
in maintaining replicative immortality [65].  
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1.1.5.5 Angiogenesis 
Even with the growth advantages described previously tumours cannot enlarge beyond 1-2 mm in 
diameter unless they are vascularised to allow delivery of oxygen and nutrients and evacuate waste 
products. Neoangiogenesis, the generation of new vessels develop from existing capillaries involves 
a complex cascade of cellular events controlled by the balance of pro-angiogenic e.g. vascular 
endothelial growth factor (VEGF) and inhibitory factors e.g. thrombospondin-1 (TSP-1). During 
tumour development an angiogenic switch is activated and involves increased production of 
angiogenic factors and/or loss of angiogenic inhibitors by tumour and stromal cells, leading to 
neoangiogenesis. However, tumour vasculature is abnormal; vessels are leaky, dilated and 
haphazardly arranged [50, 51]. 
Neuroblastoma is characterised by prominent angiogenesis [76]. Increased tumour vascularity and 
microvascular proliferation is correlated with unfavourable prognostic features including MYCN 
amplification. Aggressive tumours are associated with high expression of VEGF and other markers of 
active angiogenesis e.g. platelet-derived growth factor A [77]. Highly aggressive tumours which are 
stroma-poor demonstrate significant angiogenesis. Schwann cells, which are more abundant in 
stroma-rich tumours, exert anti-angiogenic function through secretion of numerous angiogenic 
inhibitors e.g. secreted protein acidic and rich in cysteine (SPARC). In one study, expression of SPARC 
was found to be inversely correlated with the degree of malignant progression [78]. 
1.1.5.6 Invasion and metastasis 
Metastasis is the primary reason for the resultant mortality in cancer and the invasion-metastasis 
cascade is a complex process involving a series of sequential steps to allow spread of a primary 
tumour. These steps consist of local invasion, intravasation into blood vessels and lymphatics, transit 
through the vasculature, extravasation form the vessels, colonisation growth of micrometastases 
into macroscopic tumours [50, 51].  
Matrix metalloproteinases (MMP) e.g. MMP-9 play an important role in regulation of tumour cell 
adhesion and migration. An association between overexpression of MMP2 and MMP9 has been 
observed in advanced neuroblastoma [79]. Epithelial-mesenchymal transition (EMT) occurs during 
normal neural crest development and is also an important mechanism for both the initiation of 
tumour invasion and subsequent metastasis [80]. Synergistically acting transcription factors e.g. 
Snail, Slug and Twist promote EMT by suppressing the expression of E-cadherin thus potentiating cell 
invasion. TWIST-1 has been shown to be highly expressed in a subset of metastatic tumours [81]. 
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1.1.5.7 Deregulation of tumour metabolism 
Neuroblastoma tumours require abnormally high amounts of glucose and other macromolecules to 
enable continual unchecked proliferation. It is well established these needs are met through 
alterations in key metabolic pathways [50]. In the presence of oxygen, cancer cells shift their glucose 
metabolism away from oxidative phosphorylation to glycolysis; this is termed the Warburg effect 
and has been demonstrated in neuroblastoma by the use of positron emission technology to 
visualise the avid uptake of fluorodeoxyglucose [82]. MYCN has been implicated in altered tumour 
metabolism through activation of genes involved in glycolysis, glutamine metabolism, fatty acid 
metabolism and mitochondrial function [83]. 
1.1.5.8 Evading immune destruction 
Most tumours, including neuroblastoma, arise in immunocompetent hosts. Malignant cells therefore 
require a strategy to avoid recognition and destruction by the host immune system. Neuroblastoma 
cells display downregulation of human leucocyte antigen (HLA) class 1 and adhesion molecules 
thereby impairing cell recognition by cytotoxic T cells and NK cells. [84, 85]. In addition, MYCN 
amplification down regulates HLA 1 expression [86]. Tumour-associated macrophages (discussed in 
section 1.1.5.10) are also recruited to suppress lymphocyte activity [87]. 
Neuroblastoma cells express high levels of cell surface gangliosides which are important in migration 
and adhesion. Neuroblastoma-derived gangliosides (GD) inhibit the functional activity of T, NK and 
dendritic cells and contribute to tumour induced bone marrow suppression [88]. Monoclonal-
antibody (MAb) mediated targeting of the oncofetal differentiation antigen GD2 increases 
neuroblastoma susceptibility to antibody-dependent cell-mediated cytotoxicity [33]. 
1.1.5.9 Genomic instability 
Eight hallmark features of malignancy have been discussed and it is evident that numerous 
alterations in the genomes of neoplastic cells are responsible for acquisition of all of the hallmarks. 
In addition, two enabling characteristics have been described. This refers to an increased tendency 
of alterations in the genome during the life cycle of cells and is a major enabling characteristic for 
tumourigenesis [50]. Remarkable maintenance systems minimise genomic instability and mutations 
in the genes that control these processes confer tumour cells with increased susceptibility to 
genomic instability [89]. During tumour progression cells divide continuously and mutant clones of 
tumour which are genomically heterogeneous will arise. Those clones with favourable genomic 
characteristics will survive and propagate, allowing continual tumour progression [90]. 
How do these clones acquire the necessary genomic alterations to facilitate tumour progression? 
The longstanding debate in the theory of clonal expansion is whether malignant clones evolve 
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gradually through a series of sequential genetic alterations or a single, catastrophic event [90]. 
Chromothripsis is an example of a catastrophic event and describes local shedding of a chromosome 
and random reassembly, thus leading to structural aberrations. In one study chromothripsis was 
identified in approximately 18% of high-stage neuroblastomas resulting in structural aberrations in 
genes involved in neuroblastoma pathogenesis [65].  
1.1.5.10 Tumour-promoting inflammation 
Tumour-promoting inflammation is the second enabling characteristic of tumour development. It is 
well established that tumours are densely infiltrated by leucocytes of both the innate and adaptive 
components of the immune system [91]. In neuroblastoma, CD68+ tumour-associated macrophages 
(TAM) and other myeloid-derived cells produce immunosuppressive and tumour growth-promoting 
mediators e.g. interleukins (IL). IL-6 induces a signal transducer and activator of transcription 3 
(STAT3) mediated transcriptional programme which enhances cell proliferation, further recruitment 
of suppressive myeloid cells and direct suppression of T cells and natural killer cells [92].  
1.1.6 Histopathologic classification 
Peripheral neuroblastic tumours (PNTs) are a family of tumours arising from primitive sympathetic 
precursors cell derived from the neural crest [93]. The International Neuroblastoma Pathology 
Classification (INPC) defines four morphologic categories of neuroblastic tumours: neuroblastoma, 
ganglioneuroblastoma intermixed, ganglioneuroblastoma nodular and ganglioneuroma [94] (Figure 
1.3). This classification represents a spectrum of maturation ranging from tumours composed 
predominately of undifferentiated neuroblasts to those consisting fully differentiated neurons 
surrounded by dense Schwannian stroma.  
PNTs are composed of a mixture of neuroblasts- with various degrees of differentiation- and 
Schwann cells, in various proportions. The relative abundance of each is highly significant for 
prognosis. [93]. Undifferentiated neuroblasts are small, immature blue round cells, which contain 
dense hyperchromatic nuclei, scant cytoplasm and demonstrate high mitotic activity. In contrast 
differentiated neuroblasts have a large round nucleus with a prominent nucleolus, abundant 
cytoplasm and cytoplasmic Nissl bodies (granular body composed of endoplasmic reticulum). 
Schwann-cells constitute the fibrous stroma of PNTs. The origin and function of Schwann cells in 
neuroblastic tumours is unclear. An initial hypothesis proposed that Schwann cells were part of the 
malignant process as they shared the same genomic aberrations as their neuroblast counterparts. 
However, it has also been postulated that Schwannian stromal cells secrete anti-proliferative factors 
crucial to neuronal differentiation. 
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Neuroblastoma tumours are primarily composed of nests of undifferentiated, poorly differentiated 
or differentiating neuroblasts and by definition, less than 50% Schwannian stroma 95]. As one of the 
small, blue cell tumours of infancy and childhood, neuroblastomas must be distinguished from other 
tumours in this group including the Ewing sarcoma family of tumours, rhabdomyosarcoma, 
nephroblastoma and desmoplastic small round cell tumour [96]. Histologically, neuroblastoma may 
be distinguished by the presence of eosinophilic neuritic processes (neuropil) and Homer-Wright 
pseudorosettes (a collection of neuroblasts surrounding areas of neuropil).  
Ganglioneuroblastomas are composed of neuroblasts that are undifferentiated and those that are 
transitioning towards differentiation. Ganglioneuroblastomas are further divided into intermixed 
and nodular subtypes depending on neuroblastic and Schwannian stroma development. 
Ganglioneuroblastomas, the nodular subtype in particular, demonstrate malignant potential, 
although this is far lower than for neuroblastoma [97]. 
Ganglioneuromas are the most histologically mature PNT and consist entirely of maturing/mature 
ganglion cells surrounded by Schwannian stroma. Ganglioneuromas tend occur in older patients and 
are six-to-ten times less common than neuroblastoma [97]. They often present as an asymptomatic 
mass discovered on routine radiographic study or causes a local mass effect [98, 99]. Neuroblastoma 
and ganglioneuroblastoma tumours may both undergo spontaneous maturation to more mature 
tumours, the mechanism by which and how often this occurs is unclear at present [99]. 
The prognostic significance of tumour histology was traditionally determined by the Shimada 
classification. This was modified to create the International Neuroblastoma Pathology Classification 
(INPC). The INPC is an age-linked classification based on the presence or absence of Schwannian 
stroma, degree of neuroblastic differentiation and the mitosis-karyorrhexis index (MKI). Based on 
this classification tumours are divided into favourable and unfavourable histology subgroups (Figure 
1.3) [94, 95].  
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1.1.7 Diagnosis and screening 
Confirmation of a diagnosis of neuroblastoma requires a combination of laboratory tests, multi-
modality imaging and pathology studies.  
1.1.7.1 Laboratory findings 
Several serum markers, including ferritin, neuron specific enolase (NSE), lactate dehydrogenase 
(LDH), although non-specific for neuroblastoma, demonstrate elevated levels and are predictive of 
poor outcome [100, 101].  
 
Figure 1.3: Histopathologic classification of peripheral neuroblastic tumours Simplified diagram 
of the International Neuroblastoma Pathology Classification demonstrating the histological 
subtypes of peripheral neuroblastic tumours. This classification is based on the abundance of 
Schwannian stroma and the presence/absence of neuroblastic tumour nodules and classifies 
tumours into unfavourable (UH) and favourable (FH) histological subgroups. Favourable tumours 
demonstrate increased Schwannian stroma development.  
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Neuroblastoma tumours have the capacity for secretion of catecholamine products, the metabolites 
of which, vanillylmandelic acid (VMA) and homovanillic acid (HVA), are detectable in the urine of 
90% of patients. The relative amounts of catecholamine metabolites in the urine is related to the 
degree of cellular maturation, increased dopamine levels or low HVA/VMA ratio is associated with a 
poorly differentiated tumour and indicative of poor prognosis [102]. In addition, urinary levels of 
these two catabolites can be used as markers of tumour progression or relapse [5]. 
1.1.7.2 Radiographic imaging 
Initial imaging is performed according to the presenting features e.g. in children presenting with an 
abdominal mass the initial investigation is ultrasonography [103]. Further local assessment is then 
performed by cross-sectional imaging by magnetic resonance imaging (MRI) or computed 
tomography (CT) to determine the extent of the primary tumour, organ of origin, vascular 
encasement, lymph node involvement and identify metastatic disease [104].  
MRI is the most commonly used imaging modality and offers the advantage of better tissue 
discrimination compared with CT scanning, allowing superior determination of the organ of origin 
and regional invasion [103-105]. In addition, the lack of exposure to ionising radiation is highly 
favourable in infants and children [103]. MRI is also the preferred modality for investigating 
intraspinal extension of tumours [105]. Contrast-enhanced CT is an additional imaging modality. At 
CT imaging most tumours are heterogeneous, demonstrate calcifications and may show focal areas 
of necrosis or haemorrhage [104]. Scintigraphic imaging allows identification of the primary tumour 
and sites of metastases. Meta-iodobenzylguanidine (MIBG) is structurally similar to noradrenaline 
and neuroblastoma cells express the noradrenaline transporter which allows uptake and storage of 
MIBG. 90% of neuroblastoma tumours selectively concentrate MIBG and this allows an anatomical 
assessment of tumour site and metastases [106]. MIBG is taken up by all catecholamine-producing 
tumours including ganglioneuroma, ganglioneuroblastoma, phaeochromocytoma and carcinoid 
tumours, therefore it is does not allow discrimination between these tumours. In addition, 
approximately 10% of neuroblastomas do not concentration MIBG, thus a negative scan may be 
inconclusive [97]. MIBG scanning is the imaging study of choice in evaluating the extent of cortical 
bone and bone marrow involvement. 18F-Fluorodeoxyglucose positron emission scanning exploits 
tumour cell glucose dependence to maintain aerobic glycolysis and is a valuable imaging modality in 
the assessment of MIBG-negative tumours [107].  
1.1.7.3 Biopsy 
Adequate tumour tissue sampling is paramount for diagnosis, risk stratification and treatment 
assignment. Previously, open surgical biopsy was the preferred approach to obtaining tissue 
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samples, however minimally invasive methods e.g. core needle biopsy are more commonly 
employed now. Tissue samples are obtained by core needle biopsy from multiple different regions of 
the tumour. Multiple cores are essential as significant biological and histological heterogeneity may 
exist within a single tumour [5, 108]. Tumour tissue is also utilised for molecular and genetic studies 
e.g. fluorescence in situ hybridisation to detect MYCN amplification [40]. Whole genome sequencing 
approaches are rapidly becoming more time and cost efficient and allow the identification of gene 
amplifications, chromosomal aberrations, homozygous deletions and other mutations 
simultaneously [34].  
1.1.7.4 Bone marrow evaluation 
Bone marrow infiltration is evaluated in all cases of neuroblastoma for accurate staging [103]. This is 
performed by bilateral bone marrow aspirates and biopsies, usually taken at the time of diagnosis. In 
addition, immunohistochemical staining for anti-ganglioside GD2, NSE and ferritin is also performed 
to reduce the number of false-negative cases [109].  
1.1.7.5 Screening 
Identification of neuroblastoma in infants, even with metastatic disease, leads to marginally 
improved survival [110]. This rationale led to extensive screening studies being conducted using 
urinary catecholamine analysis. Screening was found to substantially improve the detection rate, 
however tumours identified by screening were mostly clinically and biologically favourable. 
Ultimately, screening programmes do not reduce the prevalence of advanced disease or overall 
mortality and have been abandoned [111]. 
1.1.8 Neuroblastoma presentation 
The presenting features of neuroblastoma are determined by the anatomical location of the primary 
tumour, extent of disease progression, tumour dissemination and the occurrence of paraneoplastic 
phenomena. Although significant overlap exists three main clinical scenarios are recognised and are 
discussed below [103]. 
1.1.8.1 Localised tumours 
Approximately 40% of patients present with localised disease and the widespread distribution of 
sympathetic ganglia and paraganglia reflects the multiple sites at which primary tumours may 
develop (Figure 1.4) [103]. The most common site of primary tumours is the adrenal medulla 
(47.7%), followed by abdominal/retroperitoneal ganglia (23.8%), thoracic ganglia (15.1%), pelvic 
ganglia (3.0%), cervical ganglia (2.7%) and other sites (7.9%) [112]. The site of the primary tumour 
also has prognostic implications e.g. thoracic primary tumours are associated with favourable 
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prognostic features e.g. younger age at diagnosis, non-MYCN amplified and hyperdiploid tumours. 
[112]. Unusual sites of primary disease have also been described including the lung, kidney, stomach 
and thymus [97]. 
Approximately 70% of neuroblastoma tumours arise in the abdominal cavity. Adrenal medulla and 
abdominal ganglia tumours may present with abdominal pain and distension, anorexia, vomiting and 
a palpable abdominal mass detected on clinical examination is a frequent manifestation. In addition, 
abdominal and pelvic ganglia tumours may cause compression of adjacent structures leading to 
constipation or urinary retention [5]. 
Cervical or upper thoracic ganglia tumours may disrupt sympathetic neural pathways leading to 
Horner’s syndrome, the features of which include ptosis, enophthalmos, miosis and anhidrosis [113]. 
Intrathoracic neuroblastomas arise in the mediastinum; posterior mediastinal widening caused by a 
tumour mass may be detected incidentally by imaging studies obtained for other indications. 
Occasionally, large thoracic tumours can compress adjacent structures e.g. superior vena cava, 
oesophagus, trachea [114]. 
Paraspinal tumours in any body region may extend through neural foramina causing nerve root or 
spinal cord compression and occurs in 5-15% of patients [115]. The clinical manifestations of 
intraspinal extension are motor weakness, sensory deficit, back pain and sphincter dysfunction. 
Malignant spinal cord compression represents an oncological emergency and requires urgent 
intervention to avoid long-term neurological sequeale [116]. 
1.8.1.2 Metastatic disease 
Approximately 50% of patients present with evidence of haematogenous or lymphatic dissemination 
[117]. Children with metastatic disease tend to have extensive tumour burden and are severely 
unwell at presentation displaying constitutional symptoms such as fever, irritability, weight loss [1]. 
The most common sites of metastasis are bone marrow (30%), cortical bone (22%), lymph nodes 
(15%) and liver (12%) [37]. Widespread cortical bone and marrow infiltration may cause bone pain, 
limping and bone marrow suppression. An unusual site of metastasis is the retro-orbital venous 
plexus, causing periorbital ecchymoses (raccoon eyes) and proptosis (protrusion of the eyeball) [1].  
1.8.1.3 Paraneoplastic syndromes 
Two major paraneoplastic syndromes are encountered in neuroblastoma and are associated with 
localised tumours and favourable tumour biology. Opsoclonus-myoclonus syndrome (OMS), also 
called dancing eyes syndrome, occurs in 2-4% of patients with neuroblastoma and is characterised 
by opsoclonus (rapid, involuntary eye movements), myoclonus (involuntary twitching of a muscle or 
   19 
group of muscles) and cerebellar ataxia. The associated tumour is often small, localised and well-
differentiated; therefore the survival rate is highly favourable. The presence of anti-neuronal 
antibodies in patients with neuroblastoma associated OMS and favourable response to 
immunosuppressive therapy strongly supports an autoimmune aetiology [118, 119]. Refractory 
diarrhoea associated with failure to thrive and metabolic disorders are observed in approximately 
4% of patients and results from hypersecretion of vasoactive intestinal peptide (VIP) by 
differentiated tumours e.g. ganglioneuroblastomas. Surgical resection of the primary tumour usually 
leads to resolution of symptoms [120]. 
1.1.8.4 Stage 4S/MS 
An intriguing presentation of neuroblastoma is stage 4S, also referred to as stage MS in the INRG 
staging system. The hallmark of stage 4S/MS is the possibility of spontaneous tumour regression and 
favourable prognosis, even in the presence of significant tumour burden [121]. Stage 4S/MS is 
characterised by metastatic disease in children less than 18 months, with metastases confined to the 
liver, skin and/or bone marrow. Skin metastases are detected as palpable, subcutaneous nodules 
resembling a blueberry muffin appearance [122]. Extensive liver metastases cause severe 
hepatomegaly leading to massive abdominal distension, respiratory distress and bowel and renal 
impairment secondary to obstruction [5]. Several mechanisms to explain the phenomena of 
spontaneous regression are suggested including neurotrophin deprivation, immunomodulation, loss 
of telomerase activity [99]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Anatomic distribution of sympathetic ganglia. The sympathetic chain ganglia, also called 
paravertebral ganglia, are paired structures in the cervical, thoracic, abdominal and pelvic regions. 
The medulla of the adrenal gland is also considered a ganglion of the sympathetic nervous system. 
Neuroblastoma tumours may originate in any of these structures. Reproduced from Lonergan et al. 
(2002) [97] with permission. 
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1.1.9 Disease staging 
The International Neuroblastoma Risk Group (INRG) is a global collaboration formed in 2004 and has 
developed the INRG staging system (INRGSS) and INRG risk classification system. The traditional 
method of tumour staging, the International Neuroblastoma Staging System (INSS), was based on 
the surgeon’s judgement of resectability at the time of diagnosis, therefore was a subjective 
assessment [123]. In order to facilitate the comparison of clinical trials conducted across the world 
the INRG assessed the clinical data of 8 800 patients to devise a parallel staging system (Table 1.1) 
and pre-treatment classification schema (Figure 1.5) [37].  
Localised tumours are classified based on the presence of imaging-defined risk factors (IDRFs); 
surgical risk factors identified by radiographic imaging which increase the difficulty of tumour 
excision and are largely based on the number of body compartments occupied by the tumour and 
the relationship of the tumour with adjacent structures and vasculature [124].  
 
 
 
 
 
 
1.1.10 Risk stratification 
Several neuroblastoma research groups cross the world have developed models of disease risk 
stratification. The most important prognostic features are age, stage and MYCN status. These 
parameters help to define multiple patterns of disease. Low risk tumours arise in the first months of 
life and are localised; provided there is no MYCN amplification these patients have excellent survival 
with minimal treatment. Conversely, an unfavourable outcome is expected in children with tumours 
which possess MYCN amplification at any age or metastatic tumours and age > 18 months on 
diagnosis. The International Neuroblastoma Risk Group (INRG) has developed a pretreatment 
classification schema in order to develop a model of risk stratification to facilitate the delivery of 
risk-adapted treatments (Figure 1.5) [37].  
 
International Neuroblastoma Risk Group staging system (INRGSS) 
L1 Radiological risk factors absent: Localised tumour confined to one body compartment 
and not involving vital structures, as defined by the list of image-defined risk factors 
L2 Local-regional tumour with presence of one or more image-defined risk factors 
M Distant metastatic disease (except stage MS) 
MS Metastatic disease in children younger than 18 months, with metastases confined to 
the skin, liver and/or bone marrow. 
 Table 1.1: International Neuroblastoma Risk Group staging system (INRGSS)  
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INRG 
stage 
Age 
(months) 
Histologic 
category 
Grade of 
tumour 
differentiation 
MYCN 11q 
aberration 
DNA 
content 
Pre-
treatment 
risk group 
L1/L2  GN maturing: 
GNB 
intermixed 
    Very low 
NA   Very low 
Amp   High 
L2  
< 18 
Any, expect 
GN maturing 
or GNB 
intermixed 
 NA  No Low 
      Yes Intermediate 
  
 
≥ 18 
GNB nodular; 
neuroblastoma 
Differentiating NA No  Low 
   Poorly 
differentiated 
or 
undifferentiated 
 Yes  Intermediate 
    Amp   High 
M < 18   NA  Hyper-
diploid 
Low 
 < 12   NA  Diploid Intermediate 
 12 to < 
18 
  NA  Diploid Intermediate 
 < 18   Amp   High 
 ≥ 18      High 
MS  
< 18 
  NA No  Very low 
     Yes  High  
    Amp   High 
 Pre-treatment risk group Proportion of patients (%) 5-year event-free survival (%) 
Very low 28.2 > 85 
Low 26.8 > 75 to ≤ 85 
Intermediate 9.0 ≥ 50 to ≤ 75 
High 36.1 < 50 
 
Figure 1.5: The International Neuroblastoma Risk Group Consensus Pretreatment Classification 
schema and prognosis based on pre-treatment risk. GN, ganglioneuroma; GNB, 
ganglioneuroblastoma; NA, non-amplified; Amp, amplified [37]. 
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1.1.11 Principles of management  
The management of neuroblastoma includes an array of modalities. Localised tumours and 
recurrences respond well to surgical resection. However, most children with neuroblastoma have 
locally advanced or metastatic disease at presentation and will require intensive multimodal therapy 
including chemotherapy, radiotherapy, autologous haematopoietic stem cell transplantation, 
differentiation therapy and immunotherapy. In selected cases careful observation only may be the 
appropriate course of action [1, 103]. These modalities are combined on the basis of clinical and 
biological factors in the individual patient and the consequent risk-group assignment [37]. The 
principles of each treatment option and multimodal therapy in the context of risk stratification are 
discussed below.  
1.1.11.1 Surgery 
Radiographic imaging is an essential component of the pre-surgical assessment and identifies the 
presence of image-defined risk factors (IDRFs) which enables staging [124].   
Surgery has an important role both at the time of diagnosis and during treatment. Surgical resection 
of tumours aims to achieve complete resection with minimal residual viable tumour tissue. Tumour 
size, the extent of vascular encasement and the exact location are important considerations in 
selecting the surgical approach [123, 125]. Options available for most abdominal tumours include 
upper transverse, bilateral subcostal and midline transperitoneal incisions. A transthoracic extension 
can be added to any incision for excision of tumours with thoracoabdominal extension [125].  
INRG Stage L1 (Table 1.1) tumours are confined to the organ of origin e.g. adrenal gland and can be 
removed macroscopically. Stage L2 (Table 1.1) tumours have spread beyond the tumour of origin 
and are often encasing surrounding vasculature e.g. abdominal tumours and aorta/inferior vena 
cava. The tumour must be carefully exposed to determine the relationship between the tumour and 
adjacent structures. Vascular encasement and compression of the renal vessels, splenic vein, inferior 
vena cava, aorta, coeliac artery and superior mesenteric artery may occur and if identified tumour 
dissection must be performed to free the vessels [125]. Once the vessels are freed, different 
segments of the tumour are removed piecemeal. Exploration of loco-regional nodes should also be 
undertaken at the time of resection [123]. The infiltrative nature of neuroblastoma tumours means 
microscopic negative margins are difficult to obtain, thus the aim is gross total resection [1].  
Minimally invasive surgery has gained popularity in paediatric oncological surgery. Multiple study 
groups have found thoracoscopic/laparoscopic surgery is a safe option for the resection of selected 
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cases of neuroblastoma without IDRFs, however open surgery should be preferred if complete 
tumour resection is uncertain or vascular control is considered difficult [126]. 
Intraoperative and postoperative complications are not uncommon due to the extensive surgery 
often necessary. Surgical complications vary dependent on the site and extent of the primary 
tumour and include haemorrhage, injury to a vascular structure and visceral damage [5]. Injury to 
viscera occurs in 5% of cases and occasionally this will lead to removal of the affected organ e.g. 
renal infarction requiring nephrectomy [125]. Postoperative complications include bowel 
obstruction (1-5%) and wound infections or dehiscence [123].  
1.1.11.2 Chemotherapy 
Chemotherapy is the main modality of treatment for patients with metastatic and locally advanced 
disease and is indicated in low-risk patients with symptomatic involvement of vital organs [5]. A 
combination of agents is used to overcome drug resistance to individual agents. Most regimens 
involve the use of different combinations of anthracyclines, platinum based compounds, etoposide, 
microtubule inactivating agents and alkylating agents. For high-risk patients chemotherapy is 
delivered in three phases: induction of remission, consolidation of remission and eradication of 
minimal residual disease [103].   
1.1.11.3 Radiotherapy 
Neuroblastoma tumours are highly sensitive to radiotherapy and total body irradiation (TBI). TBI has 
been shown to decrease relapse and increase event-free survival in high-risk neuroblastoma [127]. 
However, its use in very young children is controversial due to the risk of long term adverse effects 
e.g. secondary malignancy [1].   
1.1.12 Risk-based multimodal therapy 
1.1.12.1 Very-low risk and low-risk neuroblastoma  
Very-low and low-risk neuroblastomas (localised tumours with favourable histology and biological 
characteristics and stage MS) account for almost half of all newly diagnosed cases of neuroblastoma 
[37]. The aim of treatment is to balance maintaining excellent patient survival whilst delivering 
minimal therapy. Infants <1 year with adrenal masses <5 cm presumed to be neuroblastoma can be 
observed without obtaining histological confirmation or surgical resection [103]. Observation 
includes physical examination, urinary catecholamine levels and imaging. This approach avoids the 
potential complications of surgery such as vital organ damage in infants [103]. For patients >1 year 
of age with localised disease that is amenable to resection the tumour should be resected. In the 
absence of MYCN amplification, any residual disease following surgical resection of the tumour is not 
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considered a risk factor for relapse, further treatment is not required and overall survival is almost 
100% [128]. For children with low-risk disease (INRG stage L2 without biological risk factors) the 
management strategy depends on the manifestation of symptoms. If present, limited chemotherapy 
is indicated. Complete resection of the primary tumour or radiotherapy is not indicated [123]. 
1.1.12.2 Intermediate-risk neuroblastoma 
Intermediate-risk neuroblastoma refers to non-MYCN amplified stage L2 tumours and metastatic 
tumours in children <18 months with diploid DNA content (Table 1.1). Children in this group are 
treated with two to eight cycles of chemotherapy followed by surgical resection of the residual 
tumour where possible [103, 123]. In patients with an unfavourable genomic profile e.g. 11q 
deletion a more intensive treatment regimen which includes radiotherapy. Based on these 
approaches, the estimated overall survival of infants with metastatic disease is >90%, however for 
children >18 months with stage L2 tumours overall survival is 70% [129]. 
1.1.12.3 High-risk neuroblastoma 
This classification includes all patients with MYCN-amplified tumours, this subgroup accounts for 20-
25% of high-risk cases. The majority of patients with high-risk disease are >18 months and have 
metastatic disease [37]. The current approach for high-risk neuroblastoma involves intensive 
induction chemotherapy to reduce tumour burden and metastases, followed by surgery to remove 
the primary tumour and subsequent myeloablative chemotherapy supported with AHSCT. This is 
followed by maintenance therapy for minimal residual disease with anti-GD2 monoclonal antibody, 
cytokine immunotherapy and differentiating therapy (Figure 1.6).  
Induction chemotherapy involves a combination of four-to-six agents, commonly carboplatin, 
cisplatin, cyclophosphamide, doxorubicin, vincristine and etoposide. Stem cell harvest is also 
performed during induction therapy for later autologous transplant. Local control of tumour spread 
is attempted by means of surgical resection of the primary tumour. However, in patients with 
advanced disease total resection is often difficult due to frequent tumour encasement of 
surrounding vasculature.  
Consolidation therapy aims to eradicate remaining tumour cells with the use of cytotoxic agents and 
radiotherapy at myeloablative doses. This eliminates tumour infiltration from the bone marrow, but 
also depletes normal bone marrow reserves, thus is followed by AHSCT. Addition of myeloablative 
therapy with AHSCT was a major step in improving event-free survival in high-risk patients [130].  
Around 50% of high-risk patients develop early or late relapse, often from minimal residual disease 
(MRD) in the bone or bone marrow [131]. 13-cis-retinoic acid induces cell growth arrest and 
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differentiation of tumour cells and has become the standard for treating MRD. 13-cis-retinoic acid 
administered after consolidation therapy was found to improve event-free survival, however overall 
survival was not increased. GD2 is a surface glycosphingolipid abundant on the surface of 
neuroblastoma cells and can be targeted by an anti-GD2 monoclonal antibody (MAb). Anti-GD2 MAb 
activates both granulocyte and natural killer cell-mediated lysis of tumour cells [33]. Granulocyte-
macrophage colony-stimulating factor (GM-CSF) increases bone marrow production of neutrophils 
and eosinophils, thus potentiating the immune response. A seminal randomised trial showed 
significant improvement in event-free survival in high-risk patients receiving combination therapy 
consisting of 13-cis-retinoic acid, anti-GD2 antibody, GM-CSF and interleukin-2 compared with 
patients receiving 13-cis-retinoic acid alone [132]. This regime is now the standard of care in most 
centres for maintenance therapy in high-risk cases [5, 103] (Figure 1.6). 
1.1.12.4 Acute and long-term sequelae of treatment 
Most patients treated for high-risk neuroblastoma experience therapy-associated acute toxicity 
including pain, mucositis, vomiting and increased risk of infection [103]. In addition, a large study of 
neuroblastoma survivors found an eight-fold increase in the incidence of chronic disease compared 
with sibling cohorts. Furthermore, survivors have an increased relative risk of mortality and 
developing a secondary malignancy including thyroid, renal and soft tissue cancers and acute 
myeloid leukaemia [127]. 
1.1.12.5 Relapsed neuroblastoma 
Relapse after induction and consolidation therapy is associated with a very poor outcome and 
survival beyond 3 years without further recurrence or death is rarely and salvage treatment involves 
chemotherapy and targeted radiotherapy [5, 103]. 
1.1.12.6. Targeted therapies 
Most children diagnosed with high-risk neuroblastoma do not respond to or relapse after 
conventional therapy, despite significant advances and multimodal therapy [1]. The identification of 
somatic gene mutations and greater understanding of signalling pathways in neuroblastoma has 
provided strong rationale for developing targeted therapies. Multiple agents which target aberrant 
signalling pathways are undergoing phase I/II testing including aurora kinase inhibitors, BET 
bromodomain inhibitors and ALK inhibitors [103, 133]. The success of anti-GD2 targeted therapy has 
created significant interest in developing additional immunomodulating therapies [33, 133].  
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1.1.13 In vivo models of neuroblastoma  
Developing novel chemotherapeutic agents against paediatric cancers including neuroblastoma 
poses a significant problem due to the relatively low number of patients available for clinical trials. 
Animal models are vital to further our understanding of the biology of neuroblastoma and in the 
development and investigation of compouds which may have anti-tumour efficacy [134, 135].  
A significant advancement in neuroblastoma research was the development of genetically 
engineered murine models (GEMM). The murine genome may be manipulated to influence the 
expression of specific genes and Weiss et al. [13] have developed the TH-MYCN murine model. Mice 
belonging to this transgenic strain overexpress the MYCN oncogene and sporadically develop 
neuroblastoma tumours in a similar pattern to humans. This discovery has facilitated research of 
MYCN amplified tumours and in vivo investigation of novel therapeutic agents. A strength of GEMMs 
is that tumours, likewise in humans, arise in immunocompetent hosts; this is favourable as the 
immune response plays a significant role in both tumour development and response to therapeutic 
agent [13, 47].  However, despite the strengths of GEMMs, tumours developed in mice are not of 
human origin, this limits the clinical translation of results obtained in GEMMs.   
 
Figure 1.6: A visual summary of the current standard of therapy for the management of high-risk 
neuroblastoma. Treatment occurs in three blocks: induction, consolidation and maintenance.  
Induction therapy involves cycles of chemotherapy to reduce primary tumour burden and 
metastases; stem-cell harvest is performed for later transplantation and surgical resection of the 
primary tumour is undertaken towards the end of induction therapy. Consolidation therapy aims to 
eradicate and residual disease from bone marrow by myeloablation followed by stem cell 
transplant. Maintenance therapy is aimed at minimal residual disease and a combination of 
immunotherapy and differentiation therapy. AHSCT, autologous haematopoietic stem cell 
transplant [103]. 
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Xenografts are an alternative animal model of cancer whereby human tissue is transplanted into an 
immunodeficient animal, most often mice. Cells may be implanted subcutaneously or orthotopically, 
whereby cells are transplanted directly into the organ in which the tumour originates e.g. the 
adrenal gland in neuroblastoma. Thus, key strengths of xenograft models are that tumours are 
derived from human tissue and chemotherapeutic compounds can be screened for anti-tumour 
efficacy in vivo [135]. Unlike GEMMs xenografts models require the host animal to be genetically 
manipulated in order to be immunodeficient.  
Biomedical research has long employed the chick embryo as an in vivo model, for example the Rous 
sarcoma virus (RSV) was identified in the chick embryo in 1911 [136]. The chick embryo displays 
molecular, cellular and anatomical homogeneity with human embryos which makes it a suitable 
model in which to recapitulate human disease [135-137]. In biomedical research, the chorioallantoic 
membrane (CAM), an extra-embryonic membrane responsible for calcium transport, gas exchange 
and water and electrolyte homeostasis, is of particular interest. Owing to its highly vascular nature, 
the CAM has been utilised as a model to study angiogenesis. However, there is increasing 
recognition of the CAM system as a xenograft model of cancer and the efficacy of this model has 
been successfully demonstrated in previous studies [137-139]. Multiple tumour cell lines have been 
effectively cultured on the CAM and xenograft tumours display the characteristics of in vivo tumours 
including solid tumour development, angiogenesis and metastasis [137-140]. This is achievable due 
to the natural immunodeficiency of the chick embryo which allows the CAM to accept tumour cells 
without mounting an immune response. Following tumour development the efficacy of 
chemotherapeutic compounds may be assessed by delivery in ovo. Tumours may subsequently be 
excised and characterised e.g. the anti-proliferative effect of a compound may be assessed by 
determining the Ki67 index [141, 142]. Compared to murine models the CAM system offers several 
advantages. As previously mentioned the immunodeficient nature of the chick allows 
xenotransplantation of any cell-line without genetic manipulation of the chick embryo, the vascular 
nature of the CAM supports rapid development of the primary tumour and the CAM system 
represents an intermediate between cultured cells and animals hence does not raise any legal or 
ethical issues [140-142]. 
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1.2 Potassium (K+) channels 
1.2.1 Overview 
Cells are enveloped by the plasma membrane, comprised by a fluid mosaic of proteins embedded in 
a phospholipid bilayer. Bipolar phospholipids e.g. phosphatidylcholine are the most abundant lipid in 
the membrane and are termed amphipathic i.e. they possess both a polar, hydrophilic head group 
and two uncharged hydrophobic tails; these moieties confer lipid molecules with the ability to form 
spontaneous bilayers in aqueous environments. The hydrophilic heads face the intra- and extra-
cellular water and the hydrophobic tails form the core of the bilayer [143]. The plasma membrane 
serves as a semi-permeable barrier that regulates the passage of solutes. The hydrophobic nature of 
the bilayer allows hydrophobic and small polar molecules to passively diffuse across the membrane 
e.g. O2 and H2O. The membrane acts a barrier to large polar or charged molecules e.g. glucose and 
ions. The passage of ions is achieved by integral membrane proteins that form channels, pumps and 
transporters. Potassium (from here on in will be referred to as K+) channels are ubiquitously 
expressed in almost all living organisms and mediate the flux of K+ across the plasma membrane. 
Conductance of K+ is vital for many cellular processes in both excitable and non-excitable cells. In 
excitable cells, they contribute to resting membrane potential and repolarise the plasma membrane 
after action potential firing. Moreover, K+ channels have important physiological roles in excitable 
and non-excitable cells including regulation of osmolarity, Ca2+ signalling, lymphocyte activation, cell 
migration, differentiation, proliferation and apoptosis [144, 145]. 
 
The K+ channel gene family is the largest and most diverse of the ion channel families. The human 
genome contains 79 genes encoding potassium channel α-subunits which can be further divided into 
4 superfamilies based on structure and function and each superfamily has distinct and defining 
features [146-148] (Figure 1.7). Nevertheless, the archetypal structure of all K+ channels is consistent 
across each superfamily. 4 α-subunits associate in radial symmetry to form multimeric channels, 
either as homomers with identical α-subunits or as heteromers with α-subunits from the same 
subfamily. Hydrophobic segments of each α-subunit, the transmembrane domain (TMD), span the 
membrane. Each subunit contains a pore forming domain and the multimeric structure forms a pore 
(P) through which K+ permeation occurs. Each channel has an N-terminus and C-terminus which is 
normally intracellular.  
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Figure 1.7: Representative structure of the transmembrane topology of potassium (K+) channel 
subunits and channel assembly. (A) Voltage-gated K+ channels (Kv) subunits comprise six 
transmembrane domains (TMD) and one pore domain. (B) Large conductance calcium-activated K+ 
channels subunits comprise seven TMDs and one pore domain. Two regulators of K+ conductance 
(RCK) domains are in the C-terminus, RCK2 is the putative Ca2+ binding site. (C) Inward rectifying K+ 
channel subunits (Kir) comprise two TMDs and one pore domain. (D) 2 pore K+ channel subunits 
(K2P) comprise four TMDs and two pore domains. Subunits are arranged circumferentially around 
the central pore as homomers/heteromers [147]. 
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1.2.2. Properties of K+ channels 
K+ channels are an example of passive transport system which demonstrates three salient 
properties: selectivity, conductivity and gating, each property is briefly discussed below.  
1.2.2.1 Selectivity 
X-ray crystallography studies of KcsA have contributed significantly to our understanding of the 
architecture and chemistry of K+ channels [149, 150]. KcsA is K+ channel which has 4 subunits, each 
of which contains 2 transmembrane domains and was isolated from Streptomyces lividans [149]. 
Despite its relatively simple topology, KcsA closely resembles eukaryotic K+ channels in terms of ion 
permeation and selectivity [149]. The pore region of the channel is lined by a highly conserved 
sequence of amino acids (TXXTXGYG) which forms the selectivity filter. In solution ions strongly 
interact with water and acquire a hydration shell. As each K+ ion passes through the narrow pore it is 
stripped of its hydration shell. To compensate for the energetic cost of dehydration, carbonyl oxygen 
atoms on the amino acid residues take the place of water oxygen atoms, therefore this arrangement 
of oxygen atoms mimics hydration. This mechanism explains why K+ channels are highly selective for 
K+ relative to sodium ions (Na+). Na+ (0.95Å radius) is a smaller ion than K+ (1.33Å radius), therefore 
would only be able to interact with oxygens on one side of the channel which is energetically less 
favourable [148, 150].  
1.2.2.2. Conductivity 
Flow of K+ is driven by the electrochemical gradient and K+ channels are able to achieve highly 
selective and high conductive rates, around 107 ions channel-1 second-1 [151]. K+ ions are conducted 
in single file and multiple ions are able occupy the selectivity filter. Resultantly the positively charged 
ions will repel each other; this electrostatic repulsion is one feature which permits rapid conduction 
[152]. 
1.2.2.3. Gating 
Channels have multiple conformational states including activation, deactivation and inactivation 
[152]. Gating is the process by which the channel moves between conformation states of the 
channel as it opens and closes. In the closed state the channel is impermeable to ions; a stimulus 
then evokes a conformational change leading to the channel opening (activation). Following 
activation some channels can shift to another conformation, inactivation, during which the channel 
is not closed but refractory to further activation and non-conducting. Deactivation is the process of 
channel going from the open to closed conformation [147].  
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1.2.3. Voltage-gated K+ channels 
The first voltage-gated K+ channel (VGKC) to be cloned was the shaker gene in Drosophila 
melanogaster (fruit fly). The legs of shaker gene mutant Drosophila display aberrant movements 
under anaesthesia [153]. In humans 40 genes encode for VGKC α-subunits across 10 gene 
subfamilies and each gene has a corresponding protein name denoted as Kvx. The 10 subfamilies 
are: KCNA (Kv1), KCNB (Kv2), KCNC (Kv3), KCND (Kv4), KCNF (Kv5), KCNG (Kv6), KCNH (Kv10/11/12), 
KCNQ (Kv7), KCNS (Kv8), KCNV (Kv9). Within each subfamily there are multiple members denoted by 
a number e.g. KCNQ2 encodes for Kv7.2. Kv5, 6, 8 and 9 subunits are unable to form functional 
homomers and can only co-assemble with Kv2 subunits [146, 147]. 
Each α-subunit of the VGKC contains six transmembrane domains (S1-6). Co-assembly of helices S5-
S6 of each subunit forms central pore domain. Helices S1-S4 comprise the voltage sensing domain 
and surrounds the central pore domain. The VSD and central pore domain are linked by the S4-S5 
linker [153]. In addition, some Kv channels can associate with ß-subunits (also called auxiliary 
subunits) which can alter the channel structure and biophysical properties e.g. members of the KCNE 
subfamily may associate with Kv7.1/Kv11.1 cardiac channels [154].  
1.2.3.1. How do VGKCs activate and inactivate? 
Structural studies are in consensus that the voltage sensing domain (VSD) consists of 4 helices (S1-4), 
specifically the S4 helix has upto 8 positively charged arginine or lysine residues which represent the 
VSD [155]. What remains unclear is the mechanism by which the VSD translocates the charge across 
the membrane when membrane potential changes and several models of voltage sensing have been 
proposed. Each model is in agreement that positive residues on the S4 helix carry out translocation 
of the charge, the S4 helix can adopt different conformations and that negative residues in other 
helices balance the positive residues [156]. To elucidate the mechanism by which the VSD and 
central pore domain are electromechanically coupled Mackinnon and colleagues have studied 
mammalian Kv1.2. They found motion of the S4 helices are transmitted to the activation gate via the 
S4-S5 linker [157]. Voltage-gated K+ channels demonstrate two mechanisms of inactivation, N-type 
and C-type. N-type inactivation is a fast process which occurs in some Kv channels. The first ~30 
amino acid residues at the N-terminus on the cytosolic aspect of the channel enter the pore to 
inhibit ion conductance [158]. Support for this mechanism comes from Fan et al. who demonstrated 
that a mutated Shaker channel lacking the N-terminus demonstrates lack of inactivation Electrostatic 
interaction occurs between the inactivation ball on the N-terminus and the T1–S1 linker region of 
Kv1.4 channel. C-type inactivation occurs in many voltage-gated K+ channels and results from 
conformational changes of the selectivity filter [159] 
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1.2.4 Calcium activated potassium channels  
The calcium activated superfamily of K+ channels (KCa) has 6 members which are distinguished by 
conductance; big conductance, KCNMA1 (KCa1.1, BK); small conductance KCNN1 (KCa2.1, SK1), 
KCNN2 (KCa2.2, SK2), KCNN3 (KCa2.3, SK3); intermediate conductance, KCNN4 (KCa3.1, IK1) and 
KCNU1 (KCa5.1) [160]. All KCa channels are tetrameric and each α-subunit has 6 transmembrane 
segments, except for the BK channel which has unique structural and functional features. The α-
subunits of BK channel each contain 7 transmembrane domains. In addition to the canonical 6 TMDs 
there is an initial TMD termed S0, preceding S1. As a result the N-terminus is extracellular. BK 
channels are activated by increased intracellular Ca2+, membrane depolarisation or both 
synergistically; segments S0-S4 from the VSD and S5-S6 form the pore-forming domain. In addition, 
the BK channel has 4 ß-subunits, encoded by KCNMB1-4, which modify the biophysical and 
pharmacological properties of the channel. The C-terminus has 2 putative regulators of K+ 
conductance (RCK) domains, RCK1 and RCK2, which is the likely site of Ca2+ binding [147].  
The KCa superfamily plays a key role in excitable and non-excitable cells. In neurons KCa channels 
contribute to action potential repolarisation, regulation of membrane potential, neuronal firing 
rates, and neurotransmitter release [161]. KCa channels are also present in the vasculature where 
they contribute to vascular tone and endothelial synthesis of vasoactive modulators [162]. SK and IK 
channels share identical topology to VGKCs are gated solely by intracellular Ca2+ and display lower 
single-channel conductance compared with BK channels [147]. 
1.2.5 Inwardly rectifying potassium channels 
Inward rectifier channels (Kir) are a unique subfamily of potassium channels; they are activated at 
membrane potential negative to equilibrium potential of K+ and allow inward flow of K+. The α-
subunits are encoded by genes denoted KCNJx [163]. The primary structure comprises 2 
transmembrane segments and a single pore domain and subunits may co-assemble as 
homotetramers or heterotetramers. 15 genes encoding α-subunits have been identified and are 
divided into 7 subfamilies (Kir1.x – Kir7.x) and further divided into 4 functional subgroups: classical, 
G protein-gated, ATP-sensitive and K+ transport [164].  
Kir channels demonstrate multiple gating mechanisms. During membrane depolarisation Mg2+ and 
polyamines physically block outward K+ conductance, on hyperpolarisation this block is released and 
allows K+ influx, thus the name inward rectifier. Other factors which regulate Kir channels include 
phosophatidylinosital-4,5-bisphosphate (PIP2), ATP and G-proteins [146, 147].  
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Kir channels are widely distributed across the body including cardiac myocytes, neurons and 
pancreatic ß-cells and have wide-ranging physiological functions [147]. For example, KATP-channels 
are formed by Kir6.x subunits which co-assemble with sulphonylurea receptor (SUR) proteins to 
form a functional channel that is inhibited by increase in the intracellular ATP/ADP ratio. This is the 
basis of insulin release in pancreatic ß-cells; raised intracellular glucose levels leads to KATP channel 
inhibition leads to membrane depolarisation, Ca2+ influx through voltage-gated calcium channels and 
insulin exocytosis [165]. Mutations of Kir channel encoding genes have been implicated in many 
human diseases, primarily of the nervous, endocrine and cardiac systems. For example loss of 
function mutations in KCNJ2, the gene encoding Kir2.1 α-subunits, leads to Andersen’s syndrome 
which predisposes those affected to potentially fatal ventricular arrhythmias [166].  
1.2.6 Two pore potassium channels  
The α-subunits of two pore potassium channels (K2P) channels are composed of 4 transmembrane 
segments and 2 pores domains. A unique feature of K2P channels is they are formed from homo- or 
hetero- dimers of α-subunits [147]. The mammalian K2P superfamily has 15 members; encoding 
genes are denoted as KCNKx, with x corresponding to the order of discovery [167]. K2P family 
members display significant biophysical differences e.g. TASK-1 is constitutively open at rest and 
functions as an open rectifier, whereas TREK-1 is an outward rectifier which requires an activating 
stimulus. Furthermore, K2P channels are regulated by physical e.g. membrane stretch and chemical 
stimuli e.g. extra-cellular protons, lipids, volatile anaesthetics and may be divided into further 
subgroups based on their regulators [168]. K2P channels activate over a range of voltages, may be 
constitutively open at rest and have a role in regulation of resting membrane potential [169]. The 
role of K2P channels in disease is less well established compared with other K+ channel superfamilies 
and few gene mutations leading to channel dysfunction have been identified. 
1.2.7 K+ channelopathies  
Channelopathies are diseases that develop due to mutations in ion channel encoding genes [170]. K+ 
channel are expressed ubiquitously throughout the body. Consistent with the widespread 
distribution of K+ channels, mutations in genes encoding K+ channels lead to dysfunction across a 
number of organ systems. Most often mutations lead to a loss of channel function, however gain of 
function mutations have also been identified [147, 170]. The list of channelopathies is rapidly 
expanding due to advances in the understanding of the role of ion channels in both physiological and 
pathophysiological processes. Table 1.2 outlines the distribution and associated channelopathies of 
specific K+ channels.  
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Disease Gene Effect on function  
Episodic ataxia, type 1 KCNA1 LoF  
Spinocerebellar ataxia type 13 KCNC3 LoF  
Brugada syndrome, type 6 KCND3 LoF  
Benign familial neonatal seizures KCNQ2, KCNQ3 LoF  
Deafness, autosomal dominant, 
type 2A 
KCNQ4 LoF  
Generalised epilepsy with 
paroxysmal dyskinesia 
KCNMA1 LoF  
Early infantile encephalopathy 
type 14 
KCNT1 LoF  
Nocturnal frontal lobe epilepsy 
type  5 
KCNT1 LoF  
Familial atrial fibrillation KCNQ1, KCNE2, KCNA5, KCNJ2,  LoF/GoF  
Long QT syndrome KCNQ1, KCNH2, KCNE1, KCNE2, 
KCNJ2, KCNJ5 
LoF  
Short QT syndrome KCNH2, KCNQ1, KCNJ2 GoF  
Bartter’s syndrome type 2 KCNJ1 LoF  
Familial hyperaldosteronism 
type 3 
KCNJ5 LoF  
EAST syndrome KCNJ10, KCNJ16 LoF  
Transient neonatal diabetes 
mellitus, type 3 
KCNJ11 GoF  
Familial hyperinsulinaemic 
hypoglycaemia type 2 
KCNJ11 LoF  
Type 2 Diabetes Mellitus KCNJ15 LoF  
Thyrotoxic periodic paralysis KCNJ18 LoF  
 
Table 1.2: Mutations in K+ channel encoding genes lead to diseases of the nervous, cardiovascular 
urinary and endocrine systems. LoF, loss of function; GoF, gain of function.  
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1.3 Kv7 channels  
1.3.1. Overview 
KCNQ genes encode members of the Kv7 subfamily of voltage gated K+ channels and 5 members of 
this subfamily- Kv7.1-5, have been identified [171]. Kv7.1 (KCNQ1) is primarily expressed in cardiac 
tissue, vascular smooth muscle cells and epithelial cells. Kv7.2-Kv7.5 (KCNQ2-5) channels are 
predominantly expressed in the peripheral and central nervous system including sympathetic, 
hippocampal and cerebellar neurons [172, 173]. 
1.3.2. Structure 
Kv7 channel subunits have 6 transmembrane domains (TMD) and a single P-loop that forms the 
selectivity filter of the pore. The P-loop contains the signature sequence TxxTxGYG [174]. All Kv7 
subunits, except Kv7.1 which has 4, have 6 positively charged amino acid residues in the S4 TMD 
which forms the voltage sensing domain. Kv7 subunits display 30-65% structural homology and have 
a highly homologous region on their intracellular C-terminus, termed the A’-domain. The length of C-
terminus is very variable, whereas the length and amino acid sequence of the N-terminus is 
relatively constant between the 5 subtypes [174, 175]. Kv7.1 subunits do no coassemble with other 
Kv7 subunits and form homomeric channels. Conversely, Kv7.3 is poorly expressed as a homomer, 
but can form heteromers with all other subunits except Kv7.1. Kv7.2, Kv7.4 and Kv7.5 subunits can 
form functional homomers [174]. In addition, Kv7 channel function may be influenced by accessory 
ß-subunits. For example, KCNE1 encodes a regulatory subunit (minK) which assembles with Kv7.1 
subunits in cardiac tissue; forming the IKs channel which is responsible for the delayed rectifier 
current of the cardiac action potential [176]. 
1.3.3. Kv7.2 and the M-current 
Generally expression of homomeric Kv7 channels produces outwardly rectifying voltage K+ currents 
that activate positive to -60 mV and display little or no inactivation. There are particular 
characteristics associated with each current whether expressed as a homomer or heteromer. KCNQ2 
encodes Kv7.2 subunits and heterologous expression of Kv7.2 subunits in a range of mammalian 
cells has demonstrated homomeric Kv7.2 channels conduct selective currents activated by 
depolarisation at membrane potential around -50 mV, exhibit slow activation and deactivation and 
lack inactivation [172, 174].   
The M-current (IKM), a voltage-gated K+ current, is widely distributed in the mammalian peripheral 
and central nervous system [177]. IKM is a non-inactivating, voltage-dependent K+ current that 
activates at -60 mV. IKM activates slowly at subthreshold potentials and does not inactivate, 
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therefore generates a steady outward current [172]. Activation of G-protein coupled receptors e.g. 
muscarinic receptors, hence the name, can suppress IKM by triggering phospholipase-Cß activation, 
leading to decreased PIP2 availability which suppresses channel function [178]. The molecular 
identity of the channel underlying the M-current was later identified to be coassembled Kv7.2 and 
Kv7.3 subunits. Heterologous expression studies demonstrate that the biophysical properties and 
pharmacological sensitivities of the Kv7.2/Kv7.3 heteromers recapitulate IKM [179]. When defined by 
biophysical properties all Kv7 homomers are capable of forming M-like current. However, in most 
native neurons functional M-channels are formed either by Kv7.2/7.3 heteromers or Kv7.2 
homomers [180]. Kv7.3/Kv7.5 heteromers have also been found to contribute to M-current [181].  
The physiological function of IKM has been characterised. As activation of IKM is relatively slow it does 
not contribute to repolarisation of action potentials. Rather IKM serves to act as a brake for repetitive 
action potential discharges and has an important role in controlling neuronal excitability [182]. In 
sympathetic neurons activation of the M-channel during the initial stages of an action potential 
serves to suppress later action potentials and abbreviate the duration and frequency spikes induced 
by sustained depolarisation. The M-current may be enhanced with the Kv7 activator, retigabine, thus 
hyperpolarising the neuron membrane potential and inhibiting spike generation. Whereas M-
channel blockade with XE991 produces a prolonged spike discharge i.e. induces tonic firing. The M-
current is believed to abbreviate action potential generation by the following mechanism. Following 
initial depolarisation of membrane potential there is increased membrane conductance and 
enhanced current passed by the M-channel, thereby causing membrane potential hyperpolarisation 
and raising the threshold for further action potential generation [172, 182].   
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1.3.4. Kv7 pharmacology 
Kv7 channels have a unique pharmacology significant potential for therapeutic benefit. A number of 
compounds have been developed with varying selectivity [183]. 
1.3.4.1. Activators 
Flupirtine and retigabine are the best characterised Kv7 activators and activate Kv7.2-5 channels. 
The main action of retigabine is to shift the current-voltage curve to the left, so that channels open 
at more hyperpolarised membrane potentials. Consequently, there is an increased outward K+ 
current and suppression of neuronal firing. A hallmark feature of multiple conditions including 
epilepsy is neuronal excitability, therefore Kv7 activation may have anticonvulsant activity [184]. 
ML213 is a relatively novel activator which is selective for Kv7.2 (EC50= 230 nM) and Kv7.4 (EC50= 510 
nM) channels [185]. 
1.3.4.2. Blockers 
Linopirdine was the first selective IKM blocker and was introduced as a cognition enhancer for 
potential application in Alzheimer’s disease, however in trials it was large ineffective due to 
relatively low IKM blocking potency, therefore requiring high doses which inadvertently caused 
cholinergic hyperstimulation effects e.g. tremors [186]. To overcome this limitation, XE991, a more 
potent inhibitor of the M-current was developed. The order potency of XE991 for homomeric Kv7 
channels is Kv7.2 (IC50= 0.7 μM), Kv7.1 (IC50= 0.8 μM), Kv7.5 (IC50= 50 μM) and Kv7.3 (IC50= 65 μM). 
XE991 potency on the Kv7.2/Kv7.3 heteromultimer channel is similar to Kv7.2 homomultimers (IC50= 
0.6 μM) [174, 183]. Another challenge of blocking Kv7 channels is maintaining specificity. Although 
with lower potency, linopirdine and XE991 can also block Kv7.1 channels in cardiac tissue. This is 
problematic due to the risk of inducing long QT syndrome and potentially fatal ventricular 
arrhythmias. XE991 is less potent on the IKs current which contributes to cardiac repolarisation 
compared with Kv7.1 homomeric channels alone (IC50= 11 μM vs. 0.8 μM) [174]. 
1.3.5 Human disease of Kv7 dysfunction  
4 of the 5 members of the Kv7 subfamily have been implicated in human disease. Indeed KCNQ1, 
KCNQ2 and KCNQ3 were first identified by positional cloning in families affected by heritable disease 
[187, 188]. The gene products of KCNQ2 and KCNQ3, Kv7.2 and Kv7.3 are expressed in most brain 
regions including the cortex, cerebellum, basal ganglia and hippocampus. Mutations in KCNQ2 and 
KCNQ3 cause benign familial neonatal seizures (BFNS), a rare, autosomal dominant epilepsy 
syndrome which causes frequent, unprovoked partial or generalised clonic seizures in the first days 
of life [189]. The consequence of mutations is loss of channel function and reduced K+ current. Given 
the physiological role of Kv7.2/Kv7.3 is to reduced neuronal excitability, a hallmark 
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pathophysiological feature of epilepsy, it is understandable that KCNQ2 and KCNQ3 mutations may 
lead to BFNS [190]. Inherited mutations of the Kv7.1 encoding gene (KCNQ1) and its regulatory 
subunit (KCNE1) may cause disruption of channel assembly and altered channel kinetics. This leads 
to impaired cardiac repolarisation and may lead to Long QT syndrome (LQTS) which predisposes 
affected individuals to potentially fatal ventricular arrhythmias [191]. Expression of KCNQ4 is 
localised to the inner ear and certain brainstem nuclei. KCNQ4 mutations are associated with non-
syndromic sensorineural deafness type 2 (DFNA2). The progressive nature of DFNA2 suggests that 
KCNQ4 currents are not essential for hearing, but reduced currents may contribute to a 
degenerative process [192]. 
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1.4 K+ channels and cancer 
1.4.1. Overview 
Many K+ channels demonstrate deregulated expression in human cancer and channels belonging to 
all four K+ channel superfamilies have been implicated [145]. Many cancer cell-lines and primary 
tumours demonstrate overexpression of K+ channels compared with the equivalent native cells from 
which they originate. However, the question exists whether overexpression initiates tumourigenesis, 
facilitates tumour progression or has no functional significance [193]. K+ channels are implicated in 
multiple oncological processes including cell proliferation, apoptosis, cell migration, metastasis and 
angiogenesis [144, 145]. The role of K+ channels in cell proliferation and apoptosis are further 
discussed below.  
1.4.2 Cell proliferation  
Uncontrolled cell proliferation is a defining feature of cancer [50] and many studies report that K+ 
channels are essential for neoplastic cell proliferation. A permissive role for K+ channel expression in 
multiple cancers is supported by numerous reports that pharmacological inhibition or genetic 
suppression of K+ channels inhibits growth in multiple cancer types and that overexpression of 
specific K+ channels in heterologous systems promotes tumourigenesis [194, 195]. Several 
mechanisms have been proposed that may explain the role of K+ channels in tumour cell 
proliferation and are discussed below.   
1.4.2.1. Regulation of membrane potential  
A significant factor that regulates the cell cycle is membrane potential, as progression of the cell 
cycle is accompanied by rhythmic membrane potential oscillations [193]. K+ channels are critical 
determinants of cell membrane potential; this ability to regulate membrane potential is thought to 
be vital for passage through the cell cycle. At the G1-S transition point of the cell cycle an increase in 
K+ current leads to a relatively hyperpolarised membrane potential (Figure 1.8). Since tumour cells 
have a relatively depolarised membrane potential it is plausible that such cells need to up-regulate 
K+ channel expression to produce the hyperpolarisation necessary to transition from G1 to S phase 
[193, 196, 197].  
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Figure 1.8: Membrane potential oscillations during the cell cycle. A transient hyperpolarisation at 
the G1-S transition point, mediated by increased K+ channel activity, has been observed in multiple 
cancer cell lines. This is followed by reduced K+ currents and transient membrane potential is 
depolarised as the cell approaches mitosis [198]. 
1.4.2.2. Control of cell volume 
Another mechanism linking K+ channel conductance to cell proliferation is regulation of cell volume 
[144]. Throughout the cell cycle regulation of osmolarity allows accurate control of cell volume. Ion 
channels, mainly K+ and Cl-, are important regulators of osmolarity by governing ion flow. At the G2-
M transition point of the cell cycle, the outward movement of K+ and Cl- is accompanied by 
cytoplasmic water efflux thus reducing cell volume; this is necessary for pre-mitotic condensation 
(PMC) and promotes successful mitotic entry [200]. A subset of medulloblastoma tumours 
demonstrates EAG2 overexpression. EAG2 enriches at the plasma membrane during G2 and mitosis 
and promotes K+ efflux for pre-mitotic condensation, with the elevated K+ current driving volume 
reduction prior to mitosis. Further to this, genetic suppression of EAG2 leads to perturbation of cell 
volume which activates tumour suppression pathways [200] 
1.4.2.3 Involvement in signalling pathways 
The canonical function of all K+ channels is K+ permeation, however all channels have a cytoplasmic 
domain which may engage in protein-protein interactions [144, 145]. It is plausible that K+ channels 
can influence oncological process independent of their capacity to enable K+ permeation. Kv1.3 has 
been shown to interact with other proteins involved in cell proliferation and apoptosis including ß1-
integrin and p56 [201, 202]. In addition, the human ether-a-go-go related (hERG) channel can form 
macromolecular complex with VEGF receptor-1 and ß1 integrin which confers a pro-migratory 
phenotype in human leukaemia cells [203]. 
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1.4.3 Apoptosis 
Voltage-gated K+ channels have emerged as important regulators of programmed cell death in 
normal and neoplastic cell types and tissues. Apoptotic volume decrease (AVD) is a hallmark event of 
incipient apoptosis and is largely attributable to K+ efflux [145, 204]. This decrease in cytoplasmic K+ 
concentration during AVD appears to promote the hallmark events of apoptosis including 
mitochondrial depolarisation, cytochrome c release from mitochondria and caspase activation [204]. 
Kv1.3 (encoded by KCNA3) has been extensively studied in the context of apoptosis. This particular 
channel is expressed at the inner membrane of the mitochondria where it is directly inhibited by the 
pro-apoptotic protein BAX which leads to cytochrome c release and initiation of apoptosis [205]. 
Pharmacological inhibition of mitochondrial Kv1.3 can induce apoptosis in macrophages and 
melanoma cell lines [206, 207]. 
1.4.4 Therapeutic potential 
Aberrant expression of potassium channels is a frequent observation in tumours and influences 
multiple oncological processes [144, 145, 208]. In many cases, overexpression of K+ channels is 
associated with accelerated disease progression and a poorer patient outcome. Beyond purely 
scientific interest this is also relevant for clinical practice. Agents that target K+ channels potentially 
offer a novel therapeutic approach in the management of cancer. Indeed, there are many approved 
K+ channel modulators currently used in clinical practice to treat a spectrum of disorders including 
diabetes, epilepsy and cardiac arrhythmias. Many of the major K+ channels involved in the 
pathophysiology of cancer have existing pharmacological modulators, for example two potent 
blockers of hERG channel, astemizole and imipramine, are licensed for other indications and have 
been shown to abolish hERG currents and decrease tumour cell proliferation in vitro and in vivo 
[209]. However, a challenge of hERG blockade is undesirable cardiovascular side effects which limit 
their clinical applicability. Despite the increasing evidence to support the role of K+ channels in 
cancer the development of cancer treatment using K+ channel-targeting compounds is at a very early 
stage. 
1.4.5 The role of K+ channels in neuroblastoma 
There are relatively few studies addressing the role of K+ channels specifically in neuroblastoma cells. 
Early studies have demonstrated a link between neuroblastoma cell proliferation and K+ channels. 
Tamoxifen and quercetin inhibited the proliferation of mouse neuroblastoma NG108-15 cells and in 
both instances it was demonstrated that this effect was somewhat mediated by K+ channel blockade 
[210, 211]. 
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The ether-a-go-go (EAG) Kv channel subfamily consists of 8 members (encoded by KCNH1-8), the 
human ether-a-go-go related (hERG) channel is an extensively studied member of this family [171]. 
Despite having the typical structure of a depolarisation activated Kv channel, hERG currents have 
unique biophysical features, principally a strongly voltage-dependent inward rectifying current. In 
cardiac myocytes the hERG channel passes the rapid component of the delayed rectified K+ current 
(IKr) which plays a significant role in cardiac repolarisation [212].  
 
The hERG channel has been widely implicated in the regulation of cell proliferation and apoptosis in 
cancer and during normal development [213]. In embryonic stages hERG currents are observed in 
neural crest-derived neurons which are replaced in mature neurons by inward rectifier currents 
[214]. Induction of differentiation in neuroblastoma derived SH-SY5Y cells, by long term exposure to 
retinoic acid, induces expression of an inward rectifier K+ current, without loss of hERG1 expression. 
This persistence of expression suggests that hERG channels confer a selective advantage to 
neuroblastoma cells [215].  
 
Arcangeli et al. demonstrated in unsynchronised SH-SY5Y neuroblastoma cells that membrane 
potential varies considerably from cell-to-cell. These variations correlate with cell-to-cell differences 
in the activation of inward rectifier currents and were not apparent after synchronising the cells in 
G1. This provided evidence to suggest inward rectifier currents may contribute to cell cycle 
progression. However, the identity of the channels that carried the inward current was unknown 
[216]. Crociani et al. later demonstrated that SH-SY5Y neuroblastoma cells express the N-truncated 
hERG1b variant alongside the full-length hERG1 protein, and heteromeric channels comprised of 
these subunits was the molecular correlate of the inward rectifier current. The hERG subunit 
expressed was cell-cycle dependent; hERG1 was up-regulated during the G1 phase and hERG1b was 
up-regulated during the S phase [217]. Another hERG variant, hERGuso, is expressed both at the 
mRNA and protein level in SH-SY5Y cells despite being absent from normal cells [218].  
 
Building on earlier studies which demonstrate hERG expression in neuroblastoma cells more recent 
studies have aimed to characterise the effect of modulation of hERG activity on neuroblastoma cell 
behaviour in vitro and in vivo. Pharmacological inhibition and genetic knockdown of hERG had a 
significant anti-proliferative effect on SH-SY5Y cells in vitro and suppressed cell cycle progression by 
arresting cells in G0/G1 phases of the cell cycle. Furthermore, the in vivo activity of hERG blockade 
and knockdown was studied in SH-SY5Y xenografted mice, which found both methods inhibited 
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tumour growth [219, 220]. These studies have demonstrated a positive role of the hERG channel in 
neuroblastoma tumour progression which warrants further investigation.  
 
Pardo et al. showed that EAG1, which encodes for Kv10.1, is normally expressed in the adult central 
nervous system and is expressed by a variety of cancer cell lines including neuroblastoma derived 
SH-SY5Y cells. Genetic knockdown of EAG1 reduced cell proliferation and implantation of CHO cells 
overexpressing EAG1 subcutaneously in immunodeficient mice led to enhanced tumour growth 
compared with controls injected with Kv1.4-expressing CHO cells. Therefore, over-expression of 
EAG1 appears to be advantageous for tumour growth in vivo [195]. 
 
Beyond the EAG family of Kv channels there have been surprisingly few studies assessing the role of 
K+ channels in neuroblastoma. Curci et al. found that both activation and inhibition of the large-
conductance Ca2+ activated K+ channel promoted cell proliferation in SH-SY5Y cells [221]. Leung et al. 
reported that non-specific blockade of Kv channels in mouse neuroblastoma N2A cells inhibited 
cAMP stimulated neurite outgrowth, a common measure of neuroblastoma cell differentiation, was 
correlated with inhibition of Kv currents in these cells. In addition, gene knockdown of Kv1.1, Kv1.4 
and Kv2.1 also inhibited cAMP stimulated neuritogenesis which suggests Kv channel-mediated K 
efflux contributes to neuritogenesis [222]. Tau is a microtubule-assembly factor that promotes 
tubulin polymerisation and stabilisation of microtubules. There is evidence to suggest tau-mediated 
alteration of Kv channels influences neuroblastoma cell proliferation. Expression of multiple Kv 
channels (Kv2.1, Kv4.1, Kv5.1, Kv7.4 Kv9.2 and Kv12.1) was identified in human SK-N-SH and mouse 
N2A neuroblastoma cell lines. In SK-N-SH and N2A cells overexpression of tau increased cell 
proliferation and induced downregulation in mRNA levels of Kv channels [223, 224]. The relevance of 
these results for human neuroblastoma are unclear, however the authors noted that tau 
overexpression is associated with resistance of some chemotherapeutic agents which bind 
microtubules e.g. taxanes therefore Kv channel expression may be associated with chemotherapy 
resistance.                                                                                   
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1.5 Aims 
 
Neuroblastoma is a highly biologically heterogeneous cancer and is often resistant to multi-modality 
treatment [1, 5, 103]. Further understanding of biological aspects of neuroblastoma may contribute 
to the development of novel therapeutic compounds. Many studies have identified a key role for K+ 
channels in tumour initiation and progression and have demonstrated application of K+ channel 
modulating compounds affects the cellular functions e.g. proliferation of many types of tumour cells 
[144, 145]. Given their surface localisation and well characterised pharmacology, K+ channels may be 
a promising therapeutic target in neuroblastoma.  
This thesis aims to investigate the role of K+ channels in neuroblastoma and the specific aims were: 
 To investigate the expression of K+ channels in primary neuroblastoma tumours. 
 To determine the expression and function of specific K+ channels in neuroblastoma cell lines. 
 To assess the effect of modulating specific K+ channels on neuroblastoma cell viability, 
proliferation and differentiation in vitro. 
 To assess the effect of K+ channel modulation in xenograft tumours using the chick embryo 
model, an in vivo model of neuroblastoma tumour development and progression. 
The methods used to achieve these aims are discussed in chapter two. Study results are collated in 
chapter three, followed by discussion and conclusion in chapter four.  
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Chapter 2: Materials and methods 
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2.1 Materials 
2.1.1 Cell lines 
Multiple neuroblastoma cell lines have been established from primary and metastatic tumours. Two 
neuroblastoma cell lines, SK-N-BE(2)-C and SK-N-AS, were cultured. SK-N-BE-(2)-C (will be referred to 
as BE2C from here on in) is a subclone of SK-N-BE(2), a cell line established from a bone marrow 
biopsy taken from a 2 year old child with disseminated neuroblastoma after repeated courses of 
chemotherapy and radiotherapy. BE2C cells possess multiple genetic aberrations: MYCN 
amplification, chromosome 1p deletion and chromosome 17 translocation. SK-N-AS (will be referred 
to as SKNAS from here on in) was established from a bone marrow biopsy from a 6 year old child 
with disseminated neuroblastoma and possesses a single copy of MYCN, chromosome 1p deletion 
and 11q deletion. These cell lines were chosen as they are characteristic of two types of clinically 
high risk neuroblastoma tumours: MYCN amplified and chromosome 11q deletion. Both cell lines 
were cultured in Dulbecco’s modified eagle media supplemented with 10% fetal bovine serum (FBS), 
1% non-essential amino acids (NEAA) and 1% penicillin streptomycin. Cells labelled with green 
fluorescent protein (GFP) and without labelling were used.  
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2.1.2 Antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary 
Antibody 
Species Application- 
Dilution 
Clonality Source Catalogue # 
Anti-ß-tubulin Mouse WB- 1:300 MC Sigma Aldrich T4026 
Anti-Kv7.2 Rabbit WB- 1:1000 
 
PC Chemicon AB5595 
Anti- Kv7.2 Rabbit WB- 1:400 PC Alomone APC-050 
Anti-Kv7.2 Rabbit WB- 1:250 
ICC- 1:200, 
1:400 
PC Abcam Ab22897 
Anti-Ki67 Rabbit ICC- 1:100 MC Abcam Ab15580 
Anti-Ki67 Mouse IHC- 1:200 MC Leica 
Biosystems 
KI67-MM1-L-
CE 
IgG1 Negative 
control 
Mouse IHC- 1:250 MC Dako X0931 
NB84 Mouse ICC- 1:200 MC Leica-
Biosystems 
NCL-NB84 
 
Table 2.1: Details of primary antibodies used. WB, Western Blot; IC, immunocytochemistry; IHC, 
immunohistochemistry; MC, monoclonal; PC, polyclonal 
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2.1.3 Fluorescent probes 
 
 
 
 
 
 
2.1.4 Therapeutic compounds  
XE991 (Cat no. 2000, Tocris Biosciences), ML213 (Cat no. 4519, Tocris Biosciences) and Palbociclib 
(PZ0199, Sigma-Aldrich, UK.) were used in this study.  
Table 2.2: Seconday  antibodies used. WB, Western Blot; IF, immunofuorescence; IHC, 
immunohistochemistry; HRP, horseradish peroxidase 
 
Secondary 
Antibody 
Host 
species  
Application-
Dilution 
Conjugate Source Catalogue # 
Anti-mouse 
IgG 
Goat IF- 1:500 Alexa 488 Thermo Fisher 
Scientfic 
A11029 
Anti-mouse 
IgG 
Goat WB- 1:10 000 HRP Fitzgerald 
Industries 
International 
43C-CB1569-FIT 
Anti-mouse 
IgG 
Goat IHC- 1:500 HRP Dako DM822 
Anti-rabbit IgG Goat IF- 1:500 Alexa 594 Thermo Fisher 
Scientific 
A-11037 
Anti-rabbit IgG Goat IF- 1:500 Alexa 488 Thermo Fisher 
Scientfic 
A11034 
Anti-rabbit IgG Goat WB- 1:5000 HRP Sigma-Aldrich A0545 
 
Probe Source Catalogue # 
Bis-(1,3-Dibutylbarbituric Acid) Trimethine Oxonol 
(DiBAC4(3)) 
Thermo Fisher 
Scientific 
B-438 
4’,6-diamidino-2-phenylindole (DAPI) Thermo Fisher 
Scientific 
D3571 
Hoechst 33342 , trihydrochloride, trihydrate Thermo Fisher 
Scientific 
H3570 
 
Table 2.3: Fluorescent probes used 
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2.2 Bioinformatics  
 
R2 Genomic Analysis and Visualisation Platform is a publically available database (http://r2.amc.nl) 
and was utilised to assess gene expression in primary neuroblastoma tumours. R2 is a bioinformatic 
platform which contains datasets from gene expression microarrays for many pathological 
conditions and normal tissues. Each dataset utilised microarray analysis to evaluate gene expression. 
Briefly, total RNA was extracted from frozen neuroblastoma tumours which contained >95% 
neuroblastoma cells and labelled cRNA was hybridized to a microarray e.g. Affymetrix Human 
genome U133 Plus 2.0. The mRNA levels were determined using a normalisation algorithm e.g. 
MAS5.0.  
R2 holds expression profiles for ≥2000 primary neuroblastoma tumours across multiple datasets. In 
addition to gene expression, datasets also document clinical and genetic details of tumour sample, 
e.g. age of patient, clinical stage, MYCN status. Furthermore, multiple modes of analysis were 
possible in R2, including gene expression in a single and multiple datasets. Figure 2.1 illustrates the 
method for selecting a dataset and inputting a gene of interest which was common to each mode of 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
             
Figure 2.1: Method of inputting gene for evaluation in a single dataset in the R2 Genomic 
Analysis and Visualisation Platform. 
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2.3 Cell Culture 
2.3.1 Routine subculturing  
All cell culture work was carried out in a laminar flow cabinet. Cells were cultured in 75 cm2 flasks 
(Corning, UK) containing 12 ml of culture media and were incubated in a humidified environment at 
37oC and 5% CO2. Cultured cells were passaged once 80-90% confluency was reached. During 
passaging existing media was removed and cells were washed with 10 ml of Hanks Balanced Salt 
Solution without Calcium and Magnesium (HBSS) (H9394, Sigma-Aldrich, UK). 0.05% trypsin/EGTA 
was then added to the flask and incubated for 4-5 minutes at 37oC and 5% CO2. Following 
trypsinisation 10 ml of culture media containing 10% FBS was added to the detached cells to 
inactivate trypsin and create a cell suspension which was transferred to a 30 ml sterile universal 
bottle (Starlab, UK). Cells were disaggregated by pipetting vertically using a 1ml pipette, seeded at a 
concentration of 1-3 x 106 cells per flask and then incubated at 37oC in a humidified environment 
containing 5% CO2. Cell lines were tested and found free of mycoplasma contamination. 
2.3.2 Culturing cells with therapeutic compounds 
For all experiments in which the effect of therapeutic compounds was investigated in vitro the 
following method was used. Cells were seeded at an appropriate density and incubated at 37oC/5% 
CO2. Drug solutions were prepared by diluting stock solution in cell culture media. After 24 hours of 
incubation, media was discarded and replaced with the same volume of media solution containing 
the compound. Control samples were cultured with cell culture media supplemented with DMSO at 
the same concentration. 
2.3.3 Recovery of cryopreserved cells 
Frozen cells were stored in 2 ml cryogenic vials in liquid nitrogen. When required, vials of frozen cells 
were removed from liquid nitrogen and thawed on ice. Cells were resuspended by adding 20 ml of 
media drop wise and centrifuged at 1 000 rpm for 10 minutes. After centrifugation the supernatant 
was discarded and the cell pellet resuspended in 7 ml culture media containing 10% FBS. Cells were 
seeded in 25 cm2 flasks and transferred into 75 cm2 flasks once 80-90% confluent. 
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2.4 Quantitative PCR (qPCR)  
The Polymerase Chain Reaction (PCR) allows amplification of small amounts of DNA. SYBR green is a 
fluorescent dye which specifically binds to double-stranded DNA and fluoresces only when bound to 
dsDNA. This property can be used to determine gene expression. At the end of each round of 
amplification the quantity of dsDNA increases and detection of fluorescent intensity increases. 
During the exponential phase of the reaction, fluorescence is directly proportional to amplification, 
thus allowing measurement of copy number. The cycle at which fluorescence exceeds the pre-
determined threshold value is termed the Cycle of quantification (Cq) value.  
2.4.1 RNA extraction 
RNA extraction was completed using the RNeasy Mini Kit (Cat no. 74104, QIAGEN). Measures to 
prevent RNA degradation included working on a dedicated work bench, decontamination of all 
surfaces and pipettes using RNAzap cleaning agent (R2020, Sigma-Aldrich) and keeping samples on 
ice throughout.  
Cells were cultured and harvested as described for subculturing (Section 2.3.1). Cell suspension was 
centrifuged at 1 000 rpm for 10 minutes, the supernatant was discarded and the pellet gently 
disrupted by tapping the tube. RNA was extracted using spin-column based isolation and utilised 3 
buffers: RLT, RW1 and RPE. To inactivate RNases, 1% ß-Mercaptoethanol was added to buffer RLT. 
350μl of buffer RLT was added to lyse cells. A 19G needle and 1 ml syringe was used to draw the 
solution up and down in order to disrupt and homogenise the cells. An equal volume of 70% ethanol 
was added and the resulting solution transferred to an RNeasy Spin Column and centrifuged at 800 x 
g for 15 seconds. The flow through was discarded and 700 μl of buffer RW1 was added and 
centrifuged at 800 x g for 15 seconds. 500 μl of buffer RPE was added and centrifuged 800 x g for 15 
seconds. The RNeasy Spin Column was transferred to a fresh collection tube and 40μl of RNAase free 
water was applied to the column membrane and centrifuged at 8000 x g for 60 seconds. RNA 
concentration (ng/μl) and quality (A260/280) were recorded using a NanoDrop spectrophotometer 
(Thermo Scientific, USA) and RNA was stored in aliquots at -80oC. 
2.4.2 cDNA synthesis 
The GoScript Reverse Transcription System (A5000, Promega, UK) was used to synthesise cDNA from 
RNA. The volume of RNA used was dependent on the concentration. Synthesis of cDNA involved two 
steps: annealing and reverse transcription. RNA samples were mixed with oligodT primers (0.5 
μg/reaction) and heated to 72oC to allow annealing of primers. The reagents and their respective 
volumes used in reverse transcription are detailed in Table 2.4. For the no reverse transcriptase 
controls nuclease-free water was added instead of reverse transcriptase. Reaction mixes were 
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placed in a thermocycler with the following settings: 25oC 5 minutes, 42oC for 60 minutes and 70oC 
for 15 minutes. The resulting cDNA was stored in aliquots at -20oC. 
 
 
 
 
 
 
 
 
 
 
 
2.4.3 Reference gene selection 
Reference genes (RG) were selected to allow normalised relative quantification of genes of interest 
to be calculated. Two genes, ubiquitin C (UBC) and hypoxanthine phosphoribosyltransferase 1 
(HPRT1) known to be stably expressed in neuroblastoma cell lines were selected [225]. 
2.4.4 Target gene selection 
2.4.4.1 K+ channel genes 
Based on the results of bioinformatic database evaluation 5 K+ channel genes were selected: KCNQ2, 
KCNMA1, KCNH2, KCNB1 and KCNG1.  
2.4.4.2 Differentiation genes 
Kruppel-Like Factor (KLF4), Stathmin-like 4 (STMN4) Roundabout, axon guidance receptor, 
homologue 2 (ROBO2) were selected to quantitatively assess the effect on differentiation of 
therapeutic compounds [226]. 
cDNA reaction mix reagents Volume per reaction 
GoScript Reaction Buffer 4 μl 
MgCl2 2 μl 
PCR Nucleotide Mix (NdTP) 1 μl 
Reverse Transcriptase 1 μl 
RNAsin Ribonuclease Inhibitor 0.5 μl 
Nuclease Free Water   6.5 μl 
RNA + OligodT primers 5 μl 
Final reaction mix 20 μl 
 Table 2.4: Reagents and corresponding volumes used during reverse transcription according to the 
manufacturer’s protocol. MgCl2, Magnesium Chloride. 
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2.4.5. Primers 
All primer sequences were obtained from published papers and origene.com. NCBI Primer Blast was 
used to assess parameters including primer and product length, GC content and annealing 
temperature. Primer sequences were located in the FASTA mRNA sequence to ensure only primers 
spanning exon-exon boundaries were selected. Primer sequences were ordered from Eurofins 
Genomics (Germany) and Sigma-Aldrich (UK). Primers were in the form of lyophilised powder and 
were resuspended using nuclease-free water (ThermoFisher Scientific, UK) in 10 μM aliquots and 
stored at -20oC. Table 2.5 below details all primer pairs used. 
 
 
 
 
 
 
 
 
 
 
2.4.5.1 Primer Efficiency  
Primer efficiency was determined for KCNQ2, KNCMA1, KCNH2, KCNG1 and KCNB1. For each set of 
primers a standard curve was constructed to calculate the gene-specific PCR efficiencies from a 2-
fold dilution series of cDNA template for each primer pair. The dilution series was made from cDNA 
samples obtained from BE2C cells and diluted in by a factor of 2 over 5 dilution factors. Real-time 
PCR was performed in triplicates as described below. Primer efficiency for UBC, HPRT1, STMN4, KLF4 
and ROBO2 had been previously determined (Grace Mather, University of Liverpool). 
 
Gene Forward sequence (5’-3’) 
 
Reverse Sequence 
UBC ATTTGGGTCGCGGTTCTTG  TGCCTTGACATTCTCGATGGT 
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT  
KCNQ2 TCATCGGTGTCTCCTTCTTCGC GAGAGGTTGGTGGCGTAGAATC 
KCNMA1 CTCTCTCGGTTGGCAGACTTGT  TATCTCTCCAGTGCCTTCGTGG 
KCNH2 GCTTGCTCAACTCCACCTC  TTTGGGGAATCTTGC 
KCNG1 TCAACCTCTCCGTCAGCACCTT TGAATGAGCCGCAGGAGGAACT 
KCNB1 GAGGAGTTCGATAACACGTGCTG GCAATGGTGGAGAGGACGATGA     
KLF4 CGCCGCTCCATTACCAAGAGC CGGTCGCATTTTTGGCACTG 
STMN4 CCTAGCAGAGAAACGGGAACA GGCGTGCTTGTCCTTCTCTT 
ROBO2 GATGTGGTGAAGCAACCAGC TGGCAGCACATCTCCACG 
 Table 2.5: Forward and reverse primer sequences for all primer pairs used in qPCR experiments. 
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2.4.6 Quantitative PCR (qPCR) 
The first step of qPCR was preparation of reaction supermixes. Table 2.6 details the reaction mix 
containing cDNA template.  
 
 
 
 
 
 
2.4.6.1 Controls 
For all experiments a no template control (NTC) was included to monitor genomic DNA 
contamination and primer-dimer formation. A no reverse transcriptase control (NRT) was also 
included whenever a new preparation of RNA was used, to monitor genomic DNA contamination.  
2.4.6.2 Plate layout 
Reaction supermixes were prepared in triplicates and 15μl of reaction supermix was carefully 
pipetted into a single well of a 96-well hard-shell PCR plate (HSS9641, BioRad, UK). The plate was 
covered by a clear seal (MSB1001, BioRad, UK) and centrifuged briefly in a microplate centrifuge. An 
example plate design can be seen below (Figure 2.2). 
 
 
 
 
 
 
The plate was transferred to a CFX connect thermocycler (BioRad, UK), which was used for all 
experiments. The thermocycler employed precise temperature control and rapid temperature 
changes for optimal cDNA amplification. Figure 2.3 outlines the cycling control for PCR amplification. 
Reagent (Concentration) cDNA template positive 
iTaq Universal SYBR Green Supermix (1x) 7.5 μl 
Forward Primer (10μM) 0.75 μl 
Reverse Primer (10μM) 0.75 μl 
Distilled Water 4 μl 
cDNA +RT 2 μl 
Total volume/well 15 μl 
 
Table 2.6: Reagents of the reaction supermix for all qPCR experiments 
1 2 3 4 5 6 
RG NTC RG NRT RG cDNA TG NTC TG NRT TG cDNA 
RG NTC RG NRT RG cDNA TG NTC TG NRT TG cDNA 
RG NTC RG NRT RG cDNA TG NTC TG NRT TG cDNA 
 Figure 2.2: Example plate layout for one reference and one target gene. RG, reference gene; TG, 
target gene; NTC, no template control; NRT, no reverse transcriptase control 
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2.4.7 Statistical analysis of qPCR data 
Data was viewed using Bio-Rad CFX Manager 3.1 software. Amplification plots and melt curves were 
inspected to detect obvious anomalies. Fold change in target gene expression in untreated and 
treated cells was calculated relative to a control sample. Results were normalised to the expression 
of reference genes (HPRT1 and UBC), compensating for differences in starting quantity of cDNA and 
reaction kinetics. 
The mean Cq value for 3 technical replicates from a single biological replicate was calculated, 
followed by the mean Cq value for 3 independent biological replicates. A commonly used method of 
calculating relative gene expression using qPCR data is the 2-ΔΔCq method; however this is based on 
the assumption that primer efficiency is 100% i.e. every PCR cycle the copy number doubles exactly. 
However, primer efficiency is often not 100%, therefore an efficiency based method of analysis was 
employed and equations used are outlined below. 
 
 
 
 
 
 
Figure 2.3: Cycling protocol for quantitative PCR amplification. The polymerase heat activation 
step of 95oC for 3 minutes was followed by 40 cycles of 95oC for 5 seconds (denaturation) and 60oC 
for 30 seconds (annealing and extension). After 40 cycles, the temperature increased 0.5oC every 5 
seconds from 65oC to 95oC to generate melt curves. 
𝑁𝑅𝑄 =
𝑅𝑄ሺ𝑇𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒ሻ
𝑅𝑄ሺ𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒ሻ
 
𝑅𝑄 =
1
𝐸𝐶𝑞
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑖𝑜 =
𝑁𝑅𝑄തതതതതതതതതതതതሺ𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡ሻ
𝑁𝑅𝑄തതതതതതሺ𝐶𝑜𝑛𝑡𝑟𝑜𝑙ሻ
 
E, primer efficiency; RQ, relative quantification; NRQ, normalised relative quantification 
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To conduct statistical analysis NRQ data requires logarithmic transformation as qPCR data are non-
linear. This brings NRQ values back to the Cq scale and allows application of standard parametric 
tests [227].  
2.5 Western blotting 
2.5.1 Cell lysate preparation  
BE2C and SKNAS cells were grown as a monolayer in 100 mm Petri dishes (Sarstedt, UK). To prepare 
cell lysate, the Petri dish was placed on ice and culture media was removed and cells washed once 
with ice cold Dulbecco’s Phosphate Buffered Saline (DPBS) without Ca2+ and Mg2+ (14190144, 
Thermo Fisher Scientific, UK). Lysis buffer (100 mM Tris-Base, 25 mM NaCl, 300 μM EDTA, 300 μM 
EGTA, 0.05% Triton-X100, pH 7.6) containing 1% protease inhibitor cocktail (P8430, Sigma, UK) was 
added to the Petri dish for 5 minutes and cells were dislodged by scraping. The resulting lysate was 
collected and centrifuged at 13 000 rpm for 10 minutes at 4oC. The supernatant was collected and 
pellet was discarded. The supernatant was mixed with an equal volume of 2x sample buffer (S3401, 
Sigma Aldrich, UK), and heated for 10 minutes at 98oC. The protein extract was stored at -20oC.  
2.5.2 Determination of protein concentration 
The protein concentration in each lysate was determined by the Pierce Bicinchoninic Acid (BCA) 
Protein Assay Kit. BCA working reagent (WR) was prepared by combining BCA reagents A (sodium, 
carbonate, sodium bicarbonate, bicinchoninc acid and sodium tartrate in sodium hydroxide) and B 
(4% cupric sulphate) in a 50:1 ratio. 5 concentrations (5-250 µg/mL) of Bovine Serum Albumin (BSA) 
were prepared by serial dilution in lysis buffer. Sample lysates were diluted 20-fold in lysis buffer. 25 
µl of each standard and unknown sample was added to separate wells in a 96 well microplate. 25 µl 
of lysis buffer was also added to wells to generate blank readings. 200 µl of WR was then added to 
each well and mixed thoroughly on a plate shaker for 30 seconds. The plate was then incubated at 
37oC for 30 minutes. After cooling to room temperature absorbance was read at 562 nm using a 
Flexstation Microplate Reader (Molecular Devices) and accompanying software, SoftMax Pro 
(Molecular Devices). Absorbance values were corrected for absorbance in blank wells. Protein 
concentration in the samples was determined by reference to a standard curve consisting of known 
concentrations of BSA.  
2.5.3 SDS-PAGE Electrophoresis  
The short plate and spacer plate were cleaned with 70% ethanol and placed into the casting frame. 
Resolving gel (375 mM Tris Base pH 8.8, 6% glycerol, 0.1% SDS, 10% Acrylamide (BioRad 161-0158, 
Bio-Rad Laboratories, USA), 0.05% Ammonium Persulphate (APS) (A-9164, Sigma Aldrich, UK), 0.1% 
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tetramethylethylenediamine (TEMED) (T-9821, Sigma Aldrich, UK) was added between the plates 
and isopropanol was overlaid to prevent desiccation of the gel. Isopropanol was removed and 
stacking gel (50 mM Tris Base pH 6.8, 0.1% SDS, 4% Acrylamide, 0.08% APS, 0.17% TEMED) was 
added above the resolving gel; a well-forming comb was inserted into the stacking gel and left to 
polymerise. Next, the plates were clamped and combs were removed. 7 µl of rainbow molecular 
weight marker (RPN800E, G.E. Healthcare, UK) was added to the first well and 25 µl of lysate were 
loaded and the clamping frame was placed into an electrophoresis cell (Mini-Protean Tetra System, 
Bio-Rad Laboratories, USA) filled with running buffer (25 mM Tris Base, 192 mM Glycine, 0.1% SDS). 
The gel was run at 160 V for 1 hour (PowerPac Basic, Bio-Rad Laboratories, USA).  
2.5.4 Western blotting 
Separated proteins were transferred from the polyacrylamide gel onto a nitrocellulose membrane. A 
‘sandwich’ was assembled, in a gel holder cassette, consisting of gauze, Whatman #3 filter paper 
(G.E. Healthcare, UK), the polyacrylamide gel and nitrocellulose membrane. To prevent drying of the 
gel, each component was soaked in transfer buffer (25 mM Tris Base, 192 mM Glycine, 20% 
Methanol). An ice pack was placed in the cell and the cell placed in ice tray to keep cool during 
transfer.  
The cassette was then placed into the electrophoresis cell and filled with transfer buffer. 100 V was 
applied for 1 hour for electrophoretic transfer. Following transfer the nitrocellulose membrane was 
washed twice in Tris-buffered saline with Tween (TBST, 20 mM Tris Base, 137 mM NaCl, 0.1% TWEEN 
20, pH 7.6). The membrane was stained with Ponceau S Solution (P7170, Sigma Aldrich, UK) to 
confirm successful transfer. The membrane was then washed in TBST to remove staining and then 
blocked by incubation with 10% non-fat milk (Marvel, UK) in TBST for 1 hour.  
Next the primary antibody was diluted to required dilution using 10% non-fat milk in TBST and the 
membrane was incubated with 1 ml of the primary antibody overnight at 4oC. The following day the 
membrane was washed in TBST 3 times for 10 minutes with agitation. The secondary antibody, 
conjugated with horseradish peroxidase, was diluted in 10% non-fat milk in TBST and incubated with 
the membrane for 90 minutes with agitation at room temperature. The membrane was again 
washed in TBST 3 times for 10 minutes. All membrane incubations were carried out at room 
temperature on a rocking platform (Rocker 25, Labnet International Inc., USA). 
2.5.5 Developing 
Presence of HRP-conjugated secondary antibodies was visualised by the enhanced 
chemiluminescence (ECL) method. The membrane was covered in ECL reagents (G.E. Healthcare, UK) 
   58 
and light was captured using auto-radiographic film (Amersham Hyperfilm, G.E. Healthcare, UK) in a 
hyper-cassette. Exposure time was dependent on the strength of the signal and varied between 1-10 
minutes. The film was processed using Kodak GBX fixer and developer solutions. Protein bands were 
sized against a pre-stained rainbow ladder.  
2.5.6 Stripping and re-blotting 
Stripping of the antibodies from the blot was performed to allow re-blotting of the membrane with a 
house-keeping protein to check for equal loading among wells. Nitrocellulose membrane were 
rehydrated with TBST and then washed in stripping solution (100 mM ß-Mercaptoethanol, 2% SDS, 
62.5 mM Tris base, pH 6.7) 2 times for 10 minutes at room temperature. Membranes were then 
rinsed in TBST and blocked using 10% non-fat milk in TBST for 1 hour. The rest of the procedure was 
as previously described for western blotting.  
2.5.7 Densitometric analysis 
ImageJ software was utilised to semi-quantify protein intensity. Films were scanned and the image 
converted to greyscale. The rectangular selection tool was used to a draw around each band of 
interest and a profile plot was created for each band. A straight line was drawn to enclose the area 
of the peak to eliminate background signal. Using the wand tracing tool the area of each peak was 
determined. The size and intensity of the band correlates with area of the peak in a profile plot 
(Figure 2.4). 
 
 
 
 
                        
 
 
 
 
 
Figure 2.4: Example of conducting densitometric analysis of bands. Rectangular boxes were 
drawn around bands. Profile plots represent the density of the contents of the rectangle. The 
taller and broader peak for Kv7.2 reflects the greater intensity of the band.  
 
  
Kv7.2 ß-tubulin 
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2.6 Immunocytochemistry  
Immunocytochemistry is a complementary technique to western blotting and is used to obtain 
information of the cellular location of the protein of interest. 
2.6.1 Cell seeding 
BE2C and SKNAS cells without GFP labelling were harvested and counted as previously described. 1 x 
104 cells were seeded on size 1 13 mm cover slips and incubated at 37oC for 18-24 hours to allow cell 
adhesion.  
2.6.2 Fixing, quenching and permeabilising of cells 
Culture medium was removed, cells were washed in DPBS, fixed with 2% PFA in PBS x1 pH 7.4 for 10 
minutes and quenched with 100 mM glycine pH 7.4 for 10 minutes. Cover slips were incubated in 
permeabilising solution (0.27 mM KCl, 0.15 mM KH2PO4, 13.7 mM NaCl, 0.8mM Na2HPO4, 0.1% 
Triton-X100, pH 7.4) and then washed in PBS (2.7 mM KCl, 1.5 mM KH2PO4, 137 mM NaCl, 8 mM 
Na2HPO4, pH 7.2) 3 times for 5 minutes. Cover slips were then incubated in blocking solution (150 
mM NaCl, 15 mM Sodium Citrate (SSC), 2% goat serum, 1% bovine serum albumin, 0.05% Triton-
X100, pH 7.2) for 30 minutes at room temperature.  
2.6.3 Antibody labelling and counterstaining 
The primary antibody was diluted in blocking solution and 200 μl of diluted primary antibody was 
applied to each cover slip and incubated overnight at 4oC. The following day, the primary antibody 
was removed and cover slips were washed in antibody washing solution (150 mM NaCl, 15 mM SSC, 
0.05% Triton-X100) for 10 minutes 3 times. The secondary antibody and DAPI were diluted in 
blocking solution, applied to each cover slip and incubated at room temperature, protected from 
light for 1 hour. Cover slips were washed 3 times for 10 minutes in washing solution. 2% PFA was 
applied to each cover slip to post-fix for 5 minutes and then washed in washing solution 3 times to 
remove the fixative and washed twice in distilled H2O to remove salt. Cover slips were allowed to air 
dry, protected from light and mounted onto slide glass using fluorescent mounting medium (Dako, 
UK) and stored at 4oC.  
2.6.4 Confocal microscopy 
A Leica confocal microscope was used to view slides using a 63x oil immersion objective. Data 
capture and extraction were carried out using Leica Confocal Software. Alexa Fluor 488 was excited 
at 488 nm using an argon-ion laser and emission light was detected at 500-550 nm.   
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2.7 DiBAC4(3) fluorescence experiments 
2.7.1 Cell seeding 
BE2C and SKNAS cells were cultured, harvested and counted as previously described. Cells were 
seeded in wells in a 96 well microplate and incubated in a humidified environment at 37oC and 5% 
CO2 for 24 hours for all experiments. The number of cells seeded and number of replicates varied 
dependent on the cell line and experiment.  
2.7.2 Solutions 
Experiments were conducted in Physiological Saline Solution (PSS) and High K+ Solution. PSS 
contained: 137 mM NaCl, 5.6 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 0.42 mM Na2HPO4 (anhydrous), 
0.44 mM Na2HPO4 (hydrated), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
4.17 mM NaHCO3, pH 7.4. High K+ solution contained: 145 mM KCl, 1 mM MgCl2, 0.42 mM Na2HPO4 
(anhydrous), 0.44 mM Na2HPO4 (hydrated), 10 mM HEPES, 4.17 mM NaHCO3, pH 7.4.  
2.7.3 DiBAC4(3) experiments 
When conducting experiments using DiBAC4(3) the method for cell seeding, working solution 
preparation, loading with DiBAC4(3) PSS and fluorescence detection was identical for all experiments 
and was as follows. On the day of experiments 0.18% glucose was added to PSS, then 2 mM 
DiBAC4(3) stock solution was diluted in this solution to obtain a 1 μM working solution. Culture 
medium was removed from each well and replaced with 1 μM DiBAC4(3) PSS and incubated at 
37oC/5% CO2 for 15 minutes. Following this, plates were transferred to a FlexStation Microplate 
Reader (Molecular Devices) where fluorescence was measured at 520 nm in response to an 
excitation wavelength of 485nm. 
Using the aforementioned design, three different experiments were conducted: (1) characterising 
DiBAC4(3) fluorescence in BE2C and SKNAS cells, (2) response to high K+ solution and (3) response to 
Kv7 channel modulation. 
2.7.3.1 Characterising DiBAC4(3) fluorescence in BE2C and SKNAS cells 
Cells were seeded in a 96 well microplate at four densities: 1 x 105, 5 x 104, 2 x 104 and 1 x 104 cells 
per well. On the day of the experiment, culture medium was removed and cells were pre-incubated 
in 100 μL of 1 μM DiBAC4(3) PSS for 15 minutes at 37oC/5% CO2. A reading of fluorescence was 
taken, then the microplate was removed from the plate reader and 100 μL DiBAC4(3) PSS was added 
to all wells containing cells. DiBAC4(3) PSS was also added to empty wells to determine background 
fluorescence. After incubation for 10 minutes at room temperature, a repeat reading of fluorescence 
was taken.  
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2.7.3.2 Response to high K+ solution in BE2C cells 
2 mM DiBAC4(3) stock solution was diluted in high K+ solution to obtain a 1 μM DiBAC4(3) solution 
with a high K+ concentration (145 mM). BE2C cells were incubated with 1 μM DiBAC4(3) PSS for 15 
minutes and a continuous, baseline reading of fluorescence was measured for 120 seconds. At this 
time point DiBAC4(3) high K+ solution was added to each well and a continuous reading of 
fluorescence was taken for a further 600 seconds. The ratio of fluorescent intensity (F/F0) was 
determined by dividing fluorescence at a given time (F) by fluorescence prior to adding DiBAC4(3) 
high K+ solution (F0).  
2.7.3.3 Response to Kv7 modulation 
Kv7 channel modulating compounds (XE991 and ML213) were dissolved in 1 μM DiBAC4(3) PSS to 
obtain a 10 μM drug solution. XE991 and ML213 stock solutions were both prepared using DMSO, 
therefore a control solution was prepared by adding DMSO to DiBAC4(3) PSS. On the day of the 
experiment cells were incubated with DiBAC4(3) PSS at 37oC/5% CO2 for 15 minutes. Following this, 
fluorescence was measured, the microplate was removed from the plate reader and 100 μl of 
DiBAC4(3) plus Kv7 drug solution or DMSO was added to each well and incubated at room 
temperature for 10 minutes. A second fluorescence reading was then taken. The change in relative 
fluorescence units (RFU) before and after addition of DMSO/compounds was determined.  
 
 
 
 
 
 
 
 
 
 
 
   62 
2.8 Functional assays 
2.8.1 Cell viability assay 
2.8.1.1 Cell seeding 
BE2C and SKNAS cells were harvested and counted as described previously (Section 2.3.1). 1 x 104 
cells were seeded per well in a 96 well microplate and incubated overnight at 37oC to allow cell 
adhesion. 3 ‘blank’ wells were prepared containing only cell culture medium. Drug solutions were 
prepared by diluting stock solution in culture medium. 18-24 hours after seeding cells the existing 
media was removed and replaced with media containing drug or DMSO. Following an incubation 
period of 72 hours, 10 μl of MTT solution (5mg/ml) was added to each well, for a final concentration 
of 0.45 mg/ml. The microplate was wrapped in foil to prevent light exposure and incubated for 4 
hours at 37oC. 100 μl 5% SDS 0.01 M HCl was added to each well and incubated at 37oC overnight. 
2.8.1.2 Absorbance detection 
Spectrophotometric absorbance was detected at 570 nm using FLUOstar Omega microplate reader 
(Molecular Devices, UK). Absorbance values were adjusted by subtracting the ‘blank’ reading (MTT 
and media only). Absorbance values from treated wells were compared with control wells (i.e. cells 
treated with DMSO) to determine the effect of the treatment on the number of viable cells. Each 
experiment was performed in triplicates and repeated ≥3 times. 
2.8.2 Cell proliferation analysis 
2.8.2.1 Cell seeding and incubation with therapeutic compounds 
Cells were seeded on size 1 13 mm glass cover slips as described previously (Section 2.6). After 24 
hours culture media was removed and replaced with drug solution or media containing DMSO.  
2.8.2.2 Fixing, quenching and permeabilisation of cells 
After a 72 hour incubation period cover slips were removed from the 24 well plate and placed into a 
staining tray. Cells were fixed with 4% PFA for 10 minutes and quenched with 200 mM Glycine pH 
7.4 for 10 minutes. For blocking and permeabilisation cover slips were incubated in blocking solution 
(1% BSA, 0.5% Triton-X in 0.12 M phosphate pH 7.4) for 1 hour at room temperature.  
2.8.2.3 Antibody labelling and counterstaining  
Mouse anti-Ki67 primary antibody was diluted in blocking solution, applied to each cover slip and 
incubated overnight at 4oC. A control cover slip was prepared by omitting the primary antibody. 
Following overnight incubation the primary antibody was removed and covers slips were washed 3 
times in HBSS. The secondary antibody and DAPI were diluted in blocking solution and applied to 
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each cover slip. After 1 hour incubation at room temperature the cover slip was washed twice in 
HBBS and once in distilled H2O. Cover slips were allowed to air dry, protected from light and 
mounted onto slide glass using fluorescence mounting medium (Dako, UK). Slides were stored at 4oC 
and protected from light.  
2.8.2.4 Quantifying Ki67 proliferative index 
Quantification of cell proliferation was carried out by manual counting. Slides were observed under a 
Leica fluorescent microscope using a x40 oil immersion objective. The number of Ki67 positive cells 
(red) in each field were counted and expressed as percentage of the total number of DAPI stained 
cells (blue) in the same field. For each cover slip a minimum of four fields were examined and 100-
200 cells were counted in each field. To eliminate bias, counting was performed blind; this was 
achieved by covering the identity of the cover slip and assigning cardinal numbers to each slide and 
checking the identity of the cover slip only after counting. Each experiment was conducted 
independently 3 times. 
2.8.3 Fluorescence activated cell sorting (FACS) 
2.8.3.1 Cell preparation 
GFP-labelled BE2C cells were seeded in 25 cm2 flasks and incubated for 18-24 hours to allow cell 
adhesion. Drugs were dissolved in culture media and existing media was replaced with drug solution 
after 24 hours.  
2.8.3.2 Sample preparation for FACS 
Cells were harvested and counted after 24 hours, as previously described. For each FACS sample to 
be analysed 1 x 106 cells in culture media were placed in polystyrene FACS tubes (Falcon, UK). Tubes 
were centrifuged at 1750 x g for 5 minutes in a tabletop centrifuge (Hermle Z400-K, Labnet 
International) and the supernatant was removed. The pellet was resuspended in 4% PFA for 5 
minutes at room temperature, followed by permeabilisation in 4% PFA, 0.05% Triton X100 for 5 
minutes at room temperature. 900 μl of PBS was added to form a 1ml cell suspension and 
centrifuged as above. The pellet was resuspended in 500 µl blocking solution (0.5% BSA, 0.1% Triton 
X100 0.12 M Phosphate), incubated for 30 minutes at room temperature and centrifuged as before. 
The pellet was incubated with 1 ml of 2.5 µg/ml of Hoechst 33342 in blocking solution (H3570, 
ThermoFisher Scientific, UK) for 30 minutes at room temperature.  
2.8.3.3 Analysis 
Samples were analysed on the FACS Canto II Flow Cytometer (BD Biosciences, USA) and for each 
   64 
sample a population of 10 000 cells were measured. All data analysis was completed using Cytobank 
online software (www.cytobank.org) and results visualised as a scatter plot or histogram.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   65 
2.9 The chick embryo model 
2.9.1 Growing tumours on the chorioallantoic membrane 
2.9.1.1 Incubation of eggs 
A batch of 24 fertilised white leghorn chicken eggs (Tom Barron Hatcheries, Preston UK) were 
incubated (Multihatch Mark II, Brinsea, UK) at 38oC and 40% relative humidity. The first day of egg 
incubation was embryonic day 0 (E0). 
2.9.1.2 Fenestration 
At E3 each egg was removed from the incubator and cleaned with 70% ethanol. To detach the 
embryo and surrounding vessels from the inner surface of the shell, an egg piercer was used to 
punch a small hole in the base of egg and a 19G gauge needle attached to a 5ml syringe was used to 
remove ~4ml of albumen. The puncture site was sealed using adhesive tape. To access the embryo 
and overlying membranes a rectangular window (20 mm x 10 mm) was created in the shell using a 
Power Craft PKW-160N Combitool, the window was sealed using adhesive tape and the eggs were 
re-incubated. 
2.9.1.3 Topical implantation of cells 
At E7 windowed eggs were removed from the incubator and assessed for survival. Cultured GFP-
labelled BE2C cells were harvested and counted as described previously. Harvested cells were 
centrifuged at 1000 rpm for 10 minutes and the pellet was placed in a separate Eppendorf tube. Eggs 
were removed individually from the incubator and the surface of the chorioallantoic membrane 
(CAM) was lightly traumatised using a small piece of sterilised lens tissue. 5 μl of 0.05% trypsin was 
applied to the surface of the CAM and 2 x 106 cells were implanted.  
2.9.1.4 Drug delivery 
At E11 survival was assessed and eggs were viewed under fluorescence using a Leica M165 FC fully 
apochromatic corrected stereo microscope to assess for tumour formation. Surviving embryos with 
tumour formation were selected for drug injection. The volume of each egg is ~45 ml and had to be 
accounted for when delivering drug solutions. XE991 was dissolved in PBS at 100 mM, to obtain a 
treatment concentration of 40 μM 200 μL of drug solution was injected into the allantois using a 19G 
needle and 1 ml syringe. 
2.9.1.5 Dissection 
At E14 eggs were removed from the incubator individually and unviable embryos were removed. The 
shell surrounding the window was removed to maximise view. Brightfield and fluorescent images 
were captured using a Leica DFC425 C camera connected to the microscope. Tumours grown on the 
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CAM were removed using size 5 dissection tweezers and dissection scissors. Dissected tumours were 
washed in HBSS before being placed into 4% PFA for 1 hour. To prepare for paraffin embedding the 
tumours were dehydrated through a series of ethanol dilutions; tumours were placed in 70% ethanol 
for 1 hour and then stored at 4OC in 100% ethanol.  
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Figure 2.5: Visual display of steps in chick embryo experiment. E0: fertilised white leghorn eggs 
were incubated in Multihatch Mark II. E3: albumen removal, windowing with power tool, 
resealing window the adhesive tape. E7: light traumatisation of CAM surface with sterile lens 
tissue improves tumour formation followed by topical implantation of BE2C cells onto surface of 
CAM.  E11: Injection of drug solution into allantois. 
E0 
 
E3 
   
E7 
             
E11 
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2.9.2 Tumour processing 
Embedding tumours in paraffin allows long term preservation and storage. Tumours were removed 
from 100% ethanol and placed in the following sequence of solutions; isopropanol twice with 
agitation for 15 minutes; 50:50 isopropanol: paraffin at 60oC for 1 hour with agitation every 15 
minutes; 100% liquid paraffin at 60oC for 1 hour; fresh 100% liquid paraffin incubated overnight at 
60oC. The following day tumours were placed in a metal mould and hot paraffin wax was poured into 
the mould using a Thermo Shandon Histocentre 3 (ThermoFisher, UK) and a plastic cassette was 
overlain. The paraffin was allowed to cool and set and plastic cassettes were subsequently stored at 
4oC.  
2.9.3 Histological preparation 
Formalin-fixed, paraffin embedded (FFPE) tissue blocks were cooled on ice prior to sectioning. 
Samples were cut into 4 μM sections using a Shandon Finese 325 microtome and S35 microtome 
blade (JDA-0100-00A, Feather). These sections were then transferred to the surface of a pre-heated 
water bath (40oC ) and then collected onto slide glass. 4-6 sections were cut from each block using 
this method. Slides were subsequently stored at 4oC until required for immunohistochemical 
staining. 
2.9.4 Antigen retrieval and deparaffinisation  
Slides were placed in a slide rack compatible with the Dako PT Link (Dako, UK); this machine allowed 
the steps of deparaffinisation, rehydration and heat induced antigen retrieval to be combined. The 
slide rack was inserted into pre-heated high pH retrieval solution (Tris/EDTA, pH 9.0) for 
deparaffinisation. High-pH (buffer, pH 9.0) antigen retrieval was performed at 96oC for 20 minutes.  
Slide racks were allowed to cool in the PT Link, after which slides were rinsed with FLEX wash buffer 
(50 mM Tris-base, 150 mM NaCl, 0.05% Tween 20, pH 7.6) to remove excess paraffin.  
2.9.5 Immunohistochemistry (IHC)  
Slide racks were transferred to the automated Dako autostainer system. IHC was performed using 
FLEX EnVisionTM reagents (Dako, UK). All steps were carried out at room temperature. Endogenous 
peroxidase was blocked by incubating slides with Peroxidase-Blocking Reagent (phosphate buffer 
containing hydrogen peroxide, 15mM NaN3) (DM821) for 5 minutes. Primary antibodies were 
diluted in antibody diluent (K8006) and slides were incubated with primary antibodies for 30 
minutes, followed by incubation a goat anti-mouse secondary antibody conjugated with horseradish 
peroxidase (DM822) for 20 minutes. Positive staining was visualised with the chromogen, 3,3’-
Diaminobenzidine (DAB), prepared by adding 1 μl of stock solution to 1 ml of substrate buffer 
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(DM823). Slides were washed with FLEX wash buffer (50 mM Tris-base, 150 mM NaCl, 0.05% Tween 
20, pH 7.6) between each incubation. 
2.9.6 Counterstaining and mounting  
The principle of counterstaining is to improve the visibility of the structure of interest by staining the 
surrounding tissue with a contrasting colour. To counterstain, slides were immersed in haematoxylin 
solution for 20 seconds, washed with running tap water, cleared in 0.5% acid alcohol and incubated 
in Scott’s tap water blueing agent for 30 seconds. Slides then underwent dehydration in a series of 
alcohol and xylene incubations before mounting with DPX mountant (Sigma, UK) on 22 x 50mm 
cover slips (630-2210, Menzel Gläser, UK). Tissue known to express the protein of interest was 
included as a positive control. Negative control involved the use of isotype specific control. 
2.9.7 Quantifying Ki67 proliferative index 
Slides were viewed under bright field microscopy and manual counting of histological sections 
allowed the quantification of Ki67 proliferative index. For each section ≥4 fields were assessed and 
100-200 cells were counted per field. Ki67 positive nuclei are stained in brown by the 
immunohistochemistry technique. Negative nuclei are counterstained in blue by  haematoxylin. The 
percentage of the brown-stained nuclei of the total number of cells determined the Ki67 index. 
Haematoxylin staining of nuclei allowed identification of both chick tissue and tumour nuclei. Chick 
tissue cells could be identified as they had a small nucleus whereas tumour tissue cells had a 
relatively larger nucleus.   
2.10 Statistical analysis of data 
Data are expressed as mean ± standard of the mean (SEM) of different treatments/experimental 
conditions. A non-paired Student’s t-test was used for statistical comparison of the mean of two 
datasets. Statistical comparisons of  the mean of two or more datasets was performed using one-
way analysis of variance (ANOVA). Following ANOVA, a post-hoc Tukey test was applied. A value of 
p<0.05 was considered statistically significant. Statistical significance indicated as * p< 0.05, ** 
p<0.01 and *** p<0.001. SigmaPlot 13.0 (Systat Software, San Jose, USA) was used for statistical 
analysis and to present results graphically. 
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Chapter 3: Results 
   71 
3.1 K+ channel gene expression in primary neuroblastoma tumours 
R2 Genomic Analysis and Visualisation Platform was utilised to evaluate K+ channel gene expression 
in normal tissue and primary neuroblastoma tumours. Figure 3.1 is an example of a single gene 
search within a dataset. KCNQ2 expression in a single dataset is demonstrated. Each data point 
represents the value of KCNQ2 gene expression plotted against individual patient samples. 
Additional parameters given are age, gender, disease stage, MYCN status, ploidy, disease risk, 
Shimada pathological classification and tissue type. The ranges of values of KCNQ2 expression in this 
dataset was 6.49 – 12.80 and the median value of expression was 11.1. 
 
 
 
 
 
 
 
 
 
 
 
The expression of all K+ channel genes was evaluated in a single primary neuroblastoma dataset 
(Jagannathan, n=100 tumours). Within the dataset each patient sample had a value of gene 
expression and the median value of gene expression across all samples was determined. In the 
example above the ranges of values of KCNQ2 expression was 6.49 – 12.80 and the median value of 
expression was 11.1. This process was repeated for all 79 K+ channel genes. 
                        
   
 
Figure 3.1:  Gene expression dot plot for KCNQ2 in a dataset of 100 neuroblastoma tumours. 
Each data point represents the value of expression for a single tumour sample. Clinical and 
genetic parameters are also displayed. Graph generated using the R2 Genomic Analysis and 
Visualisation Platform. 
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The reproducibility of results obtained in the first dataset search was tested by applying the same 
method to search 3 more primary neuroblastoma tumour datasets: Kocak, n= 649; SEQC, n= 498 and 
Asgharzardeh, n= 249. In total the median value of expression for 79 K+ channel genes was therefore 
determined in 4 datasets (n= 1496). The next aim was to determine which K+ channel genes 
demonstrated the highest level of expression. This was carried out by comparing K+ channel gene 
expression across the 4 selected datasets. The microarray platform and normalisation method 
employed by each dataset was variable, therefore the scale employed to express the value of gene 
expression varied and raw values of expression were not comparable. To account for this during 
analysis each gene was ranked based on its median value of expression within a single dataset i.e. 
the most highly expressed gene was ranked as 1, the second as 2 and continuing to the gene with 
the lowest value of expression. Subsequently, to determine the mostly highly expressed gene, the 
median ranking of each gene across all 4 datasets was determined. For example, the ranking for 
KCNQ2 in 4 datasets was 1, 1, 1 and 3, therefore the median ranking of KCNQ2 across 4 datasets was 
1. Of the 10 highest ranked genes 7 belonged to the family of voltage-gated K+ channels. 5 genes 
were consistently highly ranked across all 4 datasets: KCNQ2, KCNG1, KCNB1, KCNMA1 and KCNH2 
(Figure 3.2).   
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.2: Evaluation of K+ channel gene expression in 4 primary neuroblastoma datasets. Box 
plot representation of the median rank of the 10 most highly expressed K+ channel genes across 4 
primary neuroblastoma tumours datasets. Box- 25th and 75th percentiles; bars= minimum and 
maximum values.         
 KCNQ2 KCNG1 KCNH2 KCNMA1 KCNK3 KCNH8 KCNS3 KCNB1 KCND2 KCNJ8 
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The results from the evaluation of 4 datasets indicated that K+ channel genes belonging to the 
voltage-gated and calcium-activated families demonstrate greatest expression in primary 
neuroblastoma tumours. To validate these findings these channels were assessed in a further 10 
primary neuroblastoma datasets and this yielded similar results. Across 14 datasets KCNQ2, KCNH2, 
KCNB1, KCNMA1 and KCNG1 were still the 5 highest ranked genes (Figure 3.3). The median rank of 
KCNQ2 was still 1 and its lowest rank in any given dataset was 5. This provided robust evidence that 
KCNQ2 is the most highly expressed K+ channel gene in primary neuroblastoma tumours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Evaluation of voltage-gated and calcium-activated K+ channel genes across 14 datasets. 
Box plot representation of the median rank of 5 voltage-gated/calcium activated K+ channel genes 
across 14 datasets. Box= 25th and 75th percentiles; bars= minimum and values, dots represent 
outlying values. 
 KCNQ2 KCNH2 KCNB1 KCNMA1 KCNG1 
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3.1.1 KCNQ2 expression in histological subtypes of peripheral neuroblastic tumours 
An additional mode of analysis possible in R2 was to compare gene expression in a dataset with 
group stratifications. KCNQ2 expression was evaluated in a single dataset (n=28) where data could 
be stratified by tumour histological subtype i.e. ganglioneuroma, ganglioneuroblastoma and 
neuroblastoma. Ganglioneuroma and ganglioneuroblastoma are neuroblastic tumours are more 
histologically mature than neuroblastomas and have a better prognosis [93, 94] 
KCNQ2 was differentially expressed between histological subtypes. KCNQ2 is highly expressed in 
neuroblastomas compared with ganglioneuroma (p<0.001) and ganglioneuroblastomas (p <0.01). 
This indicated that increased expression of KCNQ2 may be a genetic marker of undifferentiated 
tumours, thereby a marker of poor prognosis (Figure 3.4).  
 
 
 
 
 
 
 
 
                                                                                                                                                    
 
 
 
 
 
 
         Ganglioneuroma      Ganglioneuroblastoma    Neuroblastoma    
Figure 3.4. KCNQ2 expression in peripheral neuroblastic tumours histologically subtypes tumours. 
Box plot representation of KCNQ2 expression in all three subtypes of peripheral neuroblastic 
tumours: neuroblastomas, ganglioneuroblastomas and ganglioneuromas. Box- 25th and 75th 
percentiles; bars= minimum and maximum values. Dots represent outlying values 
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3.2 Expression of K+ channels in neuroblastoma cell lines 
Following on from the initial assessment of K+ channel gene expression in primary neuroblastoma 
tumours, the next series of experiments aimed to evaluate K+ channel gene expression in two 
neuroblastoma cell lines. This was carried out using a combination of gene and protein expression 
analysis.  
Two heterogenous, neuroblastoma-dervied cell lines, BE2C and SKNAS, were selected as they 
represent two types of high-risk primary neuroblastoma tumours: MYCN-amplified (BE2C) and 11q 
deletion (SKNAS). All experiments were conducted using BE2C and SKNAS cells to determine if K+ 
channel expression was different between the two cell lines.  
Initial experiments were designed to determine if the K+ channel genes identified to be highly 
expressed in primary neuroblastoma tumours were expressed in BE2C and SKNAS cells and if there 
were any genes which demonstrate differential expression. The 5 K+ channel genes which 
demonstrated relatively high expression in human neuroblastoma tumours were selected for 
analysis by quantitative PCR: KCNQ2, KCNG1, KCNB1, KCNMA1 and KCNH2 (Section 3.1). 
3.2.1 Assessing K+ channel gene expression by qPCR 
3.2.1.1 Primer efficiency  
Prior to qPCR experiments, to ensure adequate optimisation, the efficiency of primer pairs was 
assessed using sample cDNA. Cq values for a 5 point dilution series were plotted against Log2 
dilution factor (DF). Linear regression analysis was used to determine the slope of the curve. Figure 
3.5 is an example plot showing how primer efficiency for the KCNQ2 primer pair was determined. 
KCNQ2 primer efficiency was 95.1%. Table 3.1 details primer efficiency for all primer pairs used.  
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Figure 3.5: KCNQ2 primer efficiency. (A) Regression analysis of a 5 point dilutions series produced a 
linear equation from which the m value was used to determine efficiency. Data represents mean Cq 
± SEM (n=3). (B) Equation used to determine primer efficiency.  
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A     
Dilution factor (DF) 1 0.5 0.25 0.125 0.0625 
Log2 DF 0 -1 -2 -3 -4 
Mean Cq value 19.31 20.43 21.47 22.46 23.47 
 
B                                      𝐸 = 100 × ሺ10−1/𝑚ሻ − 1 
R2= 0.999 
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3.2.1.2 Expression of K+ channel genes within cell lines  
The 5 most highly expressed K+ channels in primary neuroblastoma tumours were KCNQ2, KCNH2, 
KCNB1, KCNMA1 and KCNG1 (Section 3.1). The expression of these genes was evaluated in two 
neuroblastoma-derived cell lines, BE2C and SKNAS. qPCR was utilised to determine relative 
quantification values. To compensate for differences in starting quantity of cDNA and reaction 
kinetics quantification values were normalised to the expression of two reference genes, UBC and 
HPRT1. In the BE2C cell line, KCNQ2 was the most highly expressed K+ channel gene, followed by 
KCNH2. (Figure 3.6, A). In the SKNAS cell line, KCNH2 was the most highly expressed K+ channel gene 
(Figure 3.6, B). 
 
 
 
 
 
                                          
 
 
Gene Primer efficiency 
UBC 97.5% 
HPRT1 94.7% 
KCNQ2 95.1% 
KCNMA1 91.3% 
KCNH2 93.1% 
KCNG1 97.9% 
KCNB1 112.5% 
KLF4 95.8% 
STMN4 98.0% 
ROBO2 97.4% 
 
 
Table 3.1: Efficiency of all primers used during qPCR experiments. 
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Figure 3.6: K+ channel gene expression within BE2C and SKNAS cell lines. (A) BE2C cells (B) SKNAS 
cells. Relative quantification values were normalised to UBC and HPRT1 expression. Data 
represents mean ± SEM (n=3). 
A 
 
B 
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3.2.1.3 Differential expression of K+ channel genes  
To determine differential expression of K+ channel genes between BE2C and SKNAS, relative 
quantification ratios for each gene was determined for BE2C compared with SKNAS (Figure 3.7). 
Expression of KCNQ2, KCNB1 and KCNG1 was 101.51 ± 17.52 (p< 0.001), 71.91 ± 46.85 (p< 0.01) and 
5.31 ± 2.41 (p< 0.05) fold greater in BE2C cells relative to SKNAS cells, respectively. Expression of 
KCNMA1 and KCNH2 were not found to be differentially expressed in BE2C cells compared with 
SKNAS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Relative expression of K+ channel genes in BE2C and SKNAS. Normalised relative 
quantification ratios of K+ channel genes. Data are displayed for BE2C relative to SKNAS. Data 
represents mean ± SEM (n=3) 
 
        
         
*** 
** 
* 
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3.3 Western blotting 
Western blotting is an important method to identify specific proteins using antibodies. Primary 
antibodies are designed to target a unique sequence of a target protein. If a single band with 
predicted size can be detected, then the western blot results can validate the usefulness of a 
primary antibody.  
Assessment of gene expression by qPCR found expression of KCNQ2/Kv7.2 was 100 fold greater in 
BE2C cells compared with SKNAS. KCNQ2/Kv7.2 expression in BE2C and SKNAS cells was further 
investigated by western blotting. Several anti-Kv7.2 antibodies were tested (Section 2.1.2). 
Experiments using two different rabbit anti-Kv7.2 antibodies showed bands at the predicted 
molecular weight (96 kDa) in BE2C cells (Figure 3.8 and 3.10, lane A), whereas Kv7.2 expression was 
detected in SKNAS cell lysate by only one of these antibodies (Figure 3.8 and 3.10, lane C). A 
commonly used housekeeping protein is ß-tubulin. Re-blotting with a mouse anti-ß-tubulin antibody 
after stripping the membrane first blotted against anti-Kv7.2 antibody demonstrated a single band at 
50 kDa (Figure 3.8 and 3.10, lanes B and D). Re-blotting was conducted to ensure any differences 
detected in Kv7.2 expression were not due to differences in protein loading between the lanes.  
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3.3.1 Kv7.2 expression (anti-Kv7.2 antibody, Chemicon) 
In both BE2C and SKNAS cell lysates the first anti-Kv7.2 antibody (Chemicon) used showed a single 
band at the predicted molecular weight and a second band just below this (Figure 3.8). The presence 
of a second band may have been due to the presence of a non-specific band. However, the 
additional band may represent an isoform of Kv7.2 of which there are known to be 5 [228].  
 
 
 
 
 
 
 
 
 
 
 
 
 
To determine if Kv7.2 is differentially expressed in BE2C and SKNAS densitometric analysis of 
western blotting data was performed. Membranes were re-blotted with ß-tubulin, a housekeeping 
protein presumed to demonstrate constant expression between cell lines. Profile plots were drawn 
for each band of interest and housekeeping protein and the area of each peak was determined. The 
area of the peak for the Kv7.2 profile plot was divided by the area of the peak for the ß-tubulin 
profile plot. In BE2C cells expression of Kv7.2 is 5.3 fold greater than ß-tubulin, whereas in SKNAS 
Kv7.2 expression is 3.5 fold greater than ß-tubulin. Therefore, based on the assumption that ß-
tubulin expression is relatively constant expression of Kv7.2 is 1.5 fold greater in BE2C than SKNAS. 
(Figure 3.9). 
MW 
A B C D 
 
          
102 kDa 
150 kDa 
  52 kDa 
   76 kDa 
Figure 3.8 Western blot results using anti-Kv7.2 (Chemicon) and ß-tubulin primary antibodies 
on BE2C and SKNAS cell lysates. Lanes A and B: BE2C cell lysate, Lanes C and D: SKNAS cell lysate 
Lane A and C: show two bands of Kv7.2 at 96kDA, two further bands were detected at higher 
molecular weights, the identities of which were unknown, 1 minute exposure.  
Lane B and D: shows a single band of ß-tubulin at 50 kDa after re-blotting the same membrane, 1 
minute exposure.   
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3.3.2 Kv.7.2 expression (anti-Kv7.2 antibody, Abcam)  
In order to validate the results of western blotting with the first antibody, a second anti-Kv7.2 
antibody (Abcam) was used with BE2C and SKNAS protein lysate (Figure 3.10). Unconventionally, the 
lysate was prepared in non-denaturing conditions i.e. not heated with sample buffer, according to 
the manufacturer’s instructions which stated this was necessary to detect a band at the correct 
molecular weight. For comparison western blotting was also conducted using denatured lysate (data 
not shown).  
In the BE2C cell lysate a single band at the predicted molecular weight (96 kDa) was detected, but a 
corresponding band in the SKNAS cell lysate was not detected. The absence of a band in the SKNAS 
cell lysate supports the results of western blotting with the first antibody (Section 3.3.1). 
 
 
 
 
 
 
                         
 
Figure 3.9: Relative quantification of Kv7.2 expression in BE2C and SKNAS. Expression of 
Kv7.2 was 1.5 fold greater in BE2C than SKNAS (n=1). 
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Figure 3.10: Western blot results using anti-Kv7.2 (Abcam) and ß-tubulin primary antibodies on 
BE2C and SKNAS cell lysates. Lanes A and B: BE2C cell lysate, Lanes C and D: SKNAS cell lysate 
Lane A and C: show a single band of Kv7.2 at 96kDA, further bands were detected at lower and 
higher molecular weights, the identities of which were unknown, 5 minutes exposure.  
Lane B and D: shows a single band ß-tubulin at 50 kDa after re-blotting the same membrane, 5 
minutes exposure.   
. 
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3.4 Immunocytochemistry  
Immunocytochemistry was used to investigate NB84 (Figure 3.11) and Kv7.2 (Figure 3.12) expression 
in BE2C and SKNAS cells. Cells were stained with primary antibodies, mouse NB84 or goat anti-Kv7.2 
and labelled with goat anti-mouse and goat anti-rabbit secondary antibodies respectively. Secondary 
antibodies were conjugated to Alexa Fluor 488 (green). Slides were viewed using confocal 
microscopy. 
3.4.1 NB84 staining in BE2C and SKNAS cells  
NB84 is a monoclonal antibody which recognises an uncharacterised 57 kDa cytoplasmic antigen 
from human neuroblastoma tissue. It is a highly sensitive marker used in immunohistochemical 
staining of primary tumours for identifying neuroblastoma cells [229]. NB84 was used a positive 
control to validate immunocytochemistry technique and confirm detection of neuroblastoma cells. 
Visual examination of cells stained with NB84 indicated green fluorescence was present throughout 
the cytoplasm of both BE2C and SKNAS cells (Figure 3.11). Cells were counterstained with DAPI to 
identify the cell nucleus and no nuclear staining with NB84 was detected. To confirm the positive 
immunostaining, a negative control was employed; Alexa Fluor 488 was applied without the primary 
antibody and no green fluorescence was visualised.  
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Figure 3.11: Confocal images of BE2C and SKNAS cells stained with mouse NB84 (x200) and 
labelled with goat anti-mouse secondary antibody conjugated to Alexa-Fluor 488 (x500). (A) BE2C 
cells demonstrated positive cytoplasmic staining (B) SKNAS cells demonstrated positive cytoplasmic 
staining (C) Negative control of BE2C cells stained with Alexa Fluor 488 only. 
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3.4.2 Expression of Kv7.2 in BE2C and SKNAS cells  
Western blotting with an anti-Kv7.2 antibody (Abcam) demonstrated a single band at the predicted 
molecular weight in BE2C lysate (Section 3.3). To assess the cellular location of Kv7.2 
immunocytochemistry with the same antibody was conducted in both cell lines (Figure 3.12). BE2C 
and SKNAS cells were stained with a rabbit anti-Kv7.2 antibody (Abcam) and labelled with goat anti-
rabbit secondary antibody conjugated to Alexa Fluor 488 (green). Examination of both cell lines 
stained with the anti-Kv7.2 antibody found green fluorescence present throughout the cytoplasm 
and relatively less nuclear staining.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Alexa Fluor 488 DAPI Merged 
A 
 
 
  
B 
   
 
Figure 3.12: Confocal images of BE2C and SKNAS cells stained with rabbit anti-Kv7.2 (x200) and 
labelled goat anti-rabbit secondary antibody conjugated with Alexa-Fluor 488 (x500). (A) BE2C 
cells (B) SKNAS cells. 
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3.5 DiBAC4(3) results 
3.5.1 Overview 
Bis(1, 3-dibutylbarbituric acid) trimethine oxonol (DiBAC4(3)) belongs to the Oxonol family of slow-
response probes. DiBAC4(3) is an anionic, voltage-sensitive fluorescent dye. When present in the 
intracellular space DiBAC4(3) is adsorbed to intracellular membranes and proteins resulting in 
fluorescence [230]. As the membrane potential moves to more a positive value DiBAC4(3) 
accumulates in the intracellular space, according to a Nernst equilibrium distribution. Therefore, cell 
membrane depolarisation causes DiBAC4(3) to accumulate in the intrac220ellular space resulting in a 
concomitant increase in fluorescence (Figure 3.12). Measuring DiBAC4(3) fluorescence is thereby an 
indirect method by which changes in membrane potential can be assessed. DiBAC4(3) emits 
fluorescence at 516 nm in response to an excitation wavelength of 490 nm. Application of a K+ 
channel inhibitor would limit the efflux of K+ and induce membrane potential depolarisation and 
DiBAC4(3) fluorescence would increase. An activator of K+ channels would have the converse effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Distribution of DiBAC4(3) is determined by membrane potential. Depolarisation of cell 
membrane potential leads to in intracellular accumulation of dye resulting in increased fluorescence, 
whereas hyperpolarisation causes a decrease in fluorescence. 
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3.5.2 Characterising DiBAC4(3) fluorescence in BE2C and SKNAS cells 
Preliminary experiments were undertaken in order to characterise DiBAC4(3) fluorescence at a series 
of cell densities. This allowed determination of the cell density at which the fluorescent signal 
detection was optimal i.e. not too low so that the signal was undetectable or too high such that 
fluorescence saturated. 
In the BE2C cell line there was a linear relationship (R2=0.996) between cell density and relative 
fluorescence at cell densities between 1 x 104 and 5 x 104 cells per well, however fluorescence 
saturated at higher densities (Figure 3.13, A). The optimal cell density for future experiments with 
BE2C cells was determined to be 2 x 104 cells per well. In the SKNAS cell line, there was a linear 
relationship (R2=0.990) between cell density and relative fluorescence. Fluorescence did not saturate 
at higher cell densities (Figure 3.13, B). The optimal cell density for future experiments with SKNAS 
cells was determined to be 5 x 104 cells per well. 
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Figure 3.13: Characterisation of DiBAC4(3) fluorescence at a series of cell densities. (A) 
DiBAC4(3) fluorescence in BE2C cells. Fluorescence saturated at higher cell densities, therefore 
the data point at 1 x 105 was excluded from linear regression analysis. (B) DiBAC4(3) fluorescence 
in SKNAS cells. Data represents the mean ±SEM (n=6).  
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3.5.3 Response to high K+ solution in BE2C cells  
In order to determine the fluorescent signal after inducing sustained depolarisation of the cell 
membrane potential DiBAC4(3) solution containing a high K+ concentration (145 mM) was added to 
cells pre-incubated in DiBAC4(3) PSS. An increase in extracellular K+ concentration abolishes the K+ 
concentration gradient across the cell membrane, thus preventing the hyperpolarising outflow of K+. 
Resultantly there is predicted to be sustained depolarisation of the cell membrane potential, 
assuming K+ channels dominate generation of resting membrane potential.   
Addition of DiBAC4(3) high K+ solution caused an 11.21 ± 1.92% increase in fluorescent signal, thus 
demonstrating that DiBAC4(3) accumulates in BE2C cells upon depolarisation of cell membrane 
potential (Figure 3.14).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
                           
High K+ 
Figure 3.14:  Effect of high K+ solution on DiBAC4(3) fluorescence. Addition of high K+ solution at 
120 seconds caused a significant increase in DiBAC4(3) fluorescence. Data are shown as mean 
±SEM (n=6), p<0.001. 
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3.5.4 Effect of Kv7 channel modulation in BE2C and SKNAS cells 
Molecular expression studies demonstrated that Kv7.2 is expressed in BE2C cells (Section 3.4). The 
next objective was to determine if Kv7 channels are functional in BE2C and SKNAS cells. The previous 
experiment (Section 3.5.3) with DiBAC4(3) indicated that the cell membrane potential of 
neuroblastoma cells depolarised in response high K+ solution. To determine if Kv7 channels are 
functional, DiBAC4(3) fluorescence was measured in BE2C and SKNAS cells in response to XE991 and 
ML213, an inhibitor and activator of Kv7 channels respectively [174].  
In BE2C cells, 1 μM DiBAC4(3) PSS containing DMSO caused a 14.60 ± 3.77% increase in DiBAC4(3) 
fluorescence. DMSO is not known to have an effect on membrane potential and the reason for an 
increase in DiBAC4(3) fluorescence in response to a DMSO containing solution is unknown. 
Therefore, the response to Kv7 modulating compounds was calculated relative to DiBAC4(3) PSS 
containing DMSO. 10 μM ML213 caused a 5.58 ± 0.70% (p> 0.05) decrease in DiBAC4(3) fluorescence 
(Figure 3.15, A). Conversely, 10 μM XE991 caused a 5.62 ± 1.76% (p= 0.035) increase in DiBAC4(3) 
fluorescence (Figure 3.15, B).  
In SKNAS cells, 10 μM XE991 caused an 11.82 ± 5.30% (p> 0.05) increase and 10 μM ML213 caused a 
5.47 ± 2.77% (p> 0.05) decrease in DiBAC4(3) fluorescence, respectively (Figure 3.16). The respective 
changes in DiBAC4(3) fluorescence in response to both Kv7 channel modulating agents suggests that 
Kv7 channels are involved in determining membrane potential in both BE2C and SKNAS cells. 
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 Figure 3.16: Effect of Kv7 channel modulation on DiBAC4(3) fluorescence in SKNAS cells  
(A) Application of XE991 caused depolarisation of the cell membrane (n= 12, p= 0.22). (B) 
Application of ML213 caused hyperpolarisation of the membrane potential (n=12, p= 0.22). Data 
are shown as mean ± SEM. 
A 
 
B 
Figure 3.15: Effect of Kv7 channel modulation on DiBAC4(3) fluorescence in BE2C cells. (A) 
Application of ML213 caused hyperpolarisation of the membrane potential (n= 11, p= 0.067)  
(B) Application of XE991 caused depolarisation of the membrane potential (n= 17, p= 0.035). Data 
are shown as mean ± SEM. 
* 
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3.6 Effect of modulation of Kv7 channels on neuroblastoma cell behaviour in 
vitro  
K+ channel gene expression in neuroblastoma cell lines was evaluated by qPCR (Section 3.2), western 
blotting (Section 3.3), immunocytochemistry (Section 3.4) and DiBAC4(3) fluorescence experiements 
(Section 3.5). Kv7.2 was demonstrated to be highly expressed and functional in BE2C cells, therefore 
the next set experiments investigated the effect of pharmacological modulation of Kv7.2 on the 
behaviour of BE2C and SKNAS cells in vitro. The effect of Kv7 modulation on BE2C and SKNAS cell 
viability was investigated, followed by assessment of cell proliferation and differentiation. 
3.6.1 Assessing cell viability  
3.6.1.1 Overview 
MTT (3-(4,5- dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay is a colorimetric-
based assessment of cell viability. In metabolically active cells the yellow tetrazolium salt MTT is 
cleaved to form purple formazan crystals by mitochondrial reductases [231] (Figure 3.17). 
Spectrophotometric measurement of formazan absorbance is proportional to the metabolic activity 
of cells in culture, which in turn reflects the number of viable cells. However, metabolic activity is 
influenced by multiple factors including cell survival, cell proliferation and metabolic rate. 
Preliminary experiments involved characterising formazan absorbance in both BE2C and SKNAS cells. 
This was followed by assessing the effect of Kv7 modulation on BE2C and SKNAS cell viability. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: MTT reduction reaction.  Formazan absorbance is proportional to mitochondrial 
activity, which in turn reflects the number of viable cells. Therefore, measuring formazan 
absorbance allows quantitative assessment of the number of viable cells. 
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3.6.1.2 Characterising formazan absorbance in BE2C and SKNAS cells 
Preliminary experiments involved determination of absorbance at a series of cell densities to 
characterise the optimal cell density for future experiments. The optimal cell density should fall in 
the linear portion of absorbance; this was necessary to allow determination of both increases and 
decreases in absorbance.  
Plotting absorbance (570 nm) against cell density demonstrated a linear relationship for both cell 
lines (Figure 3.18), however in both cell lines saturation of the absorbance signal occurred at cell 
densities above 1 x 105 per well. The optimal cell density for future experiments was determined to 
be 1 x 104 cells per well for both cell lines. Formazan absorbance was greater in BE2C cells (Figure 
3.18, A) than SKNAS cells (Figure 3.18, B) across all cell densities evaluated. Given that higher 
absorbance reflects a greater number of viable cells, one interpretation of this finding is that BE2C 
cells were more rapidly dividing than SKNAS cells. 
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Figure 3.18: Characterisation of absorbance at a series of cell densities over 24 hours. (A) BE2C 
cells (B) SKNAS cells. For both cell lines data for cell densities >1 x 105 cells per well were excluded 
from linear regression analysis due to saturation of absorbance signal. Each data point represents 
mean ±SEM (n=3).   
 
 
R2= 0.919 
R2= 0.851 
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3.6.1.3 Effect of cycle cell inhibition on cell viability  
Palbociclib is a CDK4/6 inhibitor and has been shown to reduce cell proliferation in multiple 
neuroblastoma cell lines including BE2C [232]. To demonstrate that MTT assay is a viable method to 
detect changes in the number of viable cells, BE2C cells were cultured with 5 μM Palbociclib for 72 
hours. Palbociclib treated BE2C cells demonstrated a 43.83 ± 3.07% reduction in absorbance 
(p<0.001) (Figure 3.19). 
 
 
 
 
 
 
 
 
 
 
3.6.1.4 Effect of Kv7 channel modulation on cell viability 
Given that Kv7.2 was found to be highly expressed in BE2C cells and relative to SKNAS the effect of 
Kv7.2 modulation on cell viability was investigated. Both BE2C and SKNAS cells were cultured with 
two concentrations of XE991 (1 μM and 10 μM) and ML213 (1 μM and 10 μM) for 72 hours. XE991 
and ML213 are inhibitor and activator of Kv7 channels, respectively. Two concentrations were tested 
to determine if a dose response effect could be observed.  
BE2C cells treated with 10 μM XE991 demonstrated a 10.10 ± 1.49% reduction in formazan 
absorbance at 570 nm indicating a reduction in the number of viable cells; however this effect was 
not significant (p>0.05). Application of XE991 at a lower concentration (1 μM) caused the opposite 
effect and a 10.99 ± 2.19% increase in absorbance was observed (p>0.05) (Figure 3.20, A). SKNAS 
cells treated with XE991 10 μM demonstrated an 11.97 ± 1.06% reduction in the number of viable 
cells (p>0.05). ML213 at 1 μM and 10 μM had no significant effect on absorbance (Figure 3.20, B). 
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Figure 3.19: Effect of Palbociclib on BE2C cell viability. Cell viability was assessed by MTT assay. 
Absorbance at 570 nm was corrected for background. Data represents mean ± SEM (n=4).                                       
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Figure 3.20: Assessment of BE2C and SKNAS cell viability after 72 hours treatment with Kv7 
channel modulators. Cell viability was measured using MTT assay. (A) BE2C cells (n=4) (B) SKNAS 
cells (n=3). Absorbance at 570 nm was corrected for background. Data represents mean ± SEM. 
 
   98 
Overall, despite the lack of statistical significance, the pattern of results suggested that culturing 
BE2C and SKNAS cells with 10 μM XE991 caused a reduction in the number of viable cells. However, 
given that the lower concentration of XE991 (1 μM) increased the number of viable BE2C cells and 
had no effect on SKNAS cells, it was possible that this effect was due to cytotoxicity of the drug at 
higher concentrations. An alternative rationale for the observed reduction in cell viability may be 
that XE991 exerted an anti-proliferative effect in both cell lines. This was investigated through an 
immunofluorescence-based proliferation assay (Section 3.6.2). 
3.6.2 Immunofluorescence proliferation assay 
Assessment of cell viability by MTT assay demonstrated a reduction in the number of viable cells in 
response to the 10 μM XE991 in BE2C and SKNAS cell lines (Figure 3.20). To determine if this effect 
was due to a reduction in cell proliferation, the effect of Kv7 modulating compounds on cell 
proliferation was assessed using a Ki67 immunofluorescence assay.  
3.6.2.1 Overview 
Ki67 is preferentially expressed during the G1, S, G2 and M phases of the cell cycle and is absent at 
the protein level during G0, therefore is regarded as a marker of active cell proliferation [233]. 
Staining cells with a rabbit anti-Ki67 antibody and labelling with goat anti-rabbit secondary antibody 
conjugated with Alexa Fluor 594 (red) (Figure 3.21, A) enabled identification of proliferating cells 
whilst counterstaining with DAPI allowed identification of the cell nucleus so the total number of 
cells present (Figure 3.21, B). The number of Ki67 positive cells were expressed as a percentage of 
DAPI-stained nuclei to allow determination of the Ki67 proliferation index.  
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Figure 3.21:  Paired images of DAPI and Ki-67 staining. (A) Ki67 stained nuclei, multiple red ‘hot spots’ 
are visible. (B) DAPI-stained nuclei were counted in each field. 
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3.6.2.2 Effect of Kv7 channel modulation on BE2C and SKNAS cell proliferation 
BE2C and SKNAS cells were cultured with 1 μM and 10 μM ML213 and XE991 for 72 hours, after 
which cells were stained with a mouse anti-Ki67 antibody and a goat anti-mouse secondary antibody 
conjugated with Alexa Fluor 594. Two concentrations of ML213 and XE991 were tested to determine 
if a dose response effect could be observed. XE991 and ML213 are inhibitor and activator of Kv7 
channels, respectively 
Relative to the control, 1μM and 10 μM XE991 caused a 13.33 ± 3.94% (p> 0.05) and 32.85 ± 5.87% 
(p< 0.05) reduction in BE2C cell proliferation, respectively (Figure 3.22). 10 μM ML213 caused a 
14.61 ± 10.11% increase in BE2C cell proliferation (p> 0.05). This suggests that KCNQ2/Kv7.2 has a 
role in BE2C cell proliferation. 
In SKNAS cells, 10 μM ML213 caused a 0.39 ± 2.99% decrease in cell proliferation. 10 μM XE991 
caused a 0.95 ± 1.22% reduction in cell proliferation. Therefore, it was concluded that Kv7 
modulation had no significant effect on SKNAS cell proliferation (Figure 3.23). 
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 Figure 3.22: Effect of Kv7 modulation on BE2C cell proliferation. Ki67 index= number of Ki67 
positive expressed as a percentage of the total number of cells. Data presented relative to 
control. Data represents mean ± SEM (n=9).  
 
Figure 3.23: Effect of Kv7 modulation on SKNAS cell proliferation. Ki67 index= number of Ki67 
positive expressed as a percentage of the total number of cells. Data presented relative to control. 
Data represents mean ± SEM (n=6). 
* 
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3.6.3 Cell cycle analysis  
Fluorescence activated cell sorting (FACS) was utilised to analyse the cell cycle in BE2C cells. XE991 
demonstrated a significant reduction in cell proliferation. ML213 caused an increase in cell 
proliferation, although this did not reach significance (Figure 3.22). Preliminary experiments involved 
characterising the cell cycle in BE2C and SKNAS cells and assessing the influence of contact inhibition 
on BE2C cells. This was followed by determining if Kv7 modulation affected BE2C proliferation 
through affecting the cell cycle. Kv7 modulating compounds did not demonstrate an effect on SKNAS 
cell proliferation (Figure 3.23), therefore cell cycle analysis in response to these compounds was not 
conducted. 
3.6.3.1 Overview 
FACS is based on the principle of using flow cytometry to sort single cells based on the fluorescent 
properties of a dye. An application of FACS is cell cycle analysis. This is based on the premise that 
cells in the Gap 0 (G0) or Gap 1 (G1) phases of the cell cycle possess diploid chromosomal and DNA 
content, whereas cells in Gap 2 (G2) and just prior to mitosis (M) contain exactly double the DNA 
content (Figure 3.25). Hoechst 33342 is a dye that binds stoichiometrically to double-stranded DNA, 
therefore Hoechst labelled cells in the G2/M phase will emit twice the fluorescence.  
3.6.3.2 Gating 
Analysis of flow cytometry data is fundamentally based on the principle of gating. The parameters 
used to determine gates are forward scatter (FSC) and side scatter (SSC) and give an estimation of 
the size and granularity of cells, respectively. Gating is an essential step in analysis to eliminate to 
cell debris, non-viable cells, doublets or clumps prior to cell cycle analysis. Gates are defined by 
drawing polygons around a population of cells and only cells within defined gates are carried 
forward for analysis.  
Processed cells labelled with Hoechst 33342 were gated on cell size and granularity by plotting side 
scatter (SSC) against forward scatter (FSC). Cells with low FSC and SSC were considered to be non-
viable or cellular debris and excluded from analysis (Figure 3.24, A). 
The next step was to remove doublets and cell clumps from the analysis. Doublets and cell clumps 
fluoresce at the same wavelength as a cell with truly double DNA content, thereby producing a false-
positive result. Single cells truly in G2 will have a smaller width than doublet cells. Plotting forward 
scatter-height against forward scatter-width allowed identification and exclusion of doublets and cell 
clumps (Figure 3.24, B).  
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Figure 3.24: BE2C cell population gating scatter plots from one experiment. (A) Scatter plot 
showing the size and granularity of the BE2C cell population, 20.53% of cells read were excluded 
from further analysis. (B) Scatter plot showing doublet cell and cell clump exclusion, 9.60% cells 
were excluded from further analysis. 
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Figure 3.25: Schematic presentation of the cell cycle. The cell cycle is a series of highly regulated 
steps that govern cell proliferation and has four phases: Gap 1 (G1), Synthesis (S), Gap 2 (G2) and 
Mitosis (M). During G1 the cell increases the number of its organelles and grows in size, DNA 
content at this point is diploid (2n). Cells can enter or exit the cycle at G0 if dependent on the 
presence of mitogenic stimulation. Once a cell passes the restriction point it is committed to 
progressing to division. The ensuing S phase starts when DNA synthesis commences; when 
complete DNA content is hyperdiploid (4n). G2 allows replicated to be checked for errors prior to 
mitosis. The relatively brief M phase is the process by which the cell separates the nuclei, 
cytoplasm, organelles and cell membrane are divided into two identical daughter cells.  
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Figure 3.26: Example of labelled cell cycle histogram. The cell cycle histogram generated by FACS 
is divided into three distinct phases. The DNA content G0/G1 cells is diploid (2n), intermediate 
during S phase (2n-4n) intermediate DNA content and DNA content is hyperdiploid (4n) at G2/M. 
Two distinct peaks visible, the first represents the proportion of cell in the G0/G1 phase, these cells 
have diploid DNA content. The second peak represents the proportion of cells in the G2/M phase, 
these cells have hyperdiploid DNA content thus emit twice the fluorescence. 
G0/G1 
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3.6.3.3 Characterising the cell cycle in BE2C and SKNAS cells 
Preliminary experiments involved comparing the cell cycles of untreated BE2C and SKNAS cells. Cells 
were labelled with Hoechst 33342 and cell cycle analysis was conducted. A difference in the 
proportion of cells in each phase of the cell cycle phases was observed between BE2C and SKNAS 
cells. In BE2C (Figure 3.27, A) there were more cells in the S phase, whereas in SKNAS (Figure 3.27, 
B) more a greater proportion of cells were in the G2/M phase. There percentage of cells in the 
G0/G1 in both cell lines was similar.   
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Figure 3.27: Cell cycle analysis of untreated population of BE2C and SKNAS cells. Cell cycle 
histograms generated by FACS show the distribution of cells in each phase of the cell cycle for 
untreated (A) BE2C cells (B) SKNAS cells (C) The percentage of cells in each phase of the cell cycle are 
given (n=1). 
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3.6.3.4 Effect of cell density on BE2C cell division  
Density limitation of cell proliferation, also referred to as contact inhibition, is the process of 
arresting cell division when cells reach a high density. In culture, the growth of proliferating cells is 
often arrested once a confluent monolayer is established. This is an important anti-neoplastic 
mechanism which is often lost in cancer cells [234]. Loss of density limited cell proliferation in BE2C 
cells was apparent when as cells formed clusters and multiple layers in culture. To quantitatively 
evaluate this property, BE2C cells were cultured to obtain a highly dense population of cells (100% 
confluency) and a less dense population of cells (50% confluency). Cell cycle analysis of both 
populations of cells found similar cell cycle profiles in both populations of cells, indicating BE2C cell 
growth does not arrest at a high cell density (Figure 3.28). 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
Figure 3.28: Cell cycle analysis of high and low density populations of BE2C cells. The percentage of 
cells in each phase of the cell cycle are given. (A) Cells grown to high density i.e. 100% confluency 
(B) Cells grown to low density i.e. 50% confluency (n=1). 
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3.6.3.5 Effect of cell cycle inhibition in BE2C cells 
Palbociclib is a potent inducer of cell cycle arrest at the G1/S phase of the cell cycle and has been 
demonstrated to induce G1 arrest in BE2C cells [232, 235]. 5 μM Palbociclib was used as a positive 
control and significantly reduced the proportion of cells in the G2/M phase of the cell cycle (Figure 
3.29). It was concluded Palbociclib mediated cell cycle inhibition leads to fewer actively dividing i.e. 
cells with hyperdiploid DNA content. 
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Figure 3.29: Effect of Palbociclib on the cell cycle in BE2C cells. Cell cycle histograms generated by 
FACS show the distribution of cells in each phase of the cell cycle for (A) Control (B) 5 μM 
Palbociclib. (C) The percentage of cells in each phase of the cell cycle is given. Data are presented as 
mean ± SEM (n=3).  
   107 
3.6.3.6 Effect of Kv7 modulation in BE2C cells 
The pattern noticed with ML213 and XE991 was an increase and reduction in BE2C cell proliferation, 
respectively (Figure 3.22). Therefore, cell cycle analysis was utilised to determine whether Kv7 
modulation affected BE2C proliferation through affecting the cell cycle. XE991 and ML213 are 
inhibitor and activator of Kv7 channels, respectively. Neither 10 μM ML213 nor XE991 demonstrated 
an effect on the cell cycle (Figure 3.30). 
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Figure 3.30: Effect of Kv7 channel modulation on BE2C cell cycle. The percentages of cells in each 
phase of the cell cycle are shown. BE2C cells cultured with 10 μM ML213 and XE991 are compared 
against the control. Data are presented as mean ± SEM (n=3). 
( 
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3.7 Assessing the effect of Kv7 inhibition on BE2C cell differentiation 
 
3.7.1 Effect of XE991 on morphology of BE2C cells 
Aberrant differentiation is a feature of many cancers, including neuroblastoma. Mutations causing 
disruption to normal signalling pathways leads to deregulation of proteins required for 
differentiation. Inducing terminal differentiation of cancer cells reduces their proliferative capacity 
and promotes apoptosis. In addition, compared with traditional chemotherapy, differentiation 
therapy causes relatively little damage to normal cells [236]. Therefore, pharmacological agents 
capable of inducing neuroblast differentiation are important candidates for novel therapeutic 
compounds. A commonly measured characteristic of neuroblastic differentiation is neurite 
extension. A neurite refers to any projection from the cell body of a neuron whose length equals or 
exceeds that of the cell body [237]. To investigate the differentiating properties of XE991 BE2C cells 
were cultured with 10 μM XE991 for 72 hours. Cells were viewed under fluorescence microscopy and 
cell surface projections, akin to neurite extensions were observed in some cells (Figure 3.31, B). 
Morphological changes were compared with cells cultured with DMSO (Figure 3.31, A).  
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Figure 3.31: Effect of DMSO and XE991 on BE2C cell morphology. (A) BE2C cells treated with DMSO 
did not demonstrate changes in morphology after 72 hours. (B) XE991 treated cells demonstrated 
cellular processes (white arrows) indicative of neurite extensions (n=3 independent replicates). 
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3.7.2 Effect of XE991 on differentiation markers in BE2C cells 
Based on the evidence of observed morphological changes, XE991 may have had a differentiating 
effect on BE2C cells (Section 3.7.1). To further investigate this, quantitative assessment of cellular 
differentiation was undertaken using qPCR. Genes which demonstrate large fold changes upon 
neuroblastoma cell differentiation were selected: KLF4, STMN4 and ROBO2 [226]. KLF4 is a stem cell 
marker involved in the regulation of differentiation and its expression would be expected to 
decrease in differentiated cells [238]. STMN4 and ROBO2 are involved in neuronal differentiation. 
ROBO2 is also involved in regulation of the actin cytoskeleton and axon development. Expression of 
both would be expected to increase in differentiated cells [239, 240]. 
BE2C cells were cultured with 10 μM XE991 for 72 hours after which RNA extraction, cDNA synthesis 
and qPCR were conducted. In keeping with the low level of morphological changes observed, there 
was no significant difference in the expression of KLF4, ROBO2 and STMN in XE991 treated cells 
compared with DMSO treated cells (Figure 3.32). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 Figure 3.32: Relative expression of differentiation genes in response to 10 μM XE991. 
Normalised relative quantification ratio of differentiation genes between XE991 treated BE2C cells 
and DMSO treated cells. Data represents mean ± SEM (n=3) 
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3.8 Effect of cellular differentiation on KCNQ2 expression in BE2C cells 
Results from bioinformatic database search found KCNQ2 expression was significantly greater in 
neuroblastoma tumours compared to more histologically mature neuroblastic tumours: 
ganglioneuromas and ganglioneuroblastomas (Section 3.1.1). This led to the hypothesis that high 
KCNQ2 expression may be a marker of less differentiated cells. In our laboratory it has been 
demonstrated that BE2C cell differentiation can be induced by culturing cells with 5 μM Palbociclib 
(Rasha Swadi, University of Liverpool), an effect that is not seen in SKNAS cells. BE2C cell 
differentiation was induced by culturing BE2C cells with 5 μM Palbociclib. After 72 hours, significant 
morphological evidence of differentiation was observed in Palbociclib treated cells (Figure 3.33). 
RNA was extracted from control (DMSO) and Palbociclib treated cells, followed by cDNA synthesis 
and qPCR. There was no significant difference in KCNQ2 expression between differentiated and 
undifferentiated BE2C cells. 
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Figure 3.33: Morphological appearance of BE2C cells after 72 hours treatment with Palbociclib. 
(A) BE2C cells cultured with DMSO (B) BE2C cultured with 5 μM Palbociclib. Extensive neurite 
extensions are visible which are indicative of neuroblast differentiation.  
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3.9 Assessing the effect of XE991 on BE2C cell proliferation in vivo using the 
chick embryo model 
It has been previously demonstrated that the BE2C cell line could form tumours using the chick 
embryo model and the protocol for carrying this out has been optimised within our laboratory. 
3.9.1 Tumour formation 
XE991 had demonstrated a reduction in BE2C cell proliferation in vitro, therefore the same cell line 
was used to generate tumours in the chick embryo to investigate the anti-proliferative effect of 
XE991 in vivo. Fertilised chick eggs were incubated for a 7 day period (E0 to E7). At E7 GFP-labelled 
BE2C cells were topically implanted onto the surface of the chorioallantoic membrane (CAM) of the 
developing chick embryo in order to form tumours. At E11, in eggs where tumours were detectable, 
XE991 was topically administered to the surface of the CAM. XE991 was dissolved in PBS, therefore 
control tumours were left untreated. At E14, tumours were visible underneath the surface of the 
CAM under light microscopy (Figure 3.34, A) and were also viewed under fluorescence to detect 
GFP-labelled cells (Figure 3.34, B). Successful tumour formation was variable and a common 
outcome of topical implantation of cells was a failure to invade the CAM, with cells remaining on the 
surface. Where tumours had successfully been formed they were dissected as discrete masses, fixed 
in PFA and embedded in paraffin prior to Ki67 staining. Figure 3.35 summarises the survival of 
embryos and tumour formation.   
 
 
 
 
 
 
 
 
 
 
Figure 3.34: Example of a BE2C tumour imaged in vivo. (A) Paired bright-field (B) Green 
fluorescence images of a BE2C tumour in vivo, prior to dissection. Tumours form underneath the 
surface of the chorioallantoic membrane as a discrete, highly vascularised mass.  
A 
 
B 
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Figure 3.35: Flow chart depicting chick embryo survival and tumour formation. Fertilised eggs 
were incubated for 3 days prior to windowing. At E3 a window was created in the shell to allow 
access to the embryo and surrounding membranes and monitor embryo survival. Unfertilised eggs 
were discarded. At E7 surviving embryos were carried forward and BE2C cells were topically 
implanted on the surface of the CAM. At E11 XE991 was injected into the allantois of surviving 
embryos or left untreated. At E14 survival was reassessed and where evident tumours were 
dissected and stored.  
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3.9.2 Ki67 immunohistochemical staining of tumour sections 
3.9.2.1 Immunohistochemistry controls 
To confirm positive immunostaining, tonsillar tissue was utilised as control tissue and a positive and 
negative control were used. The first control was a positive control, tonsillar tissue is expected to 
express Ki67 and positive staining was observed on visual examination (Figure 3.35, A). For the 
second control, an isotype control was used to demonstrate the specificity of the Ki67 antibody and 
no staining was visible under visual examination (Figure 3.35, B). 
3.9.2.2 Ki67 detection in control and XE991 treated tumours 
Formalin-fixed, paraffin embedded (FFPE) sections obtained from control (Figure 3.36, A) and XE991 
treated (Figure 3.36, B) tumours were stained for Ki67 to determine proliferative index. Three XE991 
tumours were sectioned and stained, however no control tumours were successfully obtained. Two 
pre-sectioned tumours were provided by Rasha Swadi, University of Liverpool, to conduct Ki67 
staining. Immunohistochemical detection of Ki67 in control and XE991 treated tumours was not 
significantly different, therefore it was determined that XE991 did not reduce BE2C cell proliferation 
in vivo.  
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Figure 3.35: Ki67 and Haematoxylin staining of tonsillar tissue. (A) Positive control, brown spots 
visible throughout tissue represent positive Ki67 staining. (B) Negative control, isotype negative 
control, no brown spots are visible, thus Ki67 staining was not detected. 
A 
 
B 
 
 
A 
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Figure 3.36: Ki67 and Haematoxylin staining of tumour tissue. (A) Untreated control (B) XE991 
treated tumour. Ki67 staining is visible in both tissues. BE2C cells have relatively large nuclei 
compared with chick tissue which allows the two to be distinguished. 
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4.1 Rationale  
Seminal work by DeCoursey et al. demonstrated that voltage-gated K+ channels are the predominant 
channel in proliferative lymphocytes and application of K+ channel blockers inhibited DNA synthesis 
[241]. This discovery led to further research which has firmly established the role of K+ channels in 
the regulation of the cell cycle and cell proliferation. Furthermore, there is increasing evidence that 
demonstrates K+ channels are involved in the regulation of multiple oncological processes including 
apoptosis, cell migration, metastasis and angiogenesis [144, 145]. The EAG subfamily of voltage-
gated K+ channels has been extensively studied in a number of cancer types. With regards to 
neuroblastoma, most studies evaluating the expression and influence on cell behaviour of K+ 
channels in neuroblastoma have focused on a single member of the EAG family, the hERG channel 
[214-220]. The aim of this study was to build upon the existing knowledge of the role of K+ channels 
in neuroblastoma and investigate whether K+ channels contribute to neuroblastoma tumour 
development and progression. This was carried out by evaluating K+ channel expression and function 
in primary neuroblastoma tumours and cell lines. Following this, the next set of experiments aimed 
to evaluate the effect of K+ channel modulation on cell behaviour was then assessed in vitro and in 
vivo. 
4.2 K+ expression in primary neuroblastoma tumours and cell lines  
An initial bioinformatic screen identified the 5 K+ channel genes with the highest relative expression 
in primary neuroblastoma tumours: KCNQ2, KCNMA1, KCNH2, KCNG1 and KCNB1. These 5 channels 
were selected for in vitro assessment. 4 of these channels (KCNQ2, KNH2, KCNG1 and KCNB1) belong 
to the voltage-gated K+ channel superfamily (Kv) and there is substantial evidence to support the 
oncogenic potential of Kv channels [193, 207]. KCNQ2 has been comprehensively studied in the 
context of neurological disorders [175]; however its role in cancer has yet to be extensively explored. 
KNCQ2 was shown to be expressed in certain breast cancer cell lines and pharmacological inhibition 
led to reduced cell proliferation [242]. KCNMA1 (BKCa, big conductance calcium-activated potassium 
channel) has been strongly implicated in human cancers and has been shown to be overexpressed in 
human prostate cancer [243] and breast cancer [244, 245]. However, one study demonstrated 
KCNMA1 acts as a tumour suppressor in gastric cancer [246]. The role of KCNH2 (Kv11.1/hERG) in 
cancer has been widely studied and has been demonstrated to be overexpressed in a multitude of 
human cancers including endometrial cancer, leukaemia, colorectal cancer, glioblastoma multiforme 
[196]. KCNB1 (Kv2.1) was found to be expressed in endometrial cancer cells and channel inhibition 
reduces cell proliferation [247]. There is no existing evidence implicating KCNG1 (Kv6.1) in cancer. 
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Following the bioinformatic screen K+ channel gene expression in two neuroblastoma cell lines was 
assessed by qPCR. Clinically, the presence of MYCN amplification and chromosome 11q deletion are 
two features of primary neuroblastoma tumours which confer high risk [37]. Therefore, two 
neuroblastoma derived cell lines representative of these features, BE2C and SKNAS, were selected 
for in vitro studies. BE2C is a MYCN amplified neuroblastoma cell lines, whereas SKNAS cells possess 
chromosome 11q deletion. 
KCNQ2 was found to be highly expressed in BE2C cells and expression of KCNQ2 was 101 fold greater 
in BE2C relative to SKNAS cells (Figure 3.7). A previous study has demonstrated KCNQ2 is expressed 
in IMR-32 neuroblastoma cells, which share similar characteristics to BE2C cells e.g. MYCN 
amplification [248]. Neuroblastic cells represent neoplastic proliferation of the precursor cells to 
sympathetic ganglion neurons and characterisation of marker genes demonstrates that 
neuroblastoma cells have sympathetic neuronal properties [249, 250]. It is known that in 
sympathetic ganglion neurons Kv7.2 homomers and Kv7.2/3 heteromers coassemble to form M-
channels [172]. Therefore, high expression of KCNQ2 in BE2C cells may reflect the expected 
acquisition of normal neuronal properties in developing sympathetic ganglion cells, prior to their 
malignant transformation. Conversely, it is plausible that high expression of KCNQ2 observed in 
BE2C cells contributes to its aggressive phenotype. 
With regards to other K+ channel genes investigated this study, KCNH2/hERG demonstrated low 
expression in both cell lines. This was surprising given previous investigations have demonstrated a 
significant role for KCNH2 expression in the SH-SY5Y neuroblastoma cell lines [214-220]. However, 
this may be reflective of the heterogeneity of K+ channel expression in neuroblastoma cell lines. 
Overexpression of KCNMA1 has been implicated to have oncogenic potential in other cancers [243-
245], however in this study relatively low expression was observed in both cell lines. Despite 
demonstrating relatively high expression in primary neuroblastoma tumours, expression of KCNB1 
was low in BE2C and SKNAS cells; however this must be interpreted with consideration for 
inadequate primer efficiency. 
In this study protein expression of Kv7.2 was initially investigated by western blotting. The Kv7.2 
protein has an estimated molecular weight of 96 kDa and a band at this molecular weight was 
detected in both BE2C and SKNAS cell lysate using two different anti-Kv7.2 antibodies. However, 
additional bands were also detected at higher and lower molecular weights. The appearance of 
multiple bands suggested possible non-specific binding of the primary antibody which limited the 
interpretation of western blotting results in this study. Consequently the band of interest identified 
at 96 kDa may have also be non-specific. An alternative explanation for the presence of multiple 
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bands is the concentration of primary antibody used may have been too high. This may have been 
amended by using a lower concentration or using a series of dilutions to optimise the concentration. 
Nevertheless, there are alternative explanations for the presence of multiple bands unrelated to the 
specificity or concentration of the antibody. Bands at higher molecular weights may have been due 
to unresolved protein multimers or post-translational protein modifications e.g. phosphorylation, 
glycosylation, ubiquitination. Conversely, bands at a lower molecular weight may have been due to 
detection of a degraded/cleaved form or a splice variant of the protein of interest.  
There are multiple methods by which the specificity of a primary antibody may have been 
investigated. A common method is the use of a positive control i.e. a lysate in which the protein of 
interest is known to be expressed. For example, Kv7.2 is known to be expressed in rat sympathetic 
neurons [180], thus lysate derived from this source could have been used to assess antibody 
specificity. A positive result would have indicated the antibody is identifying Kv7.2. In addition, 
where available, application of a controlled peptide is an alternative method of validating the 
primary antibody. The primary antibody would be pre-incubated with the controlled peptide, a 
peptide which corresponds with the antibody epitope, thus preventing the antibody-epitope 
interaction and band detection. Furthermore, genetic knockdown of Kv7.2 expression, for example 
by RNA interference, in BE2C and SKNAS cells would have been a robust method by which antibody 
specificity could have been demonstrated. Through inhibition of mRNA translation, Kv7.2 expression 
would have been inhibited, the primary antibody would not have detected the epitope and a lack of 
band detection in the knockdown cell lysate would have demonstrated that the anti-Kv7.2 antibody 
is correctly binding to Kv7.2. With regards to the secondary antibody, non-specific binding of the 
secondary antibody may have also caused the detection of multiple bands; a no primary antibody 
control i.e. omitting addition of the primary antibody would have been a method to assess 
secondary antibody specificity.  
In this study the first anti-Kv7.2 antibody detected possible Kv7.2 expression in both BE2C and 
SKNAS cells. The second anti-Kv7.2 antibody tested showed possible expression of Kv7.2 in BE2C 
cells and no detectable expression of Kv7.2 in SKNAS cells. Overall, the results of western blotting 
were consistent with the results of qPCR. Both methods demonstrated that KCNQ2/Kv7.2 expression 
is greater in BE2C cells compared with SKNAS cells. The observed fold difference in KCNQ2/Kv7.2 
expression determined by western blotting was significantly lower than the fold difference in 
expression identified by qPCR, although this was only based on a single replicate. Nevertheless, the 
degree of correlation between gene and protein correlation is notoriously low as there are multiple 
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processes between gene transcription and translation [251]. In addition, protein degradation may 
also explain why a high protein to gene to protein expression ratio was observed.  
In this study assessment of Kv7.2 expression by immunocytochemistry was relatively inconclusive. 
Fluorescence was observed throughout the cytoplasm of both BE2C and SKNAS cells which suggests 
Kv7.2 is expressed in the cytoplasm. However Kv7.2 is a transmembrane protein and fluorescence 
would be expected to be limited to the plasma membrane. This picture may have been distorted as 
the biogenesis of most transmembrane proteins involves synthesis in the endoplasmic reticulum, 
modification in the Golgi apparatus and transport across the cytoplasm, therefore the localisation of 
Kv7.2 may not be strictly to the plasma membrane. An alternative explanation may have been that 
fluorescence was detected throughout the cytoplasm due to non-specific antibody binding of the 
primary antibody; this would correlate with the pattern of multiple bands observed by western 
blotting. In addition, there are limitations of immunocytochemistry to be considered; fluorescence is 
not permanent, as the samples were examined they underwent photobleaching and fluorescence 
faded. In addition, cells required fixation and permeabilisation, both of these procedures could have 
introduced unwanted artifacts.  
Furthermore, as mentioned for western blotting, to validate the use of anti-Kv7.2 antibodies for 
immunocytochemistry both primary and secondary antibody controls could have been employed. 
There are multiple methods by which the primary antibody may have been validated. Firstly, 
immunocytochemistry may have been undertaken with a positive control i.e. a cell type known to 
express Kv7.2 e.g. rat sympathetic ganglion neuron [180]. A negative control, a cell type known not 
to express Kv7.2, could have been employed and a negative result i.e. no fluorescence detection 
would have helped to validate the primary antibody. Similarly to western blotting, during 
immunocytochemistry the primary antibody could have been incubated with a controlled peptide, 
thus preventing epitope recognition and a negative result would have been expected. An additional 
method by which the specificity of the primary antibody may have been demonstrated would have 
been to use the genetic approach and conduct knockdown of KCNQ2 in both BE2C and SKNAS cells. 
A negative result in knockdown cells would have significantly helped to demonstrate the specificity 
of the primary antibody. An additional cause of non-specific fluorescence may be non-specific 
binding of the secondary antibody; employing a no primary antibody control i.e. only incubating cells 
with the secondary antibody should produce no fluorescent labelling, thereby demonstrating 
specific binding of the secondary antibody.  
Following on from assessing the expression of KCNQ2/Kv7.2 in BE2C and SKNAS cells, the next set of 
experiments in this study aimed to determine whether the channel was involved in governing 
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membrane potential. An indirect measure of membrane potential, DiBAC4(3) fluorescence, was used 
to determine whether Kv7.2 is functional in BE2C and SKNAS cells. XE991 caused depolarisation of 
BE2C cell membrane potential. Conversely, ML213 caused hyperpolarisation of BE2C cell membrane 
potential, although this result did not reach significance. This data indicates that KCNQ2/Kv7.2 is 
present in the BE2C cell membrane and has a role in regulating membrane potential. Despite qPCR 
and western blot data suggesting absent or low KCNQ2/Kv7.2 expression a similar pattern was 
observed in SKNAS cells. XE991 and ML213 caused depolarisation and hyperpolarisation of SKNAS 
cell membrane potential; however these results did not attain statistical significance. To directly 
measure ion channel activity patch clamp recordings would have been required.   
Given that neither XE991 nor ML213 can be regarded as specific for Kv7.2 channels the results 
obtained in this study should be interpreted with caution. At the concentration used XE991 inhibits 
homomeric Kv7.2 and Kv7.1 channels and Kv7.2/3 heteromeric channels and ML213 activates Kv7.2 
and Kv7.4 homomeric channels. Previous studies have shown that XE991 is a potent inhibitor of 
channels formed by Kv7.2 homomeric subunits (IC50= 0.7 μM), Kv7.1 homomeric subunits (IC50= 0.8 
μM) and coassembly of Kv7.2/Kv7.3 heteromers (IC50= 0.6 μM) [252]. KCNQ1/Kv7.1 expression has 
not been previously demonstrated in native sympathetic neurons or neuroblastoma cells. Previous 
studies have suggested that in early sympathetic ganglion neurons and brain development Kv7.2 
subunits are the dominant component of the native M-channel and acquisition of KCNQ3/Kv7.3 
expression occurs at a later stage during embryonic development [253, 254]. Given that neuroblastic 
cells are derived from the precursor cell of sympathetic ganglion neurons, it can be hypothesised 
that KCNQ2/Kv7.2 homomeric channels predominate in neuroblastoma cells. This would suggest 
that the effect of XE991 on membrane potential in neuroblastoma cells is through inhibition of 
KNCQ2/Kv7.2 homomeric channels. 
4.3 Role of KCNQ2/Kv7.2 in neuroblastoma cell viability and proliferation 
Does expression of KCNQ2/Kv7.2 in neuroblastoma cells drive its malignant phenotype or have no 
functional significance? To address this question the role of KCNQ2/Kv7.2 in cell viability and 
proliferation was assessed in both cell lines. 
MTT assay was utilised as an initial screen in this study to assess changes in cell viability in response 
to culturing cells with Kv7 modulating compounds. 10 μM XE991 caused a reduction in cell viability 
in both BE2C and SKNAS cells, however these results did not attain statistical significance. Previous 
investigations have shown application of Kv7.2/3 channel openers, N-ethylamide and flupirtine 
caused cell death in hippocampal neuronal cultures [255, 256].  
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Cell proliferation was assessed by determining the Ki67 proliferative index. This was achieved by 
fluorescence microscopy and manual counting. Manual quantification of the Ki67 index is subject to 
uncertainty caused by unclear immunostaining and human error [257]. In addition, manual methods 
of quantification may also suffer from bias by deliberate selection of areas of low/high proliferation 
[258]. To eliminate this potential source of bias, counting was performed blind i.e. the treatment 
condition was unknown when counting. 
10 μM XE991 caused a 33% reduction BE2C cell proliferation. 10 μM ML213 caused a 15% increase in 
the number of proliferating cells, although this did not attain statistical significance. Opposing effects 
by the KCNQ2/Kv7.2 activator and inhibitor support the hypothesis that KCNQ2/Kv7.2 is implicated 
in the regulation of neuroblastoma cell proliferation. There is very limited evidence to suggest that 
Kv7 channels play a role in cancer cell proliferation [259]. Kv7 channels have been demonstrated to 
regulate skeletal muscle cell proliferation and differentiation [260, 261].  
By what mechanism could inhibition of Kv7 channels inhibit BE2C cell proliferation? It has been 
demonstrated that membrane potential undergoes rhythmic oscillations during cell cycle 
progression [145, 146, 196]. During the G1-S transition phase of the cell cycle proliferating cells 
demonstrate a hyperpolarised membrane potential, as the cell cycle progresses to mitosis 
membrane potential undergoes depolarisation [198, 262]. This phenomenon has been observed in 
neuroblastoma cells [262]. Cell-cycle dependent changes in membrane potential are mediated by 
ion conductance and hyperpolarisation of membrane potential at the G1-S transition point is 
facilitated by K+ channel opening. Therefore, outward K+ currents contribute to cell cycle 
progression. Further to this, cell proliferation requires an accurate control of cell volume which is 
governed by cellular osmolality [145, 146]. At the G2-M transition point of the cell cycle, water 
molecules follow the flux of K+ and Cl- creating a reduction in cell volume referred to as pre-mitotic 
condensation (PMC) and impairment of PMC can delay progression of the cell cycle. K+ efflux 
appears to contribute to progression of the cell cycle at the G2-M transition phase, thus inhibition of 
K+ channels at the G2-M phase may limit cell cycle progression and cell proliferation. To achieve 
hyperpolarisation of membrane potential and PMC at the G1-S and G2-M transition points of the cell 
cycle, respectively cancer cells may require increased expression of K+ channels. Based on our 
findings KCNQ2/Kv7.2 is highly expressed in BE2C cells. Indeed, rapidly dividing cells are known to 
have a relatively depolarised membrane potential and in BE2C cells resting membrane potential is -
55 ± 3 mV [263]. Resultantly, to achieve membrane potential hyperpolarisation at G1-S and PMC at 
G2-M BE2C cells may require increased expression of KCNQ2/Kv7.2. Therefore, the anti-proliferative 
effect of XE991 in BE2C cells may be due to interference with the transient hyperpolarisation 
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necessary for cells to progress from G1 -S phase and impaired PMC at the G2-M transition. This 
hypothesis is consistent with the lack of effect of XE991 on cell proliferation in SKNAS cells which 
demonstrated significantly lower KCNQ2/Kv7.2 expression compared with BE2C cells (Figure 3.7).  
Overall modulation of KCNQ2/Kv7.2 seems to affect cell viability and proliferation, however this 
effect was not observed during cell cycle analysis. If proliferation was arrested an increase in the 
proportion of cells in the G0/G1 and decrease in S and G2/M phases of the cell cycle would be 
expected. This may be attributable to an overall small effect size on cell proliferation which was not 
significant enough to be detected by cell cycle analysis. 
4.4 Role of KCNQ2/Kv7.2 in BE2C cell differentiation 
Neuroblastoma tumours are capable of spontaneous differentiation to a benign phenotype [99]. 
Based on this observation many agents which induce differentiation have been tested in vitro as an 
experimental model for in vivo maturation of tumours [264, 265]. Differentiation therapy offers an 
alternative mechanism of action in treating neuroblastoma tumours as inducing differentiation also 
promotes growth arrest [265]. One of the most potent inducers of differentiation is retinoic acid 
(RA), an isomer of which, 13-cis RA, is used clinically and results in significantly improved overall 
survival [103, 130].  
The effect of Kv7.2 inhibition on BE2C cell differentiation was initially investigated by assessing cell 
morphology in response to culturing cells with XE991. BE2C cells demonstrated morphological 
changes reflective of cellular differentiation i.e. outgrowth of cell surface projections akin to neurite 
development (Figure 3.31, B). These changes were noted across 3 independent replicates, but were 
only notice in a limited number of cells in each field examined. Also, it must be noted that in 
comparison with other agents which are capable of inducing BE2C cell differentiation e.g. Palbociclib 
(Figure 3.33, B) these changes were significantly less pronounced. 
As cell differentiation is coupled with growth arrest it is possible that XE991 mediated morphological 
changes BE2C cells are linked to the observed reduction in cell proliferation. Indeed, voltage-gated 
K+ channels have been previously implicated in neural, cancer and stem cell differentiation [266-
268]. By what mechanism could inhibition of Kv7.2 channels induce BE2C cell differentiation? In this 
study it was demonstrated that application of XE991 caused depolarisation of BE2C cell membrane 
potential (Figure 3.16, B). Depolarisation of the membrane potential activates T- type Ca2+ channels; 
Ca2+ influx through T-type channels has been shown to promote neurite outgrowth in spinal and 
hippocampal neurons [268-270]. Furthermore, previous investigations have demonstrated genetic 
knockdown of KCNQ2 in PC12 cells, which share a common progenitor with neuroblastoma cells, 
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induced neurite outgrowth and cellular differentiation [271]. Conversely, previous investigations in 
BE2C cells documented that continuous Ca2+ influx allowed maintenance of BE2C cells in an 
undifferentiated state [272]. 
Following on from assessing cell morphology, the expression of the differentiation markers, KLF4, 
STMN4 and ROBO2 in XE991 treated BE2C cells was assessed. Sung et al. demonstrated that retinoic 
acid induces significant morphological changes and large fold changes in KLF4, STMN4 and ROBO2 
expression in neuroblastoma cells [226]. In keeping with the relatively low level of morphological 
changes seen in XE991 treated BE2C cells, there was no significant change in the expression of KLF4, 
STMN4 and ROBO2. Overall the data suggests that XE991 may induce mild morphological changes in 
BE2C cells akin to characteristic features of differentiation, but did not induce changes in the 
expression of differentiation markers. 
Another aspect of this study was to evaluate KNCQ2 expression in differentiated and 
undifferentiated BE2C cells, as evaluation of a bioinformatic database found KCNQ2 expression is 
higher in histologically mature tumours. There was no difference in expression of KCNQ2 between 
undifferentiated and differentiated BE2C cells. Previous investigations have demonstrated the IMR-
32 neuroblastoma cell line expresses two splice variants of KCNQ2, Q2 long transcript (Q2L) and Q2 
short transcript (Q2S). Q2L is predominantly expressed in differentiated cells, whereas Q2S is 
expressed mainly in undifferentiated cells [248]. The coding DNA sequence (CDS) of Q2L is 2565 base 
pairs, in comparison the CDS of Q2S is truncated and is 1182 base pairs. The KCNQ2 primer pair used 
in this study was designed to recognise both Q2L and Q2S. This suggests, in contrast to IMR-32 cells, 
that in response to differentiation the expressed KCNQ2 transcript does not change in BE2C cells.  
4.5 Role of KCNQ2/Kv7.2 in BE2C tumours in vivo  
The chick embryo model is an established model to determine the response of solid tumours to 
therapeutic compounds in vivo. There were multiple advantages of using the chick embryo model in 
this study. The rapid development, accessibility and visibility of the CAM allowed experimental 
manipulation and regular monitoring. In addition, the naturally immunodeficient nature of the chick 
embryo allowed the implantation of human neuroblastoma BE2C cells without genomic 
manipulation, whereas using a murine xenograft model would have necessitated the acquisition of 
immunodeficient mice strains. Furthermore, once BE2C cells were implanted onto the CAM, tumour 
xenografts were visible by E7; in murine models tumour formation takes 3-6 weeks [273]. 
Additionally, there were several practical benefits of using the chick embryo model. A home office 
license was not required for this study as the law permits working with eggs upto day 14 of 
incubation without obtaining a licensce; eggs were readily available from a local supplier and the 
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cost of obtaining and maintaining eggs was significantly lower in comparison with obtaining mice 
[140-142].  
Despite the aforementioned strengths of the chick embryo model all in vivo models have a common 
limitation in that species-related differences need to be taken into account when interpreting results 
from animal experiments. With specific regard to use of the chick embryo model, a limitation in this 
study was that tumour development was dependent on initial fertilisation and subsequent survival 
of the embryo. The survival of the embryo may have been compromised at multiple stages; egg 
windowing, tumour cell transplantation and drug delivery. Handling and removal of the eggs from 
the incubator at various time points also increased the risk of dehydration and infections. This risk 
was minimised by maintaining an aseptic technique, careful handling of the egg and delicate 
manipulation of the embryo. Nevertheless, the number of tumours available for 
immunohistochemical analysis was reflected by poor survival of the embryos. In particular in the 
treatment group 6/10 embryos did not survive upto E14. 
Furthermore, using the chick embryo model involved implantation of human neuroblastoma cells 
onto the chorioallantoic membrane which posed two main problems. Firstly, although the 
immunodeficient nature of the chick embryo aided in xenografting BE2C cells, it is established that 
the host immune response is a vital aspect of neuroblastoma tumour development and progression 
and human neuroblastoma most often arises in an immunocompetent host [50, 84-90]. Therefore 
the xenograft tumours developed in the CAM model may not have truly recapitulated human 
tumours. Secondly, implanting human neuroblastoma cells onto the CAM failed to replicate the 
human tumour microenvironment which may have influenced tumour behaviour.  
In this study in vivo assessment found XE991 had no significant on BE2C cell proliferation. However, 
it must be noted that in vivo assessment was limited by the very low number of tumours available 
for immunohistochemistry in both control (n=2) and treatment (n=3) groups. Given that XE991 
inhibited BE2C cell proliferation in vitro it was unclear as to why there may have been a dissociation 
between in vitro and preliminary in vivo results. One possible explanation may be that the 
expression and/or function of KCNQ2 in xenografted tumours may differ to cultured cells, therefore 
the response of xenograft tumours to XE991 may also vary. Alternatively, it is plausible that the 
effect of XE991 on BE2C cell proliferation observed in vitro may not translate to an in vivo model.  
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4.6 Limitations 
XE991 significantly influenced BE2C cell membrane potential and cell proliferation. Previous 
investigations have shown XE991 inhibits Kv7.2/7.3 heterodimers, Kv7.2 and Kv7.1 homomers with 
similar potency. Without characterising the expression and function of all Kv7 channels expressed by 
neuroblastoma cells there is uncertainty as to which channel is mediating the observed effect. For 
example, it is known that KCNQ3/5/Kv7.3/5 subunits can form heteromers with KCNQ2/Kv7.2 to 
form functional M-channels in sympathetic neurons; however gene/protein expression of these 
channels wasn’t investigated. Characterising the expression levels of these channels would help to 
determine stoichiometry of the M-channel in neuroblastoma cells. Nevertheless, as mentioned 
above, existing evidence suggests that Kv7.2 homomeric channels are the predominant Kv7 channel 
in neuroblastoma cells. Furthermore, with regards to pharmacological agents, Kv7 channels display 
significant structural homology; resultantly there is a difficulty in synthesising subtype selective 
agents [274].  
There are 79 K+ channel genes and targeting a single channel or subfamily of channels doesn’t 
account for the presence of multiple other types of K+ channels present and functional in the cell 
membrane. Any conclusions drawn based on experiments with a single channel do not account for 
the dynamic nature of ion channel conductance and membrane potential. For example, a channel 
modulating compound may induce a change in membrane potential, however ion channels work in 
concert and the activity of one type of channel can determine changes in ion flux in another channel.  
Furthermore, there are comparatively few studies investigating K+ channel physiology beyond K+ 
permeation. Kv7.2 has a large cytoplasmic domain capable of interacting with secondary messengers 
and other proteins in the cell [173]. It is plausible that channel-protein interactions influence cell 
proliferation independent of K+ permeation. Performing genetic knockdown studies would remove 
the transmembrane and cytoplasmic components of the protein; this would significantly contribute 
to determining the function of the intracellular domains of Kv7.2. 
4.7 Future direction  
Preliminary in vivo experiments using the chick embryo model were undertaken in this study. 
However, immunohistochemical detection of Ki67 staining was carried out only once due to an 
insufficient number of replicates of xenograft tumours. This limited the determination of the effect 
of XE991 on BE2C cell tumours in vivo. Further validation of the results may be obtained by 
increasing the number of xenograft tumours in both the XE991 treated and control group, followed 
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by immunohistochemical detection of Ki67 staining to assess the effect on BE2C cell proliferation in 
vivo.  
All experiments were carried out using the BE2C and SKNAS cell lines. There are many other 
neuroblastoma cell lines, thus it would be useful to extend the investigation of the expression and 
function of KCNQ2 in more cell lines to represent a wider spectrum of disease and other cancer 
types. In addition, there may be discrepancies in the results obtained in neuroblastoma cell lines, 
xenografted tumours and primary human tumours. Expression of KCNQ2/Kv7.2 in xenografted 
tumours and primary tumours from patient samples could be assessed by qPCR, western blotting 
and immunohistochemistry to further characterise the expression of KCNQ2/Kv7.2 neuroblastoma.  
In this study the aim was to assess the effect of KCNQ2/Kv7.2 modulation on cell viability, 
proliferation and differentiation. K+ channels have been implicated in a number of additional 
oncological processes including cell migration, invasion and angiogenesis [144, 145]. Future studies 
could assess the role of this channel in these processes in vitro and in vivo. 
With regards to other K+ channels, KCNH2 and KCNMA1 have been implicated in many other human 
cancers, although in this study it was found that they do not demonstrate high expression in BE2C 
and SKNAS cells. However, low expression does not preclude a significant function. The role of these 
channels and other K+ channels implicated in the development and progression of cancer should be 
assessed. 
4.8 Conclusion 
Neuroblastoma is a malignant condition that demonstrates significant clinical and biological 
heterogeneity. Further understanding of the biology of neuroblastoma may contribute significantly 
to developing novel therapeutic approaches. K+ channels are expressed ubiquitously in normal and 
malignant tissue and there is significant evidence implicating their role in oncogenesis. 
In this study we have established that K+ channels are indeed expressed by neuroblastoma cells and 
differential expression exists between two neuroblastoma cell lines. KCNQ2/Kv7.2 expression may 
contribute to the biological heterogeneity observed in neuroblastoma cell lines and primary 
tumours. Furthermore, it is evident that modulation of KCNQ2/Kv7.2 has some impact on cell 
behaviour in vitro. We hope that further work to establish the role of KNCQ2/Kv7.2 and other K+ 
channels in neuroblastoma is undertaken to ultimately gain a better understanding of the biology of 
neuroblastoma and provide a target for therapeutic compounds.  
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